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Abstract 
 
The Brazilian Unified Public Health System (SUS) shortlisted various plant species of 
interest (RENISUS) for future clinical use. However, very little is known about their 
effects on metabolic and transporter proteins, which could potentially lead to herb-drug 
interactions (HDI).  
To evaluate this, we conducted in vitro preclinical studies on twenty-four plant extracts 
to disclose their effects on CYP3A4 mRNA gene expression, intracellular glutathione 
(GSH) levels, inhibition of γ-glutamyl transferase (GGT) in HepG2 cells and P-
glycoprotein (P-gp) activity in vincristine resistant Caco-2 (Caco-2 VCR) cells. We also 
investigated whether four Brazilian native species were able to activate the human 
pregnane X receptor (hPXR) in transiently co-transfected HeLa cells.  
This preclinical research showed that all but two plant extracts were able to modulate at 
least one of the selected targets. CYP3A4 mRNA gene expression in HepG2 cells was 
significantly affected by half of the extracts. The antagonistic effect of Solanum 
paniculatum L. on hPXR could explain its ability to inhibit CYP3A4. GSH levels were 
affected by 80% of the extracts. There was depletion of intracellular GSH levels by 
Cordia verbenacea A. DC., Costus spicatus (Jacq.) Sw., Persea americana Mill., Salix 
alba L., Schinus terebinthifolia Raddi and Syzygium jambolanum (Lam.) DC. 
accompanied because of the inhibition of GGT activity. P-gp activity was modulated in 
a significant manner by 17% of the extracts.  
The approaches used for the conduction of in vitro preclinical studies in herbal 
medicines revealed a series of challenges faced especially by academics in order to 
anticipate cases of HDI. Clinicians have also to consider the presence of intrinsic factors 
such as genetic polymorphisms in each patient. The possible presence of undesirable 
interactions between RENISUS herbal medicines and essential drugs in SUS need 
eventually be clinically confirmed to attest our observed in vitro effects. 
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M-MLV Moloney murine Leukaemia Virus 
M-MLV RT Moloney murine Leukaemia Virus 
Reverse Transcriptase 
MDR1 Multi-drug resistance 1 
MNTC Maximum non-toxic concentration 
mRNA Messenger RNA 
MTA Material transfer agreement 
MTT 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl 
tetrazolium bromide 
NAPQI N-acetyl-p-benzoquinoneimine 
NAT N-acetyltransferate 
NOTIVISA Sistema de Notificações em Vigilância 
Sanitária (National notification System for 
Adverse Events and Technical 
Complaints) 
NPR Natural products reagent 
NR Neutral Red 
NSAID Nonsteroidal anti-inflammatory 
P-gp P-glycoprotein 
PAPS 3’-phosphoadenosine-5’-
phosphosulphate 
PBS Phosphate saline buffer 
PCR Polymerase chain reaction 
PD Pharmacodynamic 
PGC-1a Peroxisome proliferator-activated 
receptor g coactivator-1-a 
PK Pharmacokinetic 
PNPIC Política Nacional de Práticas Integrativas 
e Complementares (National Policy of 
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Integrative and Complementary 
Practices) 
qPCR Quantitative PCR 
QT Queixas técnicas (Technical complaints) 
REFARGEN Rede Nacional de Farmacogenética 
(Brazilian National 
Pharmacogenetics/Pharmacogenomics 
Network) 
RENAME Relação Nacional de Medicamentos 
Essenciais (Brazilian national essential 
medicines list) 
RENISUS Relação Nacional de Plantas Medicinais 
de Interesse ao SUS (Brazilian National 
List of Medicinal Plants of Interest to the 
Unified Health System) 
Rf Retention factor 
Rh-123 Rhodamine 123 
RIF Rifampicin 
RNA Ribonucleic acid 
ROS Reactive Oxygen Species 
RT-PCR Real-time polymerase chain reaction 
RT-qPCR Real-time quantitative PCR 
RXRa Retinid X receptora 
SAM S-adenosylmethionine 
SHP Small heterodimer partner 
SJW Saint John’s Wort 
SMRT Silencing mediator of retinoid and thyroid 
hormone 
SRB  Sulphorhodamine B 
SRC-1 Steroid receptor coactivator-1 
SSA Sulfosalicylic acid 
SULT Sulphotransferases 
SUS Sistema Único de Saúde (the Brazilian 
Unified Health System) 
T3 Triiodothyronine 
TC Technical complaints 
TCA Trichloroacetic acid 
TCM Traditional Chinese Medicine 
UCL University College London 
UDPGA Uridine 5’-diphosphate-glucuronic acid 
UGT UDP-glucuronosyltransferase 
UnB University of Brasília 
UV-Vis Ultraviolet/visible 
VLDL Very low-density lipoprotein cholesterol 
WHO World Health Organization 
XREM/PXRE Xenobiotic responsive enhancer 
molecule/PXRE 
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β-NADPH β-Nicotinamide adenine dinucleotide 2’-
phosphate reduced tetrasodium salt 
hydrate 
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1 GENERAL INTRODUCTION 
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1.1  HERBAL MEDICINES: TRADITIONAL USE AND SAFETY 
CONCERNS 
According to the World Health Organization (WHO), it is estimated that up 
to four billion people depend on medicinal plants for their primary health care 
due to poverty or lack of access to modern medicine, this constitutes between 
65 and 80% of the world’s population in developing countries (Silveira et al., 
2008). In contrast, in the developed world, herbal medicines are mostly used 
due to the belief that they promote healthy living (Ekor, 2013).  
The national policy on traditional medicines and regulation of herbal 
medicines report published in 2005 by WHO shows that up to 90% of the 
African population depend on traditional medicines, followed by India (70%) 
and China (40%) (WHO, 2005). Also, herbal medicines are used in primary 
health care in about 350 locations only in Brazil (Antonio et al., 2013). 
Neglected tropical diseases, such as Chagas disease and leishmaniasis, are 
endemic in many tropical countries.  As such diseases are more likely to affect 
low-income populations private pharmaceutical companies do not invest in the 
development of new medications for such conditions. Therefore, in many 
developing countries, traditional knowledge on medicinal plants is a valuable 
resource to keep the population healthy (Ndjonka et al., 2013).  
Although most of the herbal medicines traditionally used are known for 
their effectiveness on numerous conditions, safety concerns are rarely 
effectively disclosed to the population that uses them. Cases of acute toxicity 
caused by intake of herbal medicines, for example have led to acute hepatitis 
(Haller et al., 2002) and nephrotoxicity in patients (Asif, 2012). Also, chronic 
toxicity was found in herbal preparations such as the Nigerian DAS-77 (Afolabi 
et al., 2012). Cases of toxicity involving herbal medicines rarely impact the 
natural products industry. Despite the risks of consuming many herbal 
medicines (particularly with excessive chronic use), the general public 
continues to perceive such products as “natural” without being properly 
informed about the associated risks (Ekor, 2013).  
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The growth of manufactured drugs was accompanied by a series of 
events that questioned their actual safety; one of the most noted ones being 
the thalidomide case. When the pharmacological effects of thalidomide were 
first reported in 1956, regulations on the safety of new drugs were not as strict 
as they currently are. Cases of teratogenicity raised quickly due to the 
consumption of the drug by pregnant women, which led to the quick withdrawal 
of thalidomide from the market and also forced the UK and USA regulatory 
bodies to make changes in their drug safety regulations.  
A remarkable case of the natural compound aristolochic acid led to a 
similar outcome as thalidomide. In the early 1990s the cases of nephropathy 
linked to Chinese herbs among Belgian women, this was due to the introduction 
of the Chinese species Aristolochia in a popular slimming regimen. Studies on 
aristolochic acid detected its potential nephrotoxic and carcinogenic effects in 
the body. Following these findings herbs containing aristolochic acid were 
banned for medicinal use in many other countries including Canada, Australia, 
Germany, and the UK (Cosyns, 2003). The thalidomide and aristolochic acid 
cases demonstrated the potential risks that a drug could have on a population. 
However, this is not the only concern of the pharmaceutical companies. The 
risks of adverse drug reactions (ADRs) due to drug interactions are also very 
relevant in terms of drug safety (Botting, 2002). 
When drugs are taken in combination with other drugs, the chances of 
drug-drug interactions (DDI) are increased (Boobis et al., 2009). In addition to 
DDI several types of drug interactions have been identified and documented in 
the literature: drug-food, drug-chemical substance, drug-laboratory, and non-
laboratory test (Mazzari et al., 2016). DDI occur at both pharmacodynamic (PD) 
and pharmacokinetic (PK) levels. PD interactions can be defined as how drugs 
influence each other’s effects directly by a synergistic or antagonistic effect. For 
example, nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids 
lead to additive interactions and the possible PD interaction effect is an 
increased risk of gastric bleeding. PK interactions occur when a drug is able to 
alter the absorption, distribution, metabolism, and elimination (ADME) of 
another drug. An example of a PK interaction at the metabolic level is the 
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antidepressant fluvoxamine, which is a potent cytochrome P450 (CYP) 1A2 
inhibitor. The drug can interact with theophylline, which is a substrate of this 
cytochrome isoform. As a consequence of their coadministration, the 
bioavailability of theophylline will be increased as well as its toxic effects 
(Cascorbi, 2012). 
Drugs, as well as environmental pollutants, food additives and 
insecticides are exogenous substances to the body that are cleared by a series 
of chemical reactions to avoid their accumulation in the organism. Such 
substances are also called xenobiotics. Xenobiotics are defined as chemical 
entities to which an organism is exposed that are extrinsic to the normal 
metabolism of that organism. If xenobiotics are not metabolised, they can reach 
toxic concentrations in the body and thereby cause damage to tissues and 
organs (Croom, 2012). 
Herbal medicines, like any other xenobiotic, are able to cause both PD 
and PK-ADME interactions if coadministered with conventional drugs, causing 
the so-called herb-drug interactions (HDI). PD interactions between Piper 
methysticum (Piperaceae) and the benzodiazepine alprazolam is just one of 
the numerous documented. Following the hospital admission of a  54-year-old 
man in a lethargic and disoriented state after being coadministered Piper 
methysticum and alprazolam, the case report published in 1996 suggested that 
Piper methysticum might have additive effects on benzodiazepines (Almeida 
and Grimsley, 1996). One of the most popular herbal medicines, St. John’s wort 
(SJW) – Hypericum perforatum L. (Hypericaceae) - has been extensively 
studied regarding its absorption and metabolic HDI with several drugs, 
including contraceptives. In this case, the intake of SJW was found to increase 
the expression of intestinal P-glycoprotein (P-gp) and CYP3A4 in the liver, 
therefore potentially interfering with the action of drugs that are also 
metabolised by CYP3A4 (Murphy et al., 2005).  
Many of the documented metabolic HDI cases that were caused by 
traditional, the ones involving SJW were highly relevant in helping scientists to 
identify the experimental targets that identified most of the HDI events that are 
currently known.            
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1.2  EVOLUTION OF HERB-DRUG INTERACTIONS RESEARCH AND 
THE INTRODUCTION OF METABOLIC AND TRANSPORTER 
EXPERIMENTAL TARGETS  
Cases of HDI are well documented in the literature. We conducted a 
search on PubMed database using the keywords “herb-drug interactions”. This 
helps to understand the beginning and the development of this type of research 
over the years.  
The first record of a publication on HDI was in 1967 (Figure 1-1). This 
single work assessed potential interactions between herbal medicines and 
anaesthetic drugs (Pellerano, 1967). Subsequent years were marked by a few 
publications in diverse subjects where HDI were mentioned but were the main 
scope of the research. In 1974, a publication on the interaction between 
cannabinoids and phenytoin (Chesher and Jackson, 1974) triggered more 
interest in the subject. In 1975, two of the four HDI publications were about 
cannabinoids (Hine et al., 1975, Hollister and Gillespie, 1975) and in 1978 the 
single publication found was also about interactions with cannabis  (Singh and 
Das, 1978).  
In 1990, the first work on HDI involving numerous herbal medicines was 
published by a Chinese researcher who evaluated the potential interactions 
between Western antihypertensive drugs and Chinese herbal drugs (Wang, 
1990). From 1990 to 1993 more articles involving drug interactions with various 
herbal medicines were published as review articles (D'Arcy, 1991, D'Arcy, 
1992, D'Arcy, 1993).  
Interactions involving Chinese herbal medicines were again the subject 
of the only article published in 1995 according to our PubMed search (Tam et 
al., 1995). Two years later, in 1997, grapefruit (Citrus paradisi Macfad. - 
Rutaceae) and Ginkgo biloba L. (Ginkgoaceae) were investigated for their 
potential interactions with synthetic drugs (Ameer and Weintraub, 1997, 
Chermat et al., 1997) and in 1998 two more research articles (one again about 
drug interactions with grapefruit) were published (Miller, 1998, Fuhr, 1998).  
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The highest number of publications on HDI from 1967 to 1998 was four,  
with an average of 1.06 articles per year. There was a sharp increase in the 
number of published articles from 1998 (three articles) to 1999 (sixteen 
articles), this is over a 500% increase in one year. The number of publications 
published in subsequent years grew exponentially reaching a peak in 2014 
when 151 articles were published. Interestingly, a sharp drop can be observed 
in 2015 and during this search (August 2016), the number of published articles 
on HDI was almost three times less as compared to 2014.   
In addition to the number of articles, it is also possible to observe an 
evolution of the type of HDI reports. Prior to 1999 most articles focused on 
single herbs, such as SJW. In the year 2000, about 35% of the total of 
publications on HDI were based exclusively on SJW interactions (Ingram et al., 
2000, Mehta, 2000, Baede-van Dijk et al., 2000, McIntyre, 2000, Roots, 2000, 
Jordan, 2013). During the 00’s decade, SJW was the main subject of many HDI 
studies, mostly due to the publication of case reports involving the herbal 
medicine. For example, a case report published in 1999 showed that 
consumption of SJW together with other prescription antidepressants was able 
Figure 1- 1 Number of publications per year using the keyword “herb-drug interactions” on PubMed. 
Data was collected on 15 August 2016. 
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to cause severe ADRs due to HDI, particularly in elderly people (Lantz et al., 
1999). However, it was not clear how SJW could be causing such effects.     
The first attempt to elucidate one of the possible interaction mechanisms 
of SJW was published in 2000, suggesting that the herbal medicine was able 
to induce CYP3A4 and consequently reduce the efficacy of certain drugs such 
as oral contraceptives (Roby et al., 2000). This was the starting point of the 
increased number of research articles evaluating how SJW could potentially 
cause interactions with various synthetic drugs, as most of them were known 
to be metabolised mainly by CYP3A4.  
In addition to CYP3A4, other phase I metabolising enzymes such as the 
CYP isoforms CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP2E1 were 
becoming the subject of metabolic studies involving herbal medicines. The 
effects of SJW on P-gp and phase II metabolic enzymes, such as glutathione-
S-transferase (GST) started to be also investigated. Herbal medicines have 
increasingly become the subject of metabolic and transporter studies using 
similar molecular targets as the ones used for synthetic drugs but with only one 
difference: such studies are not a regulatory requirement to market traditional 
herbal medicines in many countries (Tsay et al., 2016).  
1.3 DRUG METABOLISM AND TRANSPORT: GENERAL 
CONSIDERATIONS 
Biotransformation is a process whereby a drug undergoes a series of 
processes for its conversion into metabolites with lower affinity characteristics. 
This system involves numerous mechanisms and enzymes that are 
ubiquitously present in the body (Ionescu and Caira, 2005). Some less lipid-
soluble drugs can be cleared from the body unchanged, i.e. without being 
directly affected by phase I and phase II metabolism. However, other drugs 
remain in the body and their effects can still be felt for a long time (Baxter and 
Stockley, 2008).   
Drug metabolism is normally divided into two phases: phase I 
metabolism (functionalisation reactions), which results in metabolites with 
higher polarity (usually inactive) and phase II metabolism (conjugative 
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reactions), which results in the phase I metabolites becoming even more polar 
(Figure 1-2). Phase I reactions prepare the drug for phase II metabolism by 
adding polar functional groups to the xenobiotic (Ionescu and Caira, 2005).  
 
 
 
 
 
 
 
 
 
1.3.1 Phase I metabolism: cytochrome P450 
Human drug-metabolising enzymes are present ubiquitously in the body. 
CYP450 is a family of enzymes responsible for the metabolism of various drugs. 
Over 50 human CYPs have already been isolated; the major ones found in the 
liver include CYP1A2, CYP2C9/19, CYP2D6 CYP2E1, and CYP3A4/5/7 
(Figure 1-3) (Gibson and Skett, 2001). The whole CYP family is responsible for 
metabolising about 90% of commonly used drugs. The CYP 1, 2, and 3 families 
are the most abundant families of CYP metabolising enzymes and the CYP1A2, 
CYP2C, and CYP3A4 isoforms account for the metabolism of the majority of 
prescription drugs (Atkinson, 2012). Among the main isoforms, most of the 
currently marketed medicines share drug metabolism with CYP3A4, resulting 
in severe drug interactions (Ogu and Maxa, 2000). 
The CYP monooxygenase enzymes are located in the smooth 
endoplasmic reticulum of the liver and other extrahepatic tissues. While most 
of the CYPs are located in the liver, extrahepatic metabolism also takes place 
in the kidneys, skin, gastrointestinal tract, and lungs for example. Numerous 
drugs are metabolised by CYP enzymes through oxidation reactions such as 
Figure 1- 2 Scheme of sequential drug metabolism 
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aromatic and aliphatic hydroxylation, N-dealkylation, O-dealkylation, 
deamination, oxidation and sulphoxidation (Figure 1-4). Reduction, hydrolysis, 
and hydration are other examples of phase I reactions catalysed by the CYP 
(Ionescu and Caira, 2005). The product of these functional chemical reactions 
are compounds with chemically reactive functional groups that will be further 
targeted by phase II enzymes. 
 
 
 
 
 
 
 
 
  
Figure 1- 3 Human liver CYPs represented by circles whose size and percentage approximate to their level 
of expression in human liver. 
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Figure 1- 4 Common reactions catalysed by CYP enzymes. 
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1.3.1.1 Main CYP isoforms   
1.3.1.1.1 CYP1A2 
This CYP isoform is mainly found in the liver (15%) and it metabolises 
almost 20% of the current therapeutic arsenal (Wang and Zhou, 2009). 
Examples of synthetic drugs, which are substrates for the CYP1A2, include the 
highly popular painkiller acetaminophen, the beta-blocker propranolol, the 
antidepressant clomipramine and the anticoagulant warfarin. 
1.3.1.1.2 CYP2C9 
CYP2C9 is the major CYP2C isoform found in the human liver (Mo et 
al., 2009) and it metabolises approximately 15% of clinical drugs, including the 
nonsteroidal anti-inflammatory (NSAID) ibuprofen, the antihypertensive 
losartan, the antidepressant fluoxetine, the antiepileptic phenytoin, and the anti-
hypercholesteraemic fluvastatin (Baxter and Stockley, 2008, Berka et al., 
2011). Certain endogenous bioactive substances such as steroids, melatonin, 
retinoids, and arachidonic acid are also metabolised by this CYP isoform (Mo 
et al., 2009). 
1.3.1.1.3 CYP2C19 
CYP2C19 is not only involved in the metabolism of a range of drugs but 
it also plays a crucial role in the detoxification and inactivation of some potential 
carcinogens (Wang et al., 2013). CYP2C19 is responsible for the metabolism 
of about 10% of prescribed drugs, including the proton pump inhibitor 
omeprazole, the tricyclic antidepressant amitriptyline, the selective serotonin 
reuptake inhibitor fluoxetine, the benzodiazepine diazepam, and the barbiturate 
phenobarbital (Zhou et al., 2009). 
1.3.1.1.4 CYP2D6 
Although the level of expression of CYP2D6 in the human liver is only 
about 5%, this CYP isoform metabolises about 25% of all medications in the 
human liver (Ionescu and Caira, 2005). The beta-blockers propafenone and 
timolol, the antidepressant amitriptyline, the antipsychotics haloperidol and 
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risperidone, and the antihistamine chlorphenamine are examples of drugs that 
are metabolised by this CYP isoform (Zhou et al., 2009). 
1.3.1.1.5 CYP2E1 
CYP2E1 represents 10% of the total CYPs expressed in the human liver 
and it is well known for its involvement in the metabolism of ethanol to 
acetaldehyde, and accordingly it is rapidly induced after ethanol ingestion 
(Anzenbacher and Anzenbacherova, 2001). This CYP isoform is responsible 
for the activation of some carcinogens, procarcinogens, and toxicants and it 
metabolises mainly low-molecular-weight compounds. CYP2E1 also has the 
ability to produce reactive intermediates, leading to the formation of free 
radicals such as superoxide, hydroxyl radical, and lipid peroxides (Neafsey et 
al., 2009). Acetaminophen and the anaesthetic halothane are examples of 
CYP2E1 substrates (Tateishi et al., 1998, Wolf et al., 2007).  
1.3.1.1.6 CYP3A 
The most abundant subfamily of CYPs is CYP3A. It represents about 
30% of the entire CYP450 enzymes in the liver and it is responsible for the 
biotransformation of more than 50% of therapeutic drugs. CYP3A’s main 
isoforms found in the body are 3A4, 3A5, and 3A7. CYP3A5 is more often 
detected in adolescents than in adults, where it is hardly inducible. CYP3A4 is 
mostly glucocorticoid-inducible and CYP3A7 (found only in fetal livers) has a 
role in the hydroxylation of allylic and benzylic carbon atoms (Ionescu and 
Caira, 2005). Macrolide antibiotics, antiarrhythmics, benzodiazepines, immune 
modulators, HIV antivirals, antihistamines, calcium channel blockers, and 
HMG-CoA reductase inhibitors are examples of classes of medications 
metabilised by the CYP3A subfamily (Zhou et al., 2009). The probability of HDI 
with this isoform is high and therefore a particular attention to all CYP3A 
substrates should be given in order to avoid such interactions.  
1.3.2 Phase II metabolism (conjugation reactions) 
Phase II metabolism reactions (or conjugation reactions) occur when 
metabolic enzymes react with functional groups of a drug that were formed 
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during the phase I process. Endogenous species, such as a sugar or an amino 
acid, are added to the drug in order to increase the polarity to allow its 
elimination. The two main phase II biotransformation reactions are glutathione 
(GSH) conjugation and glucuronidation. However, the other conjugative 
reactions such as sulphation, methylation, and acetylation are also relevant 
(Atkinson, 2012). The main metabolising enzymes involved in phase II 
metabolism are listed in table 1-1.  
Table 1- 1 The main phase II metabolic mechanisms and respective enzymes. 
 
 
1.3.3 Types of phase II reactions 
1.3.3.1 Glucuronidation 
Glucuronidation is a mechanism in which a glucuronide is formed by the 
reaction between the electrophilic C-1 atom of the pyranose acid ring of the co-
factor UDPGA (uridine 5’-diphosphate-glucuronic acid) and the substrate 
catalysed by UGTs. UGTs are the most important phase II enzymes, and out 
of all the conjugation enzymes in the liver, they constitute the highest amount 
(35%) (Ionescu and Caira, 2005, Caira and Ionescu, 2006). The enzyme can 
be found in the kidneys, small intestine, lung, skin, adrenals, and spleen. This 
is the most important form of conjugation of xenobiotics with chemical groups 
such as alcohols, phenols, hydroxylamines, carboxylic acids (Figure 1-5), 
amines, sulphonamides, and thiols  (Gibson and Skett, 2001).  
UGTs exists in multiple isoforms (1A1, 1A3, 1A4, 1A6, 2B4, 2B7, 2B10, 
2B11, and 2B15) and they are able to metabolise a wide range of compounds, 
hence providing the liver with the extensive capacity to glucuronidate numerous 
endogenous and xenobiotic compounds. An example of this process is: 
Phase II mechanism Enzyme involved 
Glucuronidation UDP-glucuronosyltransferase (UGT) 
Glutathione (GSH) conjugation Glutathione-S-transferase (GST) 
Sulphation Sulphotransferases (SULT) 
Methylation Methyltransferases 
Acetylation CoA-S-acetyltransferase 
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UGT2B7, which catalyses the glucuronidation of opioids, and UGT1A6 and 
UGT1A1, which target primary amines and bilirubin respectively (Gibson and 
Skett, 2001). 
 
 
 
 
1.3.3.2 GSH conjugation 
GSH is a tripeptide present in high concentrations in the liver.  It has a 
protective role, removing toxic electrophilic compounds from the body (Ionescu 
and Caira, 2005). Conjugation with GSH is catalysed by GSTs, which are a 
family of enzymes (Alpha, Mu, Pi, Sigma, Theta, Zeta, Omega, and Kappa.) 
distributed in the body and especially in the liver cytosol (Figure 1-6). GSTs 
avoid the reaction of electrophilic compounds to nucleophilic ones in 
macromolecules such as proteins and nucleic acids. When the conjugate is 
formed, it has to undergo further metabolic reactions until the final product is 
eliminated from the organism in the form of mercapturic acid (Sies and Ketterer, 
1988).  
 
  
 
 
1.3.3.3 Sulphation, methylation, and acetylation 
In addition to the two main liver conjugation reactions (GSH conjugation 
and glucuronidation), the xenobiotic transformation can also happen by 
sulphation (or sulphate conjugation), methylation (or methyl conjugation) and 
acetylation (Ionescu and Caira, 2005).  
 Sulphation is another phase II detoxification mechanism that is 
recognised as the major conjugation pathway for phenols, alcohols, amines and 
Figure 1- 5 Conjugation of a glucuronic acid (GLU) to a carboxylic acid group. 
Figure 1- 6 Conjugation of glutathione (GSH) catalysed by the enzyme glutathione-S-
transferase. 
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thiols (Ionescu and Caira, 2005). Before the phase I metabolites undergo 
sulphate conjugation, the inorganic sulphate has to be activated via ATP to form 
adenosine-5’-phosphosulphate (APS) and consequently 3’-
phosphoadenosine-5’-phosphosulphate (PAPS). SULTs will then catalyse the 
detoxification of essential drugs, such as salbutamol and acetaminophen by 
transferring a sulphuryl group from PAPS to an acceptor molecule (Gibson and 
Skett, 2001).  
Methylation is the mainly metabolic pathway for endogenous 
compounds, but it can also be the route for many drugs and xenobiotics in 
general (Weinshilboum, 1988). Methyl conjugate reactions are only possible in 
the presence of the cofactor S-adenosylmethionine (SAM) and will result in the 
formation of O-methylated, N-methylated, and S-methylated products (Gibson 
and Skett, 2001).  
The liver is the primary site for acetylation reactions, but the reaction can 
also happen in some extra hepatic sites, such as the spleen, lungs, and gut. To 
summarise, the N-acetyltransferases will catalyse the transferring of the co-
factor acetyl-coenzyme A (acetyl-CoA) to aromatic amines and sulphonamides 
and form the polar metabolites (Ionescu and Caira, 2005).  
1.3.4 The drug transporter P-glycoprotein 
Drug-transporter proteins are known to allow xenobiotics to cross 
biological membranes, the most well-known one being P-gp. P-gp was first 
discovered in 1986 as a product of the multi-drug resistance gene (MDRI) in 
cancer cells, therefore reducing the intracellular accumulation of drugs 
(Watanabe et al., 2012). 
 This protein plays a role as an efflux pump, it pushes metabolites and 
drugs out of the cells which can result in absorption alterations (Williamson et 
al., 2009). P-gp contains two ATP-binding sites, where ATP will bind in 
presence of a P-gp substrate. As a consequence, ATPase is activated in order 
to hydrolyse ATP. The energy produced by the ATP hydrolysis will allow the P-
gp to transport numerous substrates across cellular membranes (Watanabe et 
al., 2012). In the intestine, P-gp can be found on the apical surface of epithelial 
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cells. When a drug is taken up by an enterocyte, the substance can be either 
metabolised by CYP3A4 or pumped back into the lumen (Butterweck and 
Derendorf, 2008). Hence, oral delivery can be compromised (Butterweck et al., 
2004). 
1.4 INDUCTION AND INHIBITION OF DRUG METABOLISING ENZYMES 
1.4.1 Induction of drug metabolising enzymes 
As previously stated in section 1.2, studies on SJW demonstrate how 
the herbal medicine can act as a potent CYP3A4 inducer. As a consequence, 
drugs like oral contraceptives, which are metabolised by the same enzyme, will 
have their pharmacological effects altered. The increased metabolism of the 
drug due to high CYP3A4 activity will lead to a decreased blood concentration 
of the oral contraceptive and low pharmacological activity (Murphy et al., 2005). 
Consumption of metabolic enzyme inducers like SJW will, therefore, increase 
the chances of inefficacy of the coadministered drug in usual therapeutic doses 
due to HDI (Tarirai et al., 2010). 
Another example of metabolic HDI involving CYP was published as a 
case report in 2015. The authors showed that the intake of noni juice, which is 
an herbal remedy made from the fruit of Morinda citrifolia L. (Rubiaceae), is 
able to induce CYP2C9 and interact with the anti-epileptic drug phenytoin by 
decreasing its bioavailability in a 49-year-old man (Kang et al., 2015). 
The main types of drug induction are substrate-dependant induction, 
receptor-mediated and inhibitor-mediated interaction. Substrate-dependant 
induction is where the herbal drug influences the metabolism and duration of 
action of numerous other drugs. Receptor-mediated is characterized by 
interactions with important regulator pathways, which is the case of the human 
nuclear pregnane X (hPXR) and the constitutive androstane (CAR) receptors. 
These are well known also as xenobiotic sensors, which are activated by 
numerous compounds leading to the activation of their downstream target 
genes (Xie, 2009). 
The binding of xenobiotics to the receptor directly affects the clearance 
of those compounds, and consequently, protects the body from foreign 
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chemicals. Many drug metabolising enzymes involved in the metabolism of 
endogenous cellular regulators (steroids, eicosanoids) can be induced by 
hormones. For example, the growth hormone has been also proven to alter 
CYP expression (Mode et al., 1992, Cheung et al., 2006). 
Inhibitor-mediated interaction involves a stabilisation mechanism, i.e. 
the drug decreases the degradation of CYP and therefore the concentration of 
the enzyme is increased (Watkins et al., 1986). 
Phase II metabolising enzymes such as UGTs and GSTs can also be 
inducible. Induction of UGTs is highly dependent on the nature of the inducer. 
Ethanol and phenobarbital are able to induce UGTs, as well as the endogenous 
compound bilirubin (Soars et al., 2004, Hiroshi and Shigeko Shinkai and 
Takaharu, 2008). GSTs can also be induced by phenobarbital and other 
xenobiotics such as dithiolethiones (Zhang and Munday, 2008, Sasaki et al., 
1989).    
1.4.2 Inhibition of drug metabolising enzymes     
In contrast to the effects observed in the induction of drug metabolic 
enzymes, inhibition delays xenobiotic biotransformation resulting in a higher 
concentration of the compound in the bloodstream. The consequence of such 
inhibition is the increased adverse reactions due to exacerbated 
pharmacological and toxicological effects (Kobayashi et al., 2002). 
An inhibitor is a substance that interferes with the action of the enzyme, 
which will slow down the speed of the reaction. A reversible inhibitor will bind 
to an enzyme and will subsequently be released, whereas an irreversible 
inhibitor reacts with the enzyme producing a protein that will not be 
enzymatically active anymore and the original enzyme cannot be regenerated 
(Ring et al., 2014). 
The two main types of CYP inhibition are called competitive and non-
competitive inhibition. The former happens when an inhibitor competes with the 
substrate to bind to the active site of the enzyme. In this case, the inhibitor will 
block the access of the substrate to the enzyme. On the other hand, in the case 
of a non-competitive inhibition, both substrate and inhibitor will bind to different 
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sites of the enzyme. However, the enzyme cannot catalyse the reaction in as 
an efficient manner as it can in the absence of the inhibitor (Campbell and 
Farrell, 2012). Drugs like indinavir and saquinavir are competitive inhibitors, 
whereas ketoconazole and fluconazole can act as non-competitive inhibitors of 
CYP3A (Thummel and Wilkinson, 1998). 
Like phase I enzymes, phase II enzymes can also display inhibitory 
activity. A study recently performed by Liu and coworkers (2016) demonstrated 
that UGT isoforms can be inhibited by vitamin A (Liu et al., 2016), whereas 
Chang and coworkers (1998) showed that oestrogens are able to inhibit GSTs 
(Chang et al., 1998).  
1.5 FACTORS THAT INFLUENCE DRUG BIOTRANSFORMATION 
In addition to the induction and inhibition of drug metabolising enzymes, several 
factors can contribute to the variability in biotransformation. They include: 
• Genetic polymorphism 
• Disease 
• Age 
• Sex 
• Environmental factors 
1.5.1 Genetic Polymorphism 
Responses to drug consumption differ between individuals due to the 
variability of CYP content. A predefined dosage of a medicine might be enough 
to exert a pharmacological effect in one patient while needing to be adjusted to 
achieve the same effect in another patient. This can be explained by genetic 
polymorphisms within CYPs that can affect the metabolism of xenobiotics in 
general, leading to changes in drug responses and increased risk of ADRs 
(Zhou et al., 2009). For example, the bioavailability of omeprazole, which is a 
drug that is metabolised by both CYP3A4 and CYP2C19, has been 
demonstrated to be slower in Mexicans when compared with Caucasians but 
faster than that of Asians. The ethnic mixture of the Mexican population is a 
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plausible explanation for differences in the metabolic response compared to 
other ethnic groups (Gonzalez et al., 2003).  
The genomic diversity of the Brazilian population is a result of the genetic 
admixture of three groups: Europeans, Africans, and Amerindians. Due to this 
very distinctive miscegenation, polymorphisms in CYP levels are undoubtedly 
present among Brazilians (Suarez-Kurtz, 2005). The Brazilian National 
Pharmacogenetics/Pharmacogenomics Network (REFARGEN) carried out 
studies in four regions of Brazil in order to map the genetic diversity of the 
population (Suarez-Kurtz, 2004). The study divided the population into three 
distinct races: white (mainly of Europeans ascendancy), brown (indigenous 
population) and black (mainly of African descent). The results obtained from 
REFARGEN showed that numerous polymorphisms were found on 
cytochromes 1A2, 2C9, 2C19, 2D6, and 3A5 (Figure 1-7). 
Although the REFARGEN study attempted to map the genetic 
polymorphisms among the admixture races in Brazil we cannot affirm that there 
will be a correlation between the genetic polymorphisms observed in a group 
of brown Brazilian living in the north to brown Brazilians living in the south of 
the country for example.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1- 7 Genetic polymorphisms found on CYP1A2, 2C9, 2C19, 2D6, and 3A5 among 
the Brazilian population   
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1.5.2 Disease 
Diseases affecting the liver, such as cirrhosis, alcoholic liver disease, 
cholestatic jaundice, and liver carcinoma can alter organ function, and 
consequently, reduce the capacity of the body to clear drugs. Drug metabolism 
can also be affected by endocrine disorders such as diabetes mellitus, hypo-
and hyperthyroidism, pituitary disorders and bacterial and viral infections in 
general. For example, in the case of a hepatic cirrhosis, the CYP2A6 can be 
overexpressed. This isoform catalyses the bioactivation of many drugs and also 
carcinogens. Therefore, CYP2A6 is a major liver catalyst in pathological 
conditions (Ionescu and Caira, 2005).  
Malaria, which is one of the most common tropical diseases, can also 
affect the enzymes involved in the biotransformation of drugs. An impairment 
of microsomal drug metabolising activities as a result of the malaria infection 
reduces the oxidation of drugs by decreasing hepatic CYP activity (Mansor et 
al., 1991). 
1.5.3 Age 
Biotransformation contrasts can be found between newborns, the young 
and elderly due to the types and the amount of enzymes that are activated and 
expressed among those groups. Newborns are more sensitive to drug reactions 
because of the low level of development of their metabolising capacity. The 
sensitiveness of newborns lowers significantly over time until they reach 
adulthood when normal levels of enzyme activity are reached. In the elderly 
population, the biotransformation capacity may be reduced up to 30% due to 
several reasons. Reasons include decreased hepatic blood flow and mass, 
decreased absorption surface and gastrointestinal mobility and increased 
gastric pH (Klotz, 2009). 
1.5.4 Sex 
Sex is another factor that contributes to differences in the expression of 
drug metabolising enzymes. Initial findings on this subject were made in the 
1930s when researchers treated rats with barbiture and observed that the 
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female ones required only half the dose to induce sleep compared to male rats 
(Gibson and Skett, 1986). 
Another study discovered that the growth hormone may be the main 
hormonal factor that dictates the differences in the expression of CYPs and 
other drug metabolising enzymes between males and females (Waxman and 
Holloway, 2009). 
1.5.5 Environmental factors 
Heavy metals, industrial pollutants, pesticides and other chemical 
substances that are spread out in the air can potentially alter the activity of CYP 
enzymes in liver microsomes (Gillette, 1976). The activity of some drug 
metabolising enzymes may be induced if the individual is exposed to 
exogenous chemicals, including environmental pollutants. For example, most 
industrial pollutants are typically aromatic or aromatic polycyclic compounds 
and polychlorinated biophenols, which are known to cause inductive enzyme 
effects in various CYP isoforms (O'Mahony and Woodhouse, 1994, Kietz and 
Fischer, 2003).  
1.6 HERB-DRUG INTERACTIONS AND ADVERSE REACTIONS 
As previously discussed in section 1.2, reports on HDI are dated back to 
1967 and since then over 1,500 articles have been published according to 
PubMed. The documented interactions involve well-known herbs from 
Traditional Chinese Medicine (TCM), Ayurveda and many other traditional 
herbal medicines commonly used by the population of many countries and their 
biotransformation involves many metabolic and transporter mechanisms.   
1.6.1 Herb-drug interactions involving cytochrome P450 
In section 1.3.1 we showed that the CYP family is responsible for the 
metabolism of most xenobiotics. Among the various CYP isoforms, CYP1A2, 
2C9, 2C19, 2D6, 2E1, and 3A(4/5/7) are the most relevant ones because 
altogether they are responsible for the biotransformation of the majority of the 
currently marketed drugs (Mazzari and Prieto, 2014a).  
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Due to the increased popularity of SJW as an antidepressant, numerous 
interactions with CYP3A4 have been detected in vitro and in vivo, the 
interaction with oral contraceptives being one of the most remarkable cases of 
HDI (Murphy et al., 2005). As the interaction with CYP3A4 became more 
evident among researchers, the effects of SJW in other metabolic targets, such 
as CYP1A2, 2C9, 2C19, 2D6, 2E1 were also assessed. The numerous 
publications alerting to the potential interactions of SJW involving CYPs due to 
enzyme induction and/or inhibition made it possible to discuss the potential 
effects that other herbal medicines could cause on drug metabolising enzymes.  
Besides SJW, popular herbal medicines such as Ginkgo biloba L. and 
milk thistle (Silybum marianum (L.) Gaertn. - Compositae) have been 
extensively studied over the past years in order to reveal their potential to cause 
HDI due to their effects on CYP activity and/or expression. Published studies 
showed that Ginkgo biloba and milk thistle are able to modulate the effect of 
the main CYP isoforms due to the inducible and/or inhibitory effects of their 
constituents (von Moltke et al., 2004, Venkataramanan et al., 2000). 
A study published by Sugiyama and coworkers (2004) showed that 
simultaneous administration of Ginkgo biloba extract with the oral anti-diabetic 
tolbutamide potentiated the hypoglycaemic action of this drug in rats. 
Tolbutamine is metabolised by CYP2C9 and the inhibitory effect caused by the 
Ginkgo biloba extract increased both the plasma concentrations and the 
bioavailability of the drug. Hence, blood glucose levels dramatically dropped in 
rats treated with the drugs (Sugiyama et al., 2004). 
Silybin, a constituent of milk thistle, show inhibitory effects on CYP2D6, 
2E1, and 3A4 (Zuber et al., 2002). The ginsenosides Rb1, Rb2, Rc, Rd, Re, Rf, 
and Rg1 from Panax ginseng C.A.Mey. (Araliaceae) display inductive and 
inhibitory effects on CYP 1A2, 2C9, 2C19, 2D6, and 3A4 (Henderson et al., 
1999). A drug interaction study demonstrated that silymarin (140mg) given 
three times a day inhibited hepatic clearance of losartan, which is a drug used 
to treat high blood pressure, in Chinese subjects. The active metabolite of 
losartan (E-3174) is formed by CYP2C9. Due to the inhibition of the enzyme 
caused by the milk thistle constituent silymarin, the amount of E-3174 found in 
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the subjects treated also with the herbal medicine decreased compared to the 
control group (Brantley et al., 2014).     
A plethora of data on HDI involving CYP has been published 
demonstrating that herbal medicines are able to affect CYP and therefore their 
consumption should be avoided with a synthetic drug. Nonetheless, evaluation 
of this subject is very controversial. The fact that most of the published research 
on HDI is either in vitro, performed in animal models and done with fractions 
(not whole herbs) at non-physiological concentrations, explains why most of the 
‘theoretical’ HDI have never been clinically observed. Preclinical data is very 
important because it serves as a guide for clinical studies. Therefore, it is 
important that such studies are fully performed and are not abandoned in their 
initial or middle stages, which has been the case in much research on herbal 
medicines that has never reached the clinical trials stage of development 
(Brantley et al., 2014).  
1.6.2 Herb-drug interactions involving phase II metabolising enzymes 
Glucuronidation is a major route of phase II xenobiotic biotransformation 
and elimination in the body. Classes of drugs such as narcotic analgesics, 
anxiolytics, and NSAIDs are examples of therapeutic agents metabolised via 
glucuronidation mechanism. Due to the high number of exogenous compounds 
that are metabolised through this route, the characterisation of the effects of 
herbal medicines on the activity of UGTs is very important to reveal potential 
HDI (Ionescu and Caira, 2005). 
In vitro studies demonstrated that valerian extract (Valeriana officinalis 
L. - Caprifoliaceae) - used at clinical dosages are able to produce significant 
reductions in the glucuronidation of conventional drugs like acetaminophen and 
morphine, possibly caused by the inhibition of several UGTs such as 
UGT1A6/9, UGT1A1, and UGT2B7 (Alkharfy and Frye, 2007). 
Echinacea, ginkgo, milk thistle, soy, and SJW are other extracts that 
have been assessed for their effects on UGT in vitro. The extracts display 
inhibitory effects on UGT1A1, UGT 1A9, and UGT2B15. Constituents of several 
herbal medicines, such as silymarin and silybin (milk thistle), genistein (soy), 
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hypericin (SJW) and valerianic acid (valerian) are also able to modulate 
glucuronidation due to the inhibition and/or induction of various UGTs isoforms 
(Mohamed and Frye, 2011). 
GSH conjugation is also affected by xenobiotics due to the modulatory 
effects on GSTs. A study conducted by Yang and coworkers (2003) showed 
that Ginkgo biloba extract down-regulates the GST activity in microsomes from 
rat kidney (Yang et al., 2003). Lower GST activity can lead to potential adverse 
reactions caused by toxic metabolites that are detoxified by conjugation with 
GSH such as N-acetyl-p-benzoquinoneimine (NAPQI) (Henderson et al., 2000). 
GSH conjugation is the detoxification mechanism that various drugs undergo, 
including anticancer agents. Even though elevated levels of GSH are 
considered positive due to its strong antioxidant effects in the cells, the high 
activity of GSTs can weaken the effectiveness of certain anticancer drugs. GST 
P1-1, for example, is particularly induced in certain types of cancer, such as 
lung, colon, and stomach cancers. Because of its increased activity, the GST 
P1-1 enzyme is implicated in cellular resistance to chemotherapeutic agents 
(Ramsay and Dilda, 2014). 
Many other HDI involving phase II metabolising enzymes have been 
reported in the literature. As some conjugation mechanisms are the major 
detoxifying route of several important classes of drugs, such as the anticancer 
agents, more interaction studies (especially clinical studies) need to be carried 
out on herbal medicines that could potentially affect phase II enzymes and 
reactions.   
1.6.3 Herb-drug interactions involving P-glycoprotein 
Modulation of drug transporters like P-gp by herbal medicines has been 
the target of a plethora of studies. Due to its high expression and activity in 
several tissues (kidney, liver, intestine, and blood-brain barrier (BBB)), which 
are pharmacologically important epithelial barriers, the bioavailability of the 
drug could be compromised if P-gp activity is affected (Li et al., 2014). 
Inhibition or induction of P-gp activity results in altered absorption and 
bioavailability of P-gp substrates (Zhou et al., 2004). Studies have shown that 
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polyphenols from green tea (Camellia sinensis (L.) Kuntze – Theaceae) are 
able to inhibit P-gp activity, which is bolstered by the intracellular accumulation 
of the P-gp substrate rhodamine 123 (Rh-123) in Caco-2 cells (Jodoin et al., 
2002).  
SJW displays inductive effects in P-gp efflux activity. Chronic treatment 
with SJW increases the P-gp efflux in healthy subjects, which can also be 
observed in vitro by a reduced intracellular accumulation of the P-gp substrate 
Rh-123 (Hennessy et al., 2002). This inductive effect on P-gp has been 
demonstrated to attenuate the efficacy of the potent P-gp inhibitor drug 
ritonavir, which potentially leads to treatment failure (Drewe et al., 1999). 
Ezuruike and Prieto (2014) showed that some herbal medicines used in 
Nigeria for diabetes management can cause HDI at P-gp level. This is the case 
of the coadministration of medicinal plants such as Acacia nilotica (L.) Delile 
(Leguminosae), Annona senegalensis Pers. (Annonaceae), Bauhinia thonningii 
Schum. (Leguminosae), Bridelia ferruginea Benth. (Phyllanthaceae), Carica 
papaya L. (Caricaceae) and Morinda lucida Benth. (Rubiaceae) with the 
antidiabetic drug glibenclamide. According to the authors, the herbal medicines 
which exhibit inhibitory effects on P-gp and their concomitant use with 
glibenclamide increases the plasma concentration of the synthetic drug 
(Ezuruike and Prieto, 2014). 
Some examples of potential HDI previously mentioned involving 
metabolising enzymes and P-gp were conducted using in vitro and in vivo 
models in order to either predict or attest an interaction that has been already 
reported by other researchers. However, HDI of the most of the marketed 
herbal medicines have not been evaluated using the usual methods of clinical 
pharmacology, that is, preclinical metabolic studies have not been conducted 
(Skalli and Soulaymani Bencheikh, 2012). Therefore, pharmacovigilance plays 
a very important role in the detection of HDI. Unfortunately, in many cases, an 
alert about possible HDI is only made after a reported case of death believed 
to be due to treatment failure or increased toxicity of a synthetic drug.    
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1.7 PHARMACOVIGILANCE OF HERBAL MEDICINES  
The pharmacological and PK metabolic knowledge on herbal drugs 
accumulated over the last decades (summarised in the previous sections) 
prompted WHO to make an alert as to the potential risks of uncontrolled use of 
herbal medicines in conjunction with other synthetic drugs. In 2004, WHO 
issued the “Guidelines on safety monitoring of herbal medicines in 
pharmacovigilance systems”. These guidelines indicate how member countries 
should include herbal medicines within existent pharmacovigilance systems in 
order to facilitate the exchange of information on adverse reactions and HDI 
between WHO member countries (WHO, 2004).  
The WHO traditional medicine strategy, which was published by WHO 
in 2013, showed that the regulatory status of herbal medicines is quite diverse 
among WHO member countries. A medicinal plant can be registered as a food, 
a functional food, a dietary supplement, a traditional medicine, or a full licensed 
herbal medicine depending on the country’s own needs, cultural background, 
history of use of medicines, and regulations. This can potentially cause 
difficulties to pharmacovigilance systems in collecting HDI data, as for example 
a food interaction would be practically ignored and hardly detected by health 
professionals (WHO, 2013, SUS, 2006).    
In addition to the differences in the regulatory status of herbal medicines 
between many countries, other challenges can be highlighted in terms of 
pharmacovigilance of herbal medicines. The presence of numerous active 
compounds in herbal extracts, the low standardisation of herbal products, the 
problems with the nomenclature of herbs and the many sources of the herbal 
medicines used by the patients are also examples that make the detection of 
HDI by health professionals more difficult. As a consequence, HDI are likely to 
be underreported to the pharmacovigilance systems (Shaw et al., 2012). 
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1.8 USE OF HERBAL MEDICINES IN BRAZIL AND THE RISK OF HERB-
DRUG INTERACTIONS ON PATIENTS OF THE PUBLIC HEALTH 
SYSTEM (SUS) 
Brazil is the most biodiverse country on the planet and a valuable 
traditional knowledge associated with the use of medicinal plants. The total 
biodiversity of the country corresponds to between 15 and 20% of the plant 
species that are found in the world, which also encompasses medicinal plants. 
Although the country has about 60,000 catalogued plant species, only 8% have 
been studied for their bioactive compounds and 1,100 have been assessed for 
their medicinal properties (Dutra et al., 2016). The vast genetic heritage found 
in the country gives to Brazil the opportunity to be a leading country in natural 
products research that could potentially benefit millions of people who still have 
no access to costly treatments with synthetic drugs and are affected by 
neglected tropical conditions, such as dengue fever, chikungunya and the most 
recent threat, the zika fever (SUS, 2006).  
Agriculture in Brazil is the main source of income for millions of families in 
the country. Over the years, the Brazilian government has made expressive 
investments in this field in order to develop this government sector and to 
improve the research into the cultivation of plants (especially medicinal plants) 
(SUS, 2006).  
Therefore, Ministry of Agriculture and Ministry of Health have stimulated 
the development of the medicinal plants field in Brazil. They aim to integrate 
the traditional knowledge of both cultivation and medicinal use of Brazil’s 
biodiversity in order to offer alternative treatments to the entire population of 
the country by increasing the availability of herbal medicines in the Brazilian 
Unified Health System (SUS) (SUS, 2006).      
The SUS was created by the Brazilian Federal Constitution of 1988. 
According to the document, SUS has to guarantee full and free access to 
various health procedures and treatments for the entire population of Brazil. 
Currently, 180 million people rely exclusively on the health services provided 
by SUS. All medications available at SUS have been put together in a list of 
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essential medicines called RENAME. The list was created in 1975, before the 
creation of the SUS, and is based on the WHO recommendations to the 
member countries to develop a list of medicines aimed to attend to the health 
needs of the population. Since then the list has been revised and updated 
according to newly available treatments for the patients of SUS. At the moment, 
RENAME contains 440 drugs that are prescribed to treat most of the conditions 
that affect the Brazilian population (Brasil, 2014). 
Between 2013 and 2015, the search for treatments using herbal 
medicines in SUS grew 161% and over the last 3 years at least 6,000 Brazilians 
went to local pharmacies seeking the use herbal drugs (Brasil, 2016). Currently, 
only 12 herbal medicines are listed in RENAME, therefore limiting the 
prescription of those drugs to the patients of SUS (Figueiredo et al., 2014). 
In 2008, the Ministry of Health of Brazil issued a list of medicinal plants of 
interest of SUS (RENISUS). This list contains medicinal plants that have the 
potential to generate products for SUS (Table 1-2). As part of the selection 
process of the medicinal plants for the list, the Ministry of Health coordinated 
regular meetings with Brazilian researchers, representatives of the Brazilian 
Pharmacopoeia (BP) and the National Health Surveillance Agency (ANVISA). 
The work started in 2005 with a list of 237 plant species. The preliminary list 
considered plant species that were already in use in health services of the 
states and municipalities, the traditional and popular knowledge, the available 
chemical and pharmacological studies, and other plants that were in use by 
other health programs already established throughout the country. After several 
meetings, RENISUS was created containing various medicinal plant species 
that, eventually, should be available for the patients of SUS as part of RENAME 
(Brasil, 2009).  
Some of RENISUS species are widely used worldwide, for example 
Cynara scolymus L. (Compositae), Allium sativum L. (Amaryllidaceae) and 
Uncaria tomentosa (Wild. Ex Schult.) DC. (Rubiaceae). Numerous medicinal 
plants that are traditionally used in the country are also present in the BP. 
Monographs of medicinal plant species have been included in the BP since the 
launch of its first edition in 1926. From this date, four more editions have been 
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published, dating: 1959, 1977, 1996, and 2010 with a special edition issued in 
2011. More than 1000 monographs of medicinal plants, including native and 
non-native plants to Brazil, have been included in the editions (Brandão et al., 
2006, ANVISA, 2011).  
More than 500 herbal medicines were registered at ANVISA by 2008 and 
this number has certainly increased as the number of users grew as well. 
Ginkgo biloba L., Aesculus hippocastanum L. (Sapindaceae), Cynara scolymus 
L., Hypericum perforatum L., Glycine max (L.) Merr. (Leguminosae), Valeriana 
officinalis L., Panax ginseng C.A.Mey., Cassia angustifolia M.Vahl. 
(Leguminosae), Cimicifuga racemosa (L.) Nutt. (Ranunculaceae), Mikania 
glomerata Spreng., Maytenus ilicifolia Mart. ex Reissek (Celastraceae) and 
Peumus boldus Molina (Monimiaceae) are listed as the most used medicinal 
plant species by the Brazilian population. The native plants Mikania glomerata 
Spreng., Maytenus ilicifolia Mart. ex Reissek and Paullinia cupana Kunth 
(Sapindaceae) are widely used in the country as a bronchodilator, adjuvant in 
the treatment of gastric ulcers and as a stimulator of the nervous system 
respectively (Carvalho et al., 2008).  
Due to the high number of synthetic drugs available in SUS, cases of 
interactions are likely to occur when the patient has been prescribed a 
treatment with more than one drug. As a consequence, the number of drug 
interactions (especially cases of HDI at the absorption and metabolic levels) 
may increase with the implementation of RENISUS. Thus, studies on the 
effects of those herbal medicines in metabolic and transporter mechanisms are 
highly required in order to anticipate HDI that could affect the patients of SUS. 
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Table 1- 2 RENISUS plant species, traditional uses and presence in the Brazilian pharmacopoeia.  
RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses  Reference 
Achillea millefolium L. 
(Compositae) 
√ 
(ANVISA, 2011) 
Antipyretic, anti-
inflammatory, haemostatic, 
spasmolytic, diuretic, 
diaphoretic, hypotensive. 
(Williamson and Wren, 2003) 
Allium sativum L. 
(Amaryllidaceae) 
√ 
(Brandão et al., 2006) 
Antibiotic, expectorant, 
hypotensive, antithrombotic, 
anti-diabetic. 
(Williamson and Wren, 2003) 
Aloe barbadensis Mill. 
= Aloe vera (L.) Burm.f. 
(Xanthorrhoeaceae) 
√ 
(Brandão et al., 2006) 
Purgative, emmenagogue, 
aid wound healing, relieve 
burns, colonic irrigation, anti-
inflammatory, anti-
ulcerogenic, anti-tumor, 
immunomodulatory. 
(Williamson and Wren, 2003) 
Alpinia zerumbet (Pers.) B.L.Burtt 
& R.M.Sm 
(Zingiberaceae) 
_ 
For treatment of intestinal 
and cardiovascular diseases. 
(Leal-Cardoso et al., 2004)  
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Some traditional uses Reference 
Alpinia speciosa (Blume) D.Dietr. 
= Etlingera elatior (Jack) R.M.Sm. 
(Zingiberaceae) 
_ 
For treatment of earache, anti-
tumor promoting and for healing 
wounds. 
(Chan et al., 2011, 
Abdelwahab et al., 2010)  
 
Anacardium occidentale L. 
(Anacardiaceae) 
√ 
(Brandão et al., 2006) 
For treatment of toothache, sore 
gums and febrifuge in malaria. 
(Williamson and Wren, 2003) 
Ananas comosus (L.) Merr. 
(Bromeliaceae) 
_ 
Anti-inflammatory, anti-
oedematous, anti-arthritic, 
analgesic and wound-healing. 
(Williamson and Wren, 2003) 
Apuleia ferrea (Mart.) Baill. 
= Caesalpinia ferrea Mart. 
(Leguminosae) 
_ 
For treatment of gastroduodenal 
diseases. 
(Bacchi et al., 1995)  
Arrabidaea chica (Bonpl.) Verl. 
= Fridericia chica (Bonpl.) 
L.G.Lohmann 
(Bignoniaceae) 
_ 
For treatment of anaemia, 
haemorrhage, inflammation, 
intestinal colic, hepatitis, 
leukaemia and skin infections. 
(Gemelli et al., 2015, Michel 
et al., 2015)  
 
 
Artemisia absinthium L. 
(Compositae) 
√ 
(Brandão et al., 2006) 
Choleretic, anthelmintic, 
stomachic and anti-inflammatory. 
(Williamson and Wren, 2003) 
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Baccharis trimera (Less.) 
DC. 
(Compositae) 
√ 
(Brandão et al., 2006) 
√ 
(ANVISA, 2011) 
Anti-diabetic. (Oliveira et al., 2005)  
Bauhinia affinis Vogel 
= Bauhinia aculeata L. 
(Leguminosae) 
_ Anti-diabetic. (Gomez-Estrada et al., 2011)  
Bauhinia forficata Link. 
(Leguminosae) 
_ Anti-diabetic. (Damasceno et al., 2004)  
Bauhinia variegata L. 
(Leguminosae) 
_ 
Antileprotic, antigoitrogenic, 
antibacterial, antitumor, 
dysmenorrhea, tonic, astringent, 
for treatment of menorrhagia, 
tuberculosis, asthma, liver tonic, 
edema suppression, dysentery, 
ulcers, eye disease, skin 
diseases, fever and 
haemorrhoids. 
(Pani et al., 2011, Mali and 
Dhake, 2011)  
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Bidens pilosa L. 
(Compositae) 
_ 
Anti-cancer, anti-inflammatory, 
anti-diabetic, anti-hyperglycemic, 
antioxidant, immunomodulatory, 
antimalarial, antibacterial, 
antifungal, antihypertensive, 
vasodilatory and antiulcerative. 
(Bartolome et al., 2013) 
Calendula officinalis L. 
(Compositae) 
√ 
(Brandão et al., 2006) 
√ 
(ANVISA, 2011) 
Anti-inflammatory, spasmolytic, 
anti-haemorrhagic, styptic, 
vulnerary, antiseptic. 
(Williamson and Wren, 2003) 
Carapa guianensis Aubl. 
(Meliaceae) 
_ 
Anti-inflammatory, anti-allergic, 
skin diseases, arthritis, 
rheumatism, infections, wounds, 
bruises and analgesic. 
(Henriques and Penido, 
2014, Brito et al., 2013) 
 
 
Casearia sylvestris Sw. 
(Salicaceae) 
√ 
(ANVISA, 2011) 
Anti-diarrheic, anti-ophidian, flu 
and chest colds, treatment of 
gastric ulcers, wounds, burns, 
rashes, eczema, vitiligo and 
herpes. 
(Ferreira et al., 2011, 
Esteves et al., 2005) 
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Chamomilla recutita (L.) Rauchert 
= Matricaria chamomilla L. = M. 
recutita L 
(Compositae) 
_ 
Sedative, carminative, 
antispasmodic, analgesic, anti-
inflammatory and antiseptic. 
(Williamson and Wren, 2003) 
Chenopodium ambrosioides L. 
= Dysphania ambrosioides (L.) 
Mosyakin & Clemants 
(Amaranthaceae) 
√ 
(Brandão et al., 2006) 
Anthelmintic. (Williamson and Wren, 2003) 
Copaifera sp*  _ 
* Species to be used have not 
yet been defined by the Ministry 
of Health. 
_ 
Cordia verbenacea DC. 
= Cordia curassavica (Jacq.) 
Roem. & Schult. 
(Boraginaceae) 
√ 
(ANVISA, 2011) 
Antibacterial, anti-inflammatory, 
analgesic and antifungal. 
(Rodrigues et al., 2012, 
Matias et al., 2013)  
 
 
Costus scaber Ruiz & Pav. 
(Costaceae) 
_ 
Antibacterial, febrifuge, nephritic 
pain and antigonorrhoeic. 
(Lans et al., 2001, Breitbach 
et al., 2013)  
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Costus spicatus (Jacq.) Sw. 
(Costaceae) 
_ Anti-inflammatory. (Quintans Junior et al., 2010)  
Croton cajucara Benth. 
(Euphorbiaceae) 
 
_ 
For treatment of gastrointestinal 
disorders. 
(do Socorro et al., 2003)  
Croton zehntneri Pax. & K. 
Hoffm. 
(Euphorbiaceae) 
_ 
Antispasmodic, cardiovascular 
and gastroprotective. 
(da Silva-Alves et al., 2015, 
Batatinha et al., 1995)  
 
 
Curcuma longa L. 
(Zingiberaceae) 
√ 
(Brandão et al., 2006) 
√ 
(ANVISA, 2011) 
Anti-inflammatory, anti-
hepatotoxic, digestive, blood 
purifier, antiseptic and general 
tonic. 
(Williamson and Wren, 2003) 
Cynara scolymus L. 
(Compositae) 
√ 
(Brandão et al., 2006) 
√ 
(ANVISA, 2011) 
Choleretic, digestive, anti-emetic, 
liver protectant, hypolipidaemic, 
antispasmodic and antioxidant. 
(Williamson and Wren, 2003) 
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Dalbergia subcymosa Ducke 
(Leguminosae) 
_ Anti-inflammatory, antimicrobial. 
(Peters and Guerra Mde, 
1995, Oliveira et al., 2013)  
 
 
Eleutherine plicata (Sw.) Herb. 
= Eleutherine bulbosa (Mill. Urb. 
(Iridaceae) 
_ 
For treatment of giardiasis, 
amoebiasis and for treatment of 
diarrhoea. 
(Couto et al., 2016)  
Equisetum arvense L. 
(Equisetaceae) 
_ 
Haemostatic, astringent, cystitis, 
prostatitis, urethritis, enuresis, 
anti-haemorrhagic. 
(Williamson and Wren, 2003) 
Erythrina mulungu Benth. 
= Erythrina verna Vell. 
(Leguminosae) 
√ 
(Brandão et al., 2006) 
For treatment of insomnia and 
depression. 
(Flausino et al., 2007b, 
Flausino et al., 2007a)  
 
 
Eucalyptus globulus Labill. 
(Myrtaceae) 
√ 
(Brandão et al., 2006) 
Antiseptic, antispasmodic, 
expectorant, stimulant, febrifuge, 
insect repellent. 
(Williamson and Wren, 2003) 
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Eugenia uniflora L. 
= Myrtus brasiliana L. 
(Myrtaceae) 
√ 
(Brandão et al., 2006) 
Anti-diarrheic, diuretic, 
antirheumatic, antihypertensive 
and antifebrile. 
(Schapoval et al., 1994, 
Consolini et al., 1999)  
 
 
Foeniculum vulgare Mill. 
(Apiaceae) 
√ 
(Brandão et al., 2006) 
Stomachic, carminative, anti-
inflammatory, orexigenic. 
(Williamson and Wren, 2003) 
Glycine max (L.) Merr. 
(Leguminosae) 
_ Hormone-replacement-therapy. (Williamson and Wren, 2003) 
Harpagophytum procumbens DC. 
Ex 
(Pedaliaceae) 
_ 
Anti-inflammatory, anti-
rheumatic, analgesic, sedative. 
(Williamson and Wren, 2003) 
Jatropha gossypiifolia L. 
(Euphorbiaceae) 
_ 
Antihypertensive, anti-
inflammatory, antiophidian, 
analgesic, antipyretic, 
antimicrobial, healing, 
antianemic, antidiabetic, and 
antihemorrhagic. 
(Felix-Silva et al., 2014) 
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Justicia pectoralis Jacq. 
(Acanthaceae) 
√ 
(ANVISA, 2011) 
Anti-inflammatory, antimicrobial, 
bronchodilator and anxiolytic. 
(Venancio et al., 2011)  
Kalanchoe pinnata (Lam.) Pers. 
= Bryophyllum pinnatum (Lam.) 
Oken 
(Crassulaceae) 
_ 
Anti-inflammatory, 
antileishmanial. 
(Torres-Santos et al., 2003)  
Lamium album L. 
(Lamiaceae) 
_ Astringent and haemostatic. (Williamson and Wren, 2003) 
Lippia sidoides Cham. 
(Verbenaceae) 
√ 
(ANVISA, 2011) 
Antimicrobial, skin cuts, insect 
bites and sore throat. 
(Botelho et al., 2007)  
Malva sylvestris L. 
(Malvaceae) 
√ 
(Brandão et al., 2006) 
√ 
(ANVISA, 2011) 
Demulcent, pectoral, for 
treatment of colds, coughs, 
insect stings and bites. 
(Williamson and Wren, 2003) 
Maytenus aquifolium Mart. 
= Maytenus ilicifolia Mart. ex 
Reissek 
(Celastraceae) 
√ 
(Brandão et al., 2006) 
√ 
(ANVISA, 2011) 
Antiulcer. 
(Kimura et al., 2000, Corsino 
et al., 2003)  
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Mentha crispa L. 
= Mentha spicata L. 
(Lamiaceae) 
_ 
Carminative and for treatment of 
giardiasis, amebiasis and 
urogenital 
Trichomoniasis. 
(Teles et al., 2011)  
Mentha x piperita L. 
(Lamiaceae) 
√ 
(Brandão et al., 2006) 
√ 
(ANVISA, 2011) 
Spasmolytic, carminative, 
antiemetic, diaphoretic and 
antiseptic. 
(Williamson and Wren, 2003) 
Mentha pulegium L 
(Lamiaceae) 
_ 
Carminative, diaphoretic, 
stimulant and emmenagogue. 
(Williamson and Wren, 2003) 
Mentha x villosa Huds. 
(Lamiaceae) 
_ 
Anxiolytic and for treatment of 
stomachache, menstrual cramps 
and diarrhoea. 
(Sousa et al., 2009)  
Mikania glomerata Spreng. 
(Asteraceae) 
√ 
(Brandão et al., 2006) 
√ 
(ANVISA, 2011) 
Bronchodilator, antiallergic and 
antiasthmatic. 
(Santana et al., 2014)  
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Mikania laevigata Sch. Bip. ex 
Baker 
(Compositae) 
√ 
(ANVISA, 2011) 
For treatment of inflammatory 
conditions, bronchodilator 
activity, anti-ulcerogenic, 
antiophidian as well as 
antibacterial and antiparasitic 
activity. 
(Napimoga and Yatsuda, 
2010)  
Momordica charantia L. 
(Cucurbitaceae) 
_ 
For treatment of diabetes, 
asthma, skin infections and 
hypertension. 
(Williamson and Wren, 2003) 
Morus nigra L. 
(Moraceae) 
√ 
(Brandão et al., 2006) 
Laxative, diuretic, hypotensive, 
expectorant and reduction of 
blood sugar levels. 
(Williamson and Wren, 2003) 
Ocimum gratissimum L. 
(Lamiaceae) 
_ 
Antibacterial, antidiabetic and for 
treatment of many ailments, 
including upper respiratory tract 
infections, diarrhoea, headache, 
fever, eye problems, skin 
diseases, and pneumonia. 
(Ofem et al., 2012)  
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Orbignya speciosa Barb. Rodr. 
= Attalea speciosa Mart. 
(Arecaceae) 
_ Anti-inflammatory. (de Souza et al., 2011)  
Passiflora edulis Sims. 
= Passiflora incarnata L. 
(Passifloraceae) 
 
√ 
(Brandão et al., 2006) 
√ 
(ANVISA, 2011) 
Stimulant, antispasmodic, anti-
inflammatory, antianxiety, anti-
tumor, antimicrobial, antioxidant, 
tonic, hypotensive, anodyne, 
anticarcinogenic, sedative, 
hypnotic and for treatment of 
insomnia and gastrointestinal 
complaints. 
(Devaki et al., 2012, 
Williamson and Wren, 2003)  
 
 
Passiflora alata Curtis. 
(Passifloraceae) 
√ 
(Brandão et al., 2006) 
√ 
(ANVISA, 2011) 
Anxiolytic, sedative, diuretic and 
analgesic. 
(Barbosa et al., 2008, 
Rudnicki et al., 2007)  
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Persea americana Mill. 
= Persea gratissima C.F.Gaertn. 
(Lauraceae) 
√ 
(Brandão et al., 2006) 
Abortifacient, emmenagogue, 
contraceptive, anti-diarrhoeal, 
anti-hypertensive and diuretic. 
(Williamson and Wren, 2003) 
Petroselinum sativum Hoffm. 
= Petroselinum crispum (Mill.) 
Fuss 
(Apiaceae) 
√ 
(Brandão et al., 2006) 
Diuretic, spasmolytic, 
carminative, aperient, antiseptic, 
expectorant, antirheumatic and 
sedative. 
(Williamson and Wren, 2003) 
Phyllanthus amarus Schumach. 
& Thonn. = Phyllanthus niruri L. 
(Phyllanthaceae) 
√ 
(Brandão et al., 2006) 
√ 
(ANVISA, 2011) 
Diuretic, liver protectant and 
tonic, choleretic, anti-
inflammatory, kidney conditions 
and gallstones. 
(Williamson and Wren, 2003) 
Phyllanthus tenellus Roxb. 
(Phyllanthaceae) 
√ 
(Brandão et al., 2006) 
For treatment of kidney and 
bladder calculi, diabetes, 
hepatitis, jaundice and asthma. 
(Ignacio et al., 2001)  
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Phyllanthus urinaria L. 
(Phyllanthaceae) 
_ 
Anti-inflammatory, antiviral, 
antibacterial, anticancer and 
antihepatotoxic.  
(Huang et al., 2014) 
Plantago major L. 
(Plantaginaceae) 
√ 
(ANVISA, 2011) 
Anti-inflammatory, analgesic, 
diuretic and antihaemorrhagic. 
(Williamson and Wren, 2003) 
Plectranthus barbatus Andrews 
= Coleus barbatus (Andrews) 
Benth. ex G.Don 
(Lamiaceae) 
√ 
(ANVISA, 2011) 
For treatment of intestinal 
disturbance and liver fatigue, 
respiratory disorders, 
heart diseases and certain 
central nervous system 
disorders. 
(Alasbahi and Melzig, 2010, 
de Almeida Alves et al., 
2001)  
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Polygonum acre Kunth 
= Persicaria punctata (Elliott) 
Small 
(Polygonaceae) 
√ 
(ANVISA, 2011) 
For treatment of haemorrhoids 
and rheumatism, diuretic and 
emenagogue. 
(de Almeida Alves et al., 
2001)  
Polygonum hydropiperoides 
Michx. 
= Persicaria hydropiperoides 
(Michx.) Small 
(Polygonaceae) 
_ 
Stimulant, diuretic and 
emmenagogue. 
(Williamson and Wren, 2003) 
Portulaca pilosa L. 
(Portulacaceae) 
_ Analgesic, antipyretic, diuretic. (Rocha et al., 1994)  
Psidium guajava L. 
(Myrtaceae) 
√ 
(Brandão et al., 2006) 
Anti-inflammatory, antimicrobial, 
antioxidant, antidiarrheal, 
antimutagenic. 
(Ravi and Divyashree, 2014)  
Punica granatum L. 
(Lythraceae) 
√ 
(Brandão et al., 2006) 
√ 
(ANVISA, 2011) 
Taeniafuge and astringent. (Williamson and Wren, 2003) 
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Rhamnus purshiana DC. 
= Frangula purshiana Cooper 
(Rhamnaceae) 
√ 
(Brandão et al., 2006) 
Laxative. (Williamson and Wren, 2003) 
Ruta graveolens L. 
(Rutaceae) 
√ 
(Brandão et al., 2006) 
Antispasmodic and 
emmenagogue. 
(Williamson and Wren, 2003) 
Salix alba L. 
(Salicaceae) 
√ 
(Brandão et al., 2006) 
√ 
(ANVISA, 2011) 
Analgesic, anti-inflammatory, 
febrifuge and tonic. 
(Williamson and Wren, 2003) 
Schinus terebinthifolia Raddi 
(Anacardiaceae) 
√ 
(Brandão et al., 2006) 
√ 
(ANVISA, 2011) 
Anti-inflammatory and 
antimicrobial. 
(Silva et al., 2010) 
Solanum paniculatum L. 
(Solanaceae) 
√ 
(Brandão et al., 2006) 
For treatment of liver and 
gastrointestinal disorders and as 
an antimicrobial, anti-inflammatory, 
and antihypertensive. 
(Mesia-Vela et al., 2002a, 
VIEIRA et al., 2013)  
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Solidago microglossa DC. 
= Solidago chilensis Meyen 
(Compositae) 
√ 
(Brandão et al., 2006) 
Astringent, and for treatment of 
bruises and stomach disorders. 
(Bagatini et al., 2009)  
Stryphnodendron adstringens 
(Mart.) Coville 
= Stryphnodendron barbatimam 
Mart. 
(Leguminosae) 
√ 
(Brandão et al., 2006) 
For treatment of leucorrhoea, 
bleeding, diarrhoea, 
haemorrhoids and wounds. 
(Souza et al., 2007)  
 
 
Syzygium jambolanum (Lam.) DC 
= Syzygium cumini (L.) Skeels 
(Myrtaceae) 
_ 
Anti-diabetic, astringent and 
diuretic. 
(Williamson and Wren, 2003) 
Tabebuia avellanedae Lorentz ex 
Griseb. 
= Handroanthus impetiginosus 
(Mart. ex DC.) Mattos 
(Bignoniaceae) 
_ 
For treatment of infectious 
diseases including bacterial, 
fungal and viral infections, to 
enhance immune function and 
for cancer treatment. 
(Williamson and Wren, 2003) 
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RENISUS plant species and 
family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Tagetes minuta L. 
(Compositae) 
_ 
Anti-inflammatory, anti-
spasmodic, anti-parasitic, anti-
septic and sedative. 
(Karimian et al., 2014)  
Trifolium pratense L. 
(Leguminosae) 
_ 
Alterative, antispasmodic, 
expectorant, sedative and 
dermatological agent. 
(Williamson and Wren, 2003) 
Uncaria tomentosa (Willd. ex 
Schult.) DC. 
(Rubiaceae) 
_ 
For treatment of arthritis, 
rheumatism, asthma, gastric 
ulcer, skin diseases and cancer. 
(Williamson and Wren, 2003) 
Vernonia condensata Baker 
= Acmella ciliata (Kunth) Cass. 
(Compositae) 
√ 
(ANVISA, 2011) 
Analgesic, anti-inflammatory, 
antipyretic, antianemic, 
antibacterial and antiulcerogenic. 
(Boeing et al., 2016)  
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family 
Brazilian Pharmacopoeia Selected traditional uses Reference 
Vernonia polyanthes Less. 
= Vernonanthura phosphorica 
(Vell.) H.Rob. 
(Compositae) 
√ 
(ANVISA, 2011) 
Antimalarial, antipyretic, 
hypotensive, and for treatment of 
bronchitis and persistent cough. 
(Barbastefano et al., 2007)  
Zingiber officinale Roscoe 
(Zingiberaceae) 
√ 
(Brandão et al., 2006) 
√ 
(ANVISA, 2011) 
Carminative, anti-emetic, 
spasmolytic, anti-flatulent, 
antitussive, hepatoprotective, 
anti-platelet and hypolipidaemic 
agent. 
(Williamson and Wren, 2003) 
—, Not present in the BP; √, Present in the BP 
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1.9 REPORTED EFFECTS OF RENISUS MEDICINAL PLANTS ON MAIN 
PHASE I AND PHASE II METABOLIC MECHANISMS AND THE P-
GLYCOPROTEIN TRANSPORTER. 
In this chapter, we showed that herbal medicines are able to modulate 
metabolic and transporter proteins and, as a consequence, cause HDI at both 
the absorption and metabolic levels if they are coadministered with synthetic 
drugs. Also, we highlighted that the number of users of herbal medicines in 
SUS has considerably increased over the years. Statistics indicate that about 
66% of the Brazilian population have no access to commercial medicines 
(Trojan-Rodrigues et al., 2012). Even when access is granted, popular use of 
herbal medicines is often due to poor medical and pharmaceutical assistance 
and the high cost of treatment with conventional drugs (Silveira et al., 2008). 
Brazilians are also becoming more interested in “safe” and “natural” treatments 
aimed to promote healthier living. A consequence of this increased use of 
phytotherapy has been a higher number of case reports of adverse reactions 
caused by the uncontrolled consumption of herbal medicines (Silveira et al., 
2008). 
The ANVISA is in charge of the regulation of herbal medicines in the 
country and since its creation in 1999, many advances have been made in 
order to control and ensure their efficacy and safety (Balbino and Dias, 2010). 
In order to guarantee the safety of the consumption of phytomedicinal 
candidates by humans, ANVISA established a requirement that at least 20 
years of prior traditional use must be attested. In the absence of this evidence 
the efficacy and safety of the candidate need to be demonstrated by a point 
based system according to literature data, clinical evidence or an indication 
that the herb is already included in the list of simplified registration of herbal 
medicines (ANVISA, 2010). Although these regulations are relevant to improve 
the safety and efficacy of herbal medicines, PK metabolic studies on the 
traditional medicinal plants are not yet a regulatory requirement. As a 
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consequence, there is a scarcity of this kind of data which is regarded as an 
oversight in terms of safety (Ribeiro et al., 2005).  
As previously stated, the SUS is one of the biggest public health systems 
in the world and is responsible for the health care of 180 million Brazilian 
citizens (Mendes, 2013). In order to establish which medicines should be 
provided by SUS, the Brazilian Health Ministry produced a list of essential drugs 
(RENAME) according to the International Classification of Diseases (ICD) and 
epidemiological studies conducted nationwide (Brasil, 2014). Several herbal 
medicines are already part of this list, such as Cynara scolymus L., Schinus 
terebinthifolia Raddi and Rhamnus purshiana DC. However, due to the 
extensive number of plant species possessing pharmacological activity used in 
Brazil and the necessity for increased availability of herbal medicines in SUS, 
the Health Ministry determined that more herbal medicines should be provided 
by the System to the population, as part of one of the aims of the National Policy 
of Integrative and Complementary Practices (PNPIC). Consequently, 
RENISUS was published in 2008 and, from this point on, efforts have been 
concentrated on elucidating the efficacy and safety of the plant species present 
on the list (Brasil, 2009, Feijó et al., 2012). 
The profile of pharmaceutical drugs at both the absorption and metabolic 
levels is essential to determine whether or not they will interact with other 
therapeutic interventions (Ionescu and Caira, 2005). However, studies on 
metabolic and transporter targets using plant extracts are very difficult to carry 
out because of their chemical complexity (Simões and Mariot, 2003). As a 
result, there is very little data for numerous native and exotic adapted medicinal 
plants that are traditionally used in Brazil (He et al., 2010). The in vitro profiles 
of some herbal medicines in metabolic and transporter mechanisms can be 
found in the literature and, although these data are important, they are seldom 
used for the prediction of potential HDI. Thus, we will provide an overview of 
the effects of medicinal plants to be used in the SUS in the main phase I and 
phase II metabolism targets and the P-gp transporter.  
A literature search was conducted using the Library of Medicine’s 
PubMed database between May and June 2013. Included studies consisted of 
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the reported effects of the Brazilian medicinal plants of RENISUS list on the 
main liver metabolic enzymes, which are involved in phase I (functionalization 
reactions mediated by CYP) and phase II (GSH conjugation, glucuronidation, 
sulphation, methylation and acetylation) metabolism and also the assessment 
of their effects on P-gp activity. The following combinations of keywords were 
used: ‘Plant name AND, 1A2, 3A4, 3A5, 3A7, 2C9, 2C19, 2D6, 2E1’, ‘Plant 
name AND glutathione’ or ‘Plant name AND GSH’, ‘Plant name AND 
glucuronidation’ or ‘Plant name AND UGT’, ‘Plant name AND sulphation’, ‘Plant 
name AND sulphate conjugation’, ‘Plant name AND sulphotransferase’, ‘Plant 
name AND methylation’, ‘Plant name AND methyltransferase’, ‘Plant name 
AND acetylation’, ‘Plant name AND n-acetyltransferase’, ‘Plant name AND P-
glycoprotein’ or ‘Plant name AND P-gp” (Tables 1-3 to 1-11). EndNote web was 
the citation tool used to manage and organize all the references collected.  
It is important to note that RENISUS encompasses native and exotic 
adapted medicinal plant species and that we are aware of the chemical 
variability of the materials, which eventually may be harmonised by 
pharmacopoeial monographs of their respective countries. 
Also, same plant species can present different results in the literature. 
This could be explained by the using plants collected in different regions, places 
and time of the year for example. Also, observed effects may vary due to the 
extraction procedure used for the conduction of the experiment, as well as the 
models selected for the study. 
 
 	 72	
 
 
 
 
 
  
Table 1- 3 Medicinal plants listed in RENISUS with reported effects on CYP1A2 
Plant species/Family Effects on CYP1A2 References 
Allium sativum L. 
(Amaryllidaceae) 
 
+ (Le Bon et al., 2003) 
Curcuma longa L. 
(Zingiberaceae) 
 
+, - 
(Thapliyal et al., 2002, 
Volak et al., 2013) 
Eucalyptus globulus Labill. 
(Myrtaceae) 
 
- (Unger and Frank, 2004) 
Glycine max (L.) Merr. 
(Leguminosae) 
 
- (Shon and Nam, 2004) 
Harpagophytum 
procumbens DC. Ex 
(Pedaliaceae) 
 
NE, - 
(Modarai et al., 2011b, 
Unger and Frank, 2004) 
Mentha x piperita L. 
(Lamiaceae) 
 
- (Unger and Frank, 2004) 
Phyllanthus amarus 
Schumach. & Thonn. 
(Phyllanthaceae) 
 
- 
(Hari Kumar and Kuttan, 
2006) 
Punica granatum L. 
(Lythraceae) 
 
- (Faria et al., 2007a) 
Trifolium pratense L. 
(Leguminosae) 
 
- (Unger and Frank, 2004) 
—, Inhibition of enzyme expression; + Induction of enzyme expression;  
NE, No effect 
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   Table 1- 4 Medicinal plants listed in RENISUS with reported effects on CYP2C9 
Plant species/Family Effects on CYP2C9 References 
Allium sativum L. 
(Amaryllidaceae) 
 
-, + (Ho et al., 2010, Foster et al., 2001) 
Eucalyptus globulus Labill. 
(Myrtaceae) 
 
- (Unger and Frank, 2004) 
Harpagophytum procumbens 
DC. Ex 
(Pedaliaceae) 
 
NE, - (Modarai et al., 2011b) 
Mentha x piperita L. 
(Lamiaceae) 
 
- (Unger and Frank, 2004) 
Punica granatum L. 
(Lythraceae) 
 
- (Hanley et al., 2012) 
Trifolium pratense L. 
(Leguminosae) 
 
- (Unger and Frank, 2004) 
Zingiber officinale Roscoe 
(Zingiberaceae) 
 
- (Kimura et al., 2010) 
—, Inhibition of enzyme expression; + Induction of enzyme expression;  
NE, No effect 
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Table 1- 5 Medicinal plants listed in RENISUS with reported effects on CYP2C19 
Plant species/Family Effects on 
CYP2C19 
References 
Allium sativum L. 
(Amaryllidaceae) - (Foster et al., 2001) 
Eucalyptus globulus Labill. 
(Myrtaceae) - (Unger and Frank, 2004) 
Harpagophytum procumbens 
DC. Ex 
(Pedaliaceae) 
NE (Modarai et al., 2011b) 
Mentha x piperita L. 
(Lamiaceae) - (Unger and Frank, 2004) 
Trifolium pratense L. 
(Leguminosae) - (Unger and Frank, 2004) 
 
 
Plant species/Family 
 
Effects on CYP2D6 References 
Allium sativum L. 
(Amaryllidaceae) NE (Markowitz et al., 2003) 
Eucalyptus globulus Labill. 
(Myrtaceae) - (Unger and Frank, 2004) 
Harpagophytum 
procumbens DC. Ex 
(Pedaliaceae) 
NE, - (Modarai et al., 2011b) 
Mentha x piperita L. 
(Lamiaceae) - (Unger and Frank, 2004) 
Phyllanthus amarus 
Schumach. & Thonn. 
(Phyllanthaceae) 
- (Hari Kumar and Kuttan, 2006) 
Punica granatum L. 
(Lythraceae) - (Usia et al., 2006) 
Trifolium pratense L. 
(Leguminosae) - (Unger and Frank, 2004) 
Table 1- 6 Medicinal plants listed in RENISUS with reported effects on CYP2D6 
—, Inhibition of enzyme expression;  
NE, No effect 
—, Inhibition of enzyme expression; 
NE, No effect 
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—, Inhibition of enzyme expression; 
NE, No effect 
Plant species/Family Effects on CYP2E1 References 
Allium sativum L. 
(Amaryllidaceae) 
 
- (Le Bon et al., 2003) 
Curcuma longa L. 
(Zingiberaceae) 
 
NE (Salama et al., 2013) 
Glycine max (L.) Merr. 
(Leguminosae) 
 
NE (Shon and Nam, 2004) 
Momordica charantia L. 
(Cucurbitaceae) 
 
- (Raza et al., 1996) 
Phyllanthus amarus 
Schumach. & Thonn. 
(Phyllanthaceae) 
 
- 
(Hari Kumar and Kuttan, 
2006) 
Phyllanthus urinaria L. 
(Phyllanthaceae) 
 
- (Shen et al., 2008) 
Punica granatum L. 
(Lythraceae) 
 
- (Faria et al., 2007a) 
Table 1- 7 Medicinal plants listed in RENISUS with reported effects on CYP2E1 
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—, Inhibition of enzyme expression; NE, No effect, ND, No data 
*CYP3A4, *CYP3A5, *CYP3A7 
Table 1- 8 Medicinal plants listed in RENISUS with reported effects on CYP3A 
Plant species/Family 
 
Effects on CYP3A References 
Allium sativum L. 
(Amaryllidaceae) NE,-*
,*,* (Hajda et al., 2010, Foster et al., 2001) 
Chamomilla recutita (L.) 
Rauchert (Compositae) ND*
,*,-* (Budzinski et al., 2000) 
Curcuma longa L. 
(Zingiberaceae) ND*
,*,NE* (Graber-Maier et al., 2010) 
Eucalyptus globulus Labill. 
(Myrtaceae) ND*
,*,-* (Unger and Frank, 2004) 
Foeniculum vulgare Mill. 
(Apiaceae) ND*
,*,-* (Subehan et al., 2006, Subehan et al., 2007) 
Harpagophytum 
procumbens DC. Ex 
(Pedaliaceae) 
ND*,*,NE,-* (Modarai et al., 2011b, Unger and Frank, 2004) 
Mentha x piperita L. 
(Lamiaceae) ND*
,*,-* (Unger and Frank, 2004) 
Momordica charantia 
L.(Cucurbitaceae) ND*
,*,-* (Raza et al., 1996) 
Phyllanthus amarus 
Schumach. & Thonn. 
(Phyllanthaceae) 
-*,*,* (Hari Kumar and Kuttan, 2006) 
Punica granatum L. 
(Lythraceae) -*
,*,* (Faria et al., 2007a) 
Trifolium pratense L. 
(Leguminosae) ND*
,*,-* (Budzinski et al., 2000) 
Uncaria tomentosa (Willd. 
ex Schult.) DC. 
(Rubiaceae) 
ND*,*,-* (Budzinski et al., 2000) 
Zingiber officinale Roscoe 
(Zingiberaceae) ND*
,*,-* (Kimura et al., 2010) 
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Table 1- 9 Medicinal plants listed in RENISUS with reported effects on GSH levels 
 
Plant species/Family 
 
Effects on GSH 
levels 
References 
Achillea millefoilum L. 
(Compositae) + (Potrich et al., 2010) 
Allium sativum L. 
(Amaryllidaceae) + (Ip and Lisk, 1997) 
Aloe vera (L.) Burm.f./Aloe 
barbadensis Mill. 
(Xanthorrhoeaceae) 
-,+ (Hegazy et al., 2012, Kaithwas et al., 2011) 
Anacardium occidentale L. 
(Anacardiaceae) + (Singh et al., 2004) 
Baccharis trimera (Less.) 
DC.(Compositae) - (Nogueira et al., 2011) 
Bauhinia forficata 
Link.(Leguminosae) - (Damasceno et al., 2004) 
Bauhinia variegata 
L.(Leguminosae) + (Rajkapoor et al., 2006) 
Calendula officinalis L. 
(Compositae) + 
(Preethi and Kuttan, 
2009) 
Chamomilla recutita (L.) 
Rauchert (Compositae) + (Al-Hashem, 2010) 
Croton cajucara 
Benth.(Euphorbiaceae) + (Rabelo et al., 2010) 
Curcuma longa L. 
(Zingiberaceae) + (Rong et al., 2012) 
Cynara scolymus 
L.(Compositae) +,NE (Miccadei et al., 2008) 
Foeniculum vulgare Mill. 
(Apiaceae) + (Zhang et al., 2012b) 
Glycine max (L.) Merr. 
(Leguminosae) + (Barbosa et al., 2011) 
Mentha pulegium L. 
(Lamiaceae) + (Alpsoy et al., 2011) 
Mentha x piperita 
L.(Lamiaceae) + (Sharma et al., 2007) 
Mikania glomerata Spreng 
(Asteraceae) NE (Barbosa et al., 2012) 
Momordica charantia L. 
(Cucurbitaceae) + 
(Raza et al., 1996, Raza 
et al., 2000) 
Phyllanthus amarus 
Schumach. & Thonn. 
(Phyllanthaceae) 
+ 
(Karuna et al., 2009, 
Kumar and Kuttan, 2004, 
Kumar and Kuttan, 2005, 
Maity et al., 2013) 
Phyllanthus niruri L. 
(Phyllanthaceae) + 
(Manjrekar et al., 2008, 
Bhattacharjee and Sil, 
2006) 
 	 78	
+, Increase GSH levels; —, Decrease GSH levels; NE, No effect; 
 
+, Increased enzyme activity; —, Decreased enzyme activity 
 
+, Increased efflux activity; —, Decreased efflux activity; NE, No effect 
 
Plant species/Family Effects on GSH 
levels 
References 
Psidium guajava L. 
(Myrtaceae) 
+ (Tandon et al., 2012) 
Ruta graveolens L. 
(Rutaceae) 
+ (Ratheesh et al., 2011) 
Zingiber officinale Roscoe 
(Zingiberaceae) 
+,NE (Ajith et al., 2007) 
Table 1- 10 Medicinal plants listed in RENISUS with reported effects on UGT  
Plant species/Family Effects on UGT  References 
Allium sativum L.  
(Amaryllidaceae) 
 
+ (Ip and Lisk, 1997) 
Curcuma longa L. 
(Zingiberaceae) 
 
- (Naganuma et al., 2006) 
Plant species/Family Effects on P-gp 
efflux activity 
References 
Achillea millefolium L. 
(Compositae) 
 
- (Haidara et al., 2006) 
Allium sativum L. 
(Amaryllidaceae) 
 
+ (Hajda et al., 2010) 
Curcuma longa L. 
(Zingiberaceae) 
 
NE, - 
(Graber-Maier et al., 
2010, Ampasavate et 
al., 2010) 
Table 1- 11 Medicinal plants listed in RENISUS with reported effects on P-gp efflux activity  
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1.10 AIM OF THE THESIS 
As highlighted earlier the SUS aims to include more herbal medicines to 
RENAME within the coming years. However, the intake of those herbal 
medicines by the patients of SUS could potentially cause HDI if they are 
coadministered with essential medicines. Due to the types of effects that herbal 
medicines could cause in phase I and phase II metabolising enzymes and P-
gp, the present study aims to answer whether selected RENISUS herbal 
medicines are able to modulate designated metabolic and transporter targets 
in vitro in order to forestall HDI with some essential medicines available in SUS.   
To achieve this, we carried out an experimental evaluation of the in vitro 
effects of twenty-four plant extracts from twenty-three RENISUS medicinal 
plant species selected based on data collected in our literature analysis on 
different cell detoxification and transport mechanisms; as a means of identifying 
potential HDI. Parts of this experimental evaluation have been previously 
published as an original research article (Mazzari et al., 2016).  
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2 MATERIALS AND METHODS 
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2.1 CHEMICALS AND REAGENTS 
Cell Culture. HepG2 and Caco-2 cell lines were from Sigma Aldrich at 
passages 100 and 43 respectively. HeLa cells were donated by Dr. Paul Webb 
from the Houston Methodist Institute for Technology at passage 20. All cell 
culture reagents were from Gibco® Invitrogen unless otherwise stated. 
Vincristine 2mg/mL was purchased from Hospira Ltd.  
HPTLC analysis. Water, dichloromethane (>99.8%, contains amylene as a 
stabilizer), ethyl acetate (>99.7%) and methanol (>99.9%) all ChromasolvPlus 
for HPLC provided by Sigma Aldrich. Acetic acid (glacial) analytical reagent 
grade provided by Fisher Scientific. Formic Acid 98% provided by Rectapur® 
VWR. Caffeic acid was from Kotch-light Laboratories LTD. Rutin hydrate, 
quercetin dehydrate and gallic acid all from Sigma Aldrich. Diphenylborinic acid 
2-aminoethyl ester (98%) and coumarin laser grade (99% UV-Vis) were 
provided by ACROS organics. Luteolin (HPLC grade) was from Extrasynthése. 
Chlorogenic acid provided by Cayman Chemical Co. Polyethylene glycol 4000 
grade was from Fisher Scientific.  
HPLC analysis. All solvents (water HPLC gradient grade, glacial acetic acid 
and methanol) were purchased from Fisher Scientific UK. Caffeic acid, 
catechin, rutin, quercetin, and chlorogenic acid were from Sigma Aldrich. 
Cell viability assays. Sulphorhodamine B (SRB), neutral red (NR), (3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) (MTT), trichloroacetic 
acid (TCA), glacial acetic acid, 96% ethanol, hydrochloric acid (HCl), 
Isopropanol and Tris base were from Sigma Aldrich. 
CYP3A4 mRNA gene expression assay. Oligonucleotide primers were 
custom-synthesized by Invitrogen Life Technologies and Sigma Aldrich. 
TRIzol® (Total RNA Isolation Reagent), Oligo (dT) 12-18 primers, M-MLV 
Reverse Transcriptase, RNAseOUT, DNAse I Amplification Grade and 100mM 
dNTP set were purchased from Invitrogen Life Technologies.  SYBR Green 
(2xqPCR Master Mix premixed with SYBRgreen) was obtained from Amethyst 
reagents (Cambridge Bioscience). Rifampicin (RIF) and DMSO were 
purchased from Sigma Aldrich.  
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hPXR assay. Lipofectamine® 2000 was purchased from Invitrogen. RIF and 
Luciferase assay system were obtained from Sigma Aldrich and Promega 
respectively. 
Intracellular Glutathione assay. Buthionine sulfoximine (BSO), L-glutathione 
reduced, glutathione reductase (GR), 5-5’-dithiobis(2-nitrobenzoic acid) 
(DTNB), β-Nicotinamide adenine dinucleotide 2’-phosphate reduced 
tetrasodium salt hydrate (β-NADPH), Triton-X and sulfosalicylic acid (SSA) 
were from Sigma Aldrich.  
GGT activity assay. g-glutamyl-p-nitroanalide (GpNA), p-nitroaniline, glycyl-
glycine (Gly-Gly), Tris base and acivicin were from Sigma Aldrich. 
Rh-123 uptake assay. Rh-123 was from Sigma Aldrich. Verapamil (Securon 
IV 2.5mg/mL) was from Abbott Laboratories Ltd.   
2.2 PREPARATION OF PLANT MATERIALS 
2.2.1 Selection criteria and ethical clearance  
The medicinal plants used for our in vitro preclinical studies were 
selected according to the results found in the literature review (chapter 1). 
Originally, we planned to work with all plant species where no preclinical 
published data had been found. However, it was not possible to obtain all the 
plant species from the main natural products suppliers in Brazil. Therefore we 
conducted our work with 23 plant species, which were readily available for 
purchasing and collection with three different suppliers in Brazil: Santosflora 
Comércio de Ervas (Mairiporã, São Paulo, Brazil), Florien (Piracicaba, São 
Paulo, Brazil) and “Farmácia Viva Brasília” (Brasília, DF – Brazil), via UnB.  
In order to conduct our research, we had to first to deal with a series of 
regulations to access the Brazilian genetic heritage ‘component’, which is 
controlled by the Conselho de Gestão do Patrimônio Genético (Genetic 
Heritage Council) or CGEN. According to CGEN, in order to purchase and/or 
collect medicinal plants in Brazil for research purposes and to transport them 
to the UK, we needed to first to establish an institutional agreement between 
UCL and a Brazilian institution that would be legally responsible for the whole 
process (Appendix 7.1). We contacted several Brazilian universities exploring 
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a possible collaboration. We eventually received a positive feedback from Dr. 
Damaris Silveira from the Faculty of Life Sciences of the University of Brasília 
(UnB) (Brasília – Distrito Federal) who was willing to help us with all the 
bureaucratic processes.  
The second step was to elaborate the project and send a clear plan of it 
to CGEN and to the Instituto Brasileiro do Meio Ambiente e dos Recursos 
Naturais Renováveis (Brazilian Institute of Environment and Renewable 
Natural Resources)  or IBAMA. The plan had details of the type of research to 
be carried out with the selected plant extracts and included materials, 
methodologies and a timetable for the execution of the entire project (Appendix 
7.2).  
The third (and last) step was the production of a material transfer 
agreement (MTA) document, which was countersigned by the legal 
representatives of University College London (UCL) and UnB (Appendix 7.3). 
All documents were prepared by us and sent to Brazil between November 2013 
and March 2014. 
2.2.2 Processing of plant materials 
The plants were grown and processed according to good manufacturing 
practices established by ANVISA, ensuring validity and quality (Carvalho et al., 
2014). All whole plant handling and extraction were performed at UnB. All used 
parts of the plants were subjected to a 20-minute infusion in order to mimic 
traditional use (Academia Nacional de Medicina (Madrid Spain), 1954). For 
infusion, boiled distilled water (300mL) was added to the plant material (20g) 
with continuous stirring for 15 minutes on a laboratory hot plate magnetic stirrer 
(IKA WERKE labortechnik electric stirrer). All extracted plant samples were 
allowed to stand until cold before filtering with a Buchner flask. All the filtered 
extracts were frozen in round bottom flasks and then freeze dried (Edwards 
Pirani 501 Savant super modulo freeze drier) to obtain the dried extract. The 
lyophilised extracts were immediately sent to UCL School of Pharmacy and 
stored at -18°C throughout the studies.  
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2.3 PHYTOCHEMICAL ANALYSIS 
2.3.1 HPTLC analysis 
Extracts were diluted to a concentration of 50mg/mL in methanol. Control 
compounds were made at a concentration of 1mg/mL, also diluted in methanol. 
A CAMAG Linomat 5 was used to apply 5µL of the samples to TLC silica gel 
60 F254 aluminium sheets. The plates were developed using a CAMAG ADC2 
automatic developing chamber. The method included 30-second pre-drying, 10 
minutes humidity control using magnesium chloride to 48.3% relative humidity 
and 20 minutes saturation time, using saturation pads all done at 25.2°C. The 
mobile phase used was ethyl acetate: formic acid: water (82:9:9). During 
development, the solvent front was allowed to migrate 80mm before a drying 
time of 5 minutes. For derivatization, we used natural products reagent (NPR) 
followed by PEG 4000 (Reich and Schibli, 2007). All visualization and analysis 
were done using CAMAG TLC visualizer both before and after derivatization. 
2.3.2 HPLC analysis 
Phytochemical analysis of all samples of the freeze-dried plant extracts 
was carried out using a high-performance liquid chromatography (HPLC) 
system- Agilent 1200 series equipped with an ultraviolet/visible (UV-Vis) diode 
array detector to obtain a ‘fingerprint’ of the samples. The conditions used for 
the analysis have previously been used for the detection of phenolic 
compounds in plant samples (Giner et al., 1993). 
The stationary phase was a Phenomenex® synergi Polar-RP80A 
column (250mm x 4.6mm, I.D = 4µm) maintained at 40°C and protected with a 
Nova-Pak® C18 guard column. The mobile phase was a binary system 
consisting of (A) water-glacial acetic acid (99.8:0.2, v/v) and (B) methanol-
glacial acetic acid (99.8:0.2, v/v). The gradient elution program for the mobile 
phase was 10-20% B (0-5 minutes), 20-50% B (5-65 minutes), 50-80% B (65-
75 minutes) and 80-100% B (75-80 minutes) at a flow rate of 1mL/minute. The 
injected volume of the sample was 10µL and the UV-Vis spectra were recorded 
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in the range 190 to 400nm, while chromatographic peaks were monitored at 
254 and 360nm.  
The plant extracts were prepared as 25mg/mL solutions in either micro-
filtered double distilled water or HPLC-grade methanol. Five plant phenolic 
compounds: caffeic acid, catechin, rutin, quercetin, and chlorogenic acid were 
used as standards at concentrations between 0.5 and 1mg/mL in methanol, 
depending on the intensity of the peak. Samples were filtered through a 0.45µm 
syringe filter (Millipore Millex® PTFE) before the analysis. 
2.4 IN VITRO STUDIES 
2.4.1 Mammalian cell culture techniques 
2.4.1.1 Human liver hepatocellular carcinoma (HepG2), colorectal carcinoma 
cells (Caco-2) and cervix adenocarcinoma (HeLa) cells 
Human liver hepatocellular carcinoma, or simply HepG2, is an accepted 
cell line model commonly used for in vitro drug metabolism studies as they keep 
some specialised functions when compared to human hepatocytes (HH). 
HepG2 also preserves the activity of several phase I, phase II, and antioxidant 
enzymes (Vidyashankar et al., 2010). Besides, HepG2 cells have the 
advantage of ready availability and assurance in reproducibility of experiments 
(Hewitt and Hewitt, 2004). HepG2 cells were used in our study to evaluate the 
CYP3A4 mRNA gene expression, intracellular GSH levels, and GGT activity. 
Caco-2 cells are widely used for in vitro drug transport studies. The 
capacity of Caco-2 to form monolayers with morphological and functional 
similarities to the human intestinal epithelium, meant the cell line received 
recognition from the Food and Drug Administration (FDA) as a viable model 
that replicates human intestinal absorption (Chen et al., 2016). Our drug 
transport study is focused on the P-gp efflux activity, and we therefore used 
vincristine resistant Caco-2 cells (Caco-2 VCR) model, which displays a more 
pronounced efflux activity mechanism than normal Caco-2 (Eneroth et al., 
2001).  
Henrietta Lacks (HeLa) cervix adenocarcinoma cells were discovered in 
1951 and became the first human cancer cell line immortalised in tissue culture 
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(Lucey et al., 2009). HeLa is one of the most versatile cancer cell lines and it is 
widely used in molecular biology, especially due to its easy and efficient 
transfection with plasmids using Lipofectamine (Nikcevic et al., 2003).  Among 
some uses in molecular biology, transfected HeLa cells have been the choice 
of researchers for evaluating hPXR-dependent gene expression, including 
proteins like CYPs (Lemaire et al., 2006). HeLa cells were therefore our choice 
for studying the effect of four RENISUS plant extracts on hPXR. 
2.4.1.2 Resuscitation of frozen cell stocks 
Cell lines are usually stored in frozen form (in liquid nitrogen) when not 
in use. The cells used in this study were in this form when purchased. To 
resuscitate them, the cells were thawed rapidly at 37°C by placing the vial of 
cells in a pre-heated water bath. The thawed cells were then diluted slowly into 
a centrifuge tube containing the appropriate warm growth media to eliminate 
DMSO, which is toxic to cells. DMSO is used as a cryoprotectant to prevent 
crystallisation, which will otherwise cause cells to lyse during cryopreservation. 
The tubes were then centrifuged (Biofuge primo R Heraeus centrifuge) for 5 
minutes at 1000rpm to separate the cell pellet from the culture media. Inside 
the laminar flow cabinet, the media was removed from the centrifuge tube and 
the cells were properly resuspended in 15mL of pre-warmed complete media. 
They were then transferred to a culture flask pre-labelled with the name of the 
cell line, passage number, and date. An inverted microscope (Nikon TMS 
10/0.25 lens) was used to check the morphology of the cells before placing in 
an incubator (Ezuruike, 2015).              
2.4.1.3 Subculture/maintenance 
HepG2, Caco-2, and HeLa cells were stocked in DMSO and frozen in 
liquid nitrogen until they were used. When the cells were needed they were 
taken out of the liquid nitrogen and defrosted in the water bath (37°C) for 
approximately 4 minutes and then transferred to a flask containing 15mL of pre-
warmed media and centrifuged at 1000rpm for 5 minutes at 18°C. The media 
(supernatant) was removed and the cells were re-suspended with 5mL of the 
same media and then transferred to a cell culture flask containing 15mL of pre-
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warmed media and incubated. The cells were checked regularly in order to 
observe their growing. Cells were incubated in culture flasks (TPP, surface area 
75cm2) containing 20mL of HepG2 medium (MEM Alpha + GlutaMax 1x) or 
Caco-2 and HeLa medium (DMEM Alpha + Glutamax 1x), 1% (v/v) penicillin-
streptomycin antibiotic (10,000 units/mL penicillin and 10,000 µg/mL 
streptomycin) and 10% heat-inactivated foetal bovine serum-EU. Caco-2 cells 
were also incubated with vincristine (20nM). The media was kept in the fridge 
(2°C - 8°C) and prior to its use in cells, the media was placed for 30 minutes in 
the water bath (37°C) (Ezuruike, 2015).  
2.4.1.4 Cell passage (propagation) 
When the cells reached around 70% of confluence the cell passing 
procedure was performed. The old media was aspirated from the cell culture 
flask and the cells were washed with 5mL of phosphate saline buffer (PBS) to 
remove the remaining media. After removing the PBS, 1.2mL of 0.25% (w/v) 
trypsin/EDTA was added to the flask, it was then placed in the incubator until 
the cells detached. Afterwards, the volume of media was added according to 
the split ratio desired and the new flasks were then placed in the incubator again 
allowing the cells to grow (Ezuruike, 2015).  
2.4.1.5 Cell counting 
The confluence of the flask was checked and then the media was 
aspirated. The cells were then rinsed with 5mL of PBS and 1.2mL of 
trypsin/EDTA was added to detach the cells. The flask was put in the incubator 
for approximately 3 minutes. Afterwards, the flask was placed in the laminar 
flow cabinet and 190µL of trypan blue stain 0.4% was placed in an eppendorf 
plus 10µL of the cell suspension. The microcentrifuge tube was mixed on a 
rotamixer for a few seconds and 10µL of the trypan blue cell suspension were 
added to each side of a Neubauer haemocytometer that was placed in an 
inverted microscope (Nikon TMS). The cells were then counted and plated out 
according to the number of cells desired per well (Ezuruike, 2015).  
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2.4.2 Cell Viability Assays 
2.4.2.1 The SRB assay 
2.4.2.1.1 Background 
Toxicity of HepG2 cells was assessed using SRB assay. The SRB 
(Figure 2-1) assay is commonly applied for testing cytotoxicity in a wide range 
of cell lines. The assay relies on the binding of the negatively charged pink 
aminoxanthine dye by protein components of cells that have been treated and 
fixed with TCA. The sulphonic groups present in the SRB dye has the ability to 
bind to basic amino acids residues under mildly acidic conditions. The dye is 
able then to dissociate under basic conditions. The number of viable cells is 
detected according to the amount of dyed ones, which is proportional to the cell 
mass due to the stoichiometric binding of the SRB dye to fixed cells. When the 
cells are lysed the colour becomes more intense and the absorbance increases 
(Houghton et al., 2007). The reason why this assay was selected for cytotoxicity 
analysis is that SRB is a quite reliable method and the results correlate well 
with those of tetrazolium dye MTT for example (Vichai and Kirtikara, 2006).  
 
 
 
 
  
 
 
 
 
 
 
 
 
2.4.2.1.2 Experiment protocol 
The method used for this assay is as described in Houghton and 
coworkers (2007) with slight modifications. After 24 hours incubation of HepG2 
cells (2 × 104 cells/well) with the plant extracts (100µg/mL) and serial dilutions 
of the positive control ethanol, media containing the samples was removed and 
cells were fixed with 100µL of cold 40% w/v TCA solution in deionized water. 
Figure 2- 1 SRB chemical structure. 
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The plates were incubated at 4°C for 1 hour and then immersed five times in 
tap water. The TCA-fixed cells were stained by adding 100µL of SRB solution 
(0.4 % SRB in 0.1% glacial acetic acid) and left at room temperature for 1 hour. 
Afterwards, the plates were quickly rinsed four times with 1% acetic acid and 
flicked to remove unbound dye and then left to air-dry overnight. After drying 
completely, the protein bound SRB was solubilised by adding 100µL of Tris 
base buffer solution (10mM) to each well. The plates were agitated in an orbital 
shaker for 30 minutes (IKA MS3 basic shaker). The optical density was 
measured at 492nm by using a microplate plate reader Infinite M200 (Tecan 
Trading AG, Switzerland) and the viability was calculated as follows: % viability 
= (O.DS-O.DB/O.DM-O.DB) x 100; where O.DS is the optical density of the 
sample (either drug or plant extract), O.DB is the optical density of the blank 
wells without cells, O.DM is the optical density of the wells of the positive control 
containing only complete media (Houghton et al., 2007).  
2.4.2.2 Neutral Red Uptake assay 
2.4.2.2.1 Background 
Toxicity of Caco-2 VCR cells was determined using the neutral red 
assay. The assay was based on the uptake of neutral red (3-amino-m-
dimethylamino-2-methylphenazine hydrochloride) (Figure 2-2), a supravital 
dye, and its accumulation in the lysosomes of viable uninjured cells. The uptake 
of the dye depends on the cell’s capacity to maintain pH gradients, through the 
production of ATP. The dye is weakly cationic and at physiological pH, presents 
a net charge close to zero, enabling it to penetrate the cell membranes by non-
ionic passive diffusion and concentrates in the lysosomes. Inside the lysosome, 
there is a proton gradient to maintain a pH lower than that of the cytoplasm. 
Thus the dye becomes charged and is retained, where it binds to anionic and/or 
phosphate groups of the lysosomal matrix (Repetto et al., 2008).  
Extraction of the dye from the viable cells was done using an acidified 
ethanol solution, and the absorbance of the solubilised dye is quantified 
spectrophotometrically at 540nm. Quantification of the dye extracted from the 
cells have been shown to be linear with cell numbers, both by direct cell counts 
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and by protein determinations of cell populations (Weyermann et al., 2005). 
Given that the toxicity of the extracts is inversely proportional to the viability of 
the cells, more toxic extracts result in fewer cells being available for neutral red 
uptake.  The neutral red assay has been identified as a reliable in vitro assay 
that can be used to estimate in vivo starting doses for acute toxicity based on 
its low coefficient of variation from several inter- and intra-laboratory 
experiments (Interagency Coordinating Committee on the Validation of 
Alternative Methods (ICCVAM), 2001). 
 Originally, SRB was the cytotoxicity method chosen for Caco-2 VCR 
cells. However, the washing steps were washing away the cell monolayer and 
therefore we had to choose a less aggressive method to avoid chances of cell 
detachment from the 96-well plate, hence the selection for this study.  
 
 
 
 
 
Figure 2- 2 Chemical structure of neutral red dye. 
 
2.4.2.2.2 Experiment protocol 
The method used for this assay is as described in Repetto and 
coworkers (2008) with slight modifications. Caco-2 VCR cells (1 x 104 cells/well) 
were plated out in each of the inner wells of a sterile, flat-bottom 96-well plate. 
The plate was then incubated overnight at 37°C, 5% CO2/95% O2.  
The next day, the plant extracts to be tested (100µg/mL), including the 
serial dilutions of the positive control hydrogen peroxide were made in complete 
media from the appropriate stock solutions. 
After 24 hours incubation, the growth media was carefully aspirated from 
each well of the microplate and replaced with 200µL of the test solution in 
replicates. Complete media without drug was added to some of the wells with 
cells as well as the outer wells without cells, in order to act as a positive control 
and a blank respectively. The microplate was then incubated for 24 hours. 
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Neutral red (40µg/mL) in complete media was prepared in a centrifuge tube 
from a stock solution of 4mg/mL in PBS and incubated overnight, wrapped in 
foil paper at the same temperature as the cells. 
Subsequently, the neutral red solution was centrifuged for 10 minutes at 
≈ 1800 rpm to remove precipitated dye crystals. The microplate was then 
removed from the incubator and the media in each of the wells was gently 
aspirated off and replaced with 100µL of the neutral red solution in each well of 
the plate and then incubated for another 2 hours. After incubation, each well of 
the plate was gently rinsed with PBS (150µL) and the washing solution removed 
by decanting or gently tapping the plate (Ezuruike, 2015).  
150µL of neutral red destain solution (96% ethanol, deionised water, 
glacial acetic acid; 50%:49%:1%) was added to each well of the plate after the 
washing step. The plate was immediately shaken on a microplate shaker for at 
least 10 minutes until the neutral red had been completely extracted from the 
cells and formed a homogenous solution. The optical density (O.D)/absorbance 
of the neutral red extract was read out in the plate reader at 540nm. The 
percentage viability for each of the concentrations of the drug/extract was 
estimated as previously stated in section 2.4.2.1.2 (Repetto et al., 2008).  
2.4.2.3 The MTT assay 
2.4.2.3.1 Background 
Toxicity of HeLa cells was measured using MTT assay. When the yellow 
water soluble tetrazolium salt reaches the mitochondria, the succinate 
dehydrogenase enzyme cleaves the tetrazolium ring, converting the salt into 
insoluble purple formazan crystals. As the reaction is mitochondria-dependant, 
the formazan crystals will only be formed in viable cells and will remain there 
due to the impermeability of the compound to the cell membranes. Only after 
the addition of an acidified isopropanol solution the product is liberated and can 
readily be detected and quantified by a colorimetric method (Fotakis and 
Timbrell, 2006). MTT was chosen for cytotoxicity analysis of the HeLa cells 
because it is one of the most standard and popular methods for such 
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assessment in cells that are submitted to transfection (Bednarek et al., 2008, 
Li et al., 2006, Cheng et al., 2007). 
2.4.2.3.2 Experiment protocol 
The method used for this assay is as described in José Ruiz and 
coworkers (2006) with some modifications. After 24 hours incubation of HeLa 
cells (2 × 104 cells/well) with the plant extracts (100µg/mL) and serial dilutions 
of the positive control ethanol, media containing the samples was removed and 
200µL of fresh media containing 50µL of MTT (1mg/mL) were added to each 
well. After 4 hours incubation, the solution was carefully aspirated and replaced 
by 150µL of MTT solubilisation solution (0.04M HCl in isopropanol). Plates were 
shaken until crystals were completely dissolved and absorbance was measured 
at 570nm in the plate reader and the viability for each of the concentrations of 
the drug/extract was estimated as previously described in section 2.4.2.1.2 
(José Ruiz et al., 2006). 
2.4.3 CYP3A4 mRNA gene expression assay 
2.4.3.1 Background 
Changes in mRNA expression in a cell caused by a xenobiotic can be 
measured several ways, but quantitative PCR (qPCR) is the “gold standard” 
technology to quantify nucleic acids. qPCR is a very sensitive and robust 
technique that collects fluorescent signals from one or more polymerase chain 
reactions over a range of cycles (Dorak, 2007).  
 Briefly; after the mRNA is extracted from a tissue or cell, it needs to be 
retro-transcribed into complementary DNA (cDNA) and this is accomplished by 
using a DNAse, reverse transcriptase enzyme, an oligoprimer, dNTPs (dATP, 
gGTP, dCTP, and dTTP), RT buffer and RNase inhibitor. Before the beginning 
of the cDNA synthesis, mRNA is treated with a DNase in order to digest single 
– and double (dsDNA) – stranded DNA, by the cleavage of each strand of 
dsDNA independently. In the presence of Mg2+, DNase cleaves each strand of 
dsDNA independently and randomly. In the presence of Mn2+, the enzyme 
cleaves both DNA strands at approximately the same site (Figure 2-3). 
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The first strand cDNA synthesis occurs by the incubation of the mRNA 
with a poly(T) tail oligoprimer, which will anneal the poly(A) tail of mRNA in a 
designed temperature. The reverse transcriptase, RNAse inhibitor, dNTPs and 
RT buffer are added to the reaction and transcription will occur at a certain 
temperature, which will be assigned according to the reverse transcriptase 
enzyme used. When the enzyme is deactivated by an increased temperature, 
the cDNA is formed (Figure 2-4).  
The synthesised cDNA is then mixed with a DNA polymerase, a target 
primer sequence (forward and reverse primers) and a fluorescent dye. The 
DNA polymerase is an enzyme that helps catalyse the polymerization of the 
deoxynucleotides into a DNA strand. One of the target primers will anneal to 
the start of the target DNA and another one will anneal to the end of the 
sequence. The fluorescent dye will bind to the DNA and the light will be 
captured and recorded by the system. The more copies of the target gene are 
present in the sample over a range of cycles (denaturation, annealing, and 
extension), the higher will be the intensity of the fluorescence signal (Figure 2-
5). 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2- 3 Cleavage of dsDNA by DNAse in presence of Mg2+ and Mn2+. 
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Figure 2- 4 Graphical representation of cDNA synthesis from RNA template. After extraction, RNA is 
mixed with a oligoprimer, dNTP's and reverse transcriptase enzyme (M-MLV). The oligoprimer is a poly(T) 
tail sequence, which will anneal to the poly(A) tail of the RNA molecule. When dNTPs, buffer and a reverse 
transcriptase enzyme (such as M-MLV) is added to the sample, a complementary strand of DNA (or 
cDNA) is synthesized. 
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Figure 2- 5 Graphical representation of the addition of a target primer sequence and a Master Mix 
containing SYBRâ Green dye and Taq polymerase enzyme. This reaction results in an increase in 
fluorescence signal during the PCR analysis. SYBRâ Green as a free dye displays very low fluorescence 
and it will not bind to the single stranded or denaturated DNA. At the annealing stage, when a double-
stranded structure is formed, SYBRâ Green will bind to it and, as a result, an increase in fluorescent signal 
is observed. During the extension stage, which is conducted by the enzyme Taq polymerase, the 
fluorescent signal increases according to the number of SYBRâ Greendye molecules bound per double-
stranded molecule. This process is repeated in each cycle until it reaches a total of 40 cycles. 
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2.4.3.2 Experiment protocol 
2.4.3.2.1 Total RNA extraction from HepG2 cells 
After exposing HepG2 cells (5 × 105 cells/well) to plant extracts 
(100µg/mL) or the CYP3A4 inducer RIF (50µM) or the CYP 3A4 inhibitor DMSO 
1% for 96 hours, total RNA extraction started by lysing the cells with TRIzol® 
Reagent (1mL). The homogenised sample was transferred to 1.5mL 
RNAse/DNAse free microfuge tubes and incubated for 5 minutes at room 
temperature to permit complete dissociation of the nucleoprotein complex. 
Chloroform (200µL) was added to each sample and the microfuge tubes were 
centrifuged at 12,000 x g for 15 minutes at 4°C. The mixture separated into a 
lower red phenol-chloroform phase, an interphase, and a colourless upper 
aqueous phase, where the RNA remains. The aqueous phase of the samples 
was transferred to new 1.5mL RNAse/DNAse free microfuge tubes and 100% 
isopropanol (500µL) was added in order to precipitate the RNA. The tubes were 
let at room temperature for 10 minutes and centrifuged at 12,000 x g for 10 
minutes at 4°C. The supernatant was removed and the RNA pellet was left in 
the tubes for washing. The washing step was conducted by adding 1mL of 75% 
ethanol to each tube and the centrifuged at 12,000 x g for 10 minutes at 4°C. 
This step was repeated twice and after the removal of the ethanol solution, the 
RNA pellet was air dried for 30 minutes. The RNA was resuspended with 
RNAse free water (100µL) and the quantity, quality and integrity of the samples 
were assessed by agarose gel electrophoresis and NanoDrop, respectively. 
2.4.3.2.2 Agarose gel electrophoresis-assessment of the integrity of RNA 
The integrity of total RNA from HepG2 cells was assessed by visual 
inspection of the two rRNAs 28s and 18s on agarose gels. Ethidium bromide 
(1µL) was added to 1% agarose gel solution and the cooled molten agarose 
solution was poured into the gel tray containing a 10-well foaming comb. After 
30 minutes, the gel was set and the tank was filled with 1 x TAE buffer. Gel 
loading dye (1µL) was added to 5µL total RNA and this was loaded into each 
lane.  
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2.4.3.2.3 NanoDrop reading-assessment of the purity and quality of RNA 
The quantity and quality of RNA were determined by adding 1.5µL of the 
RNA sample to the Nanodrop 2000 (Thermo Scientific). Differential readings 
were made at 230, 260, and 280nm. 
2.4.3.2.4 cDNA synthesis 
Prior to the reverse transcription, RNA samples were treated with DNase 
I (1U/µL) to avoid genomic contamination. cDNA synthesis started by adding 
1µg of total RNA to 0.5mL RNAse/DNAse free microfuge tubes containing 
10mM (1µL) dNTP Mix (10mM each dATP, dGTP, dCTP and dTTP at neutral 
pH, Oligo (dT)12-18 (500 µg/mL) (1µL), and sterile distilled water up to 12µL 
volume. The samples were heated at 65°C for 5 minutes and chilled at 4°C for 
2 minutes to let the primer anneal to the RNA in an MJ Mini Personal Thermal 
Cycler (Bio-Rad). 5X First-Strand Buffer (4µL), 0.1 DDT (2µL) and RNase 
OUTä Recombinant Ribonuclease Inhibitor (40 units/ µL) (1µL) were added to 
the samples tubes and the mixture was incubated at 37°C for 2 minutes. The 
Moloney murine Leukaemia Virus Reverse Transcriptase (M-MLV RT) 
(200U/µL) (1µL) was added to each sample and the tubes were incubated for 
50 minutes at 37°C. The reaction was then inactivated by heating the samples 
at 70°C for 15 minutes. 
2.4.3.2.5 RT-qPCR conditions and analysis 
CYP3A4 sense strand primer sequence was 5’- 
CAAGGACAACATAGATCGTTACATATACACACCCTTTGGAAG-3’ and the 
antisense strand primer was 5’-
AGCTCAATGCATGTACAGAATCCCCGGTTA-3’. The β-actin gene was used 
to control for variations in RNA loading within the experimental conditions. The 
sense strand primer sequence was 5’- CGTACCACTGGCATCGTGAT-3’and 
the antisense strand primer was 5’- GTGTTGGCGTACAGGTCTTTG-3’. The 
RT-qPCR was carried out in 96-well plates using a Pikoreal™ Real-Time PCR 
detection system (Thermo Scientific). Each well contained a final reaction 
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volume of 10µL (5.0µL MasterMix with SYBR Green, 2.0µL cDNA template 
diluted appropriately, 0.5µL of each primer at a final concentration 0.3mM and 
2.0µL of RNAse/DNAse free distilled water). The PCR reaction was performed 
under the following schema: initial denaturation at 95°C for 2 minutes, then 40 
cycles of denaturation at 95°C for 15 seconds, annealing at 55°C (β-actin) or 
60°C (CYP3A4) for 30 seconds, and extension at 72°C for 30 seconds. 
At the end of the run, a melting curve was generated by heating the 
amplicon from 60 to 95◦C in order to confirm the specificity of the amplification 
of each primer pair. All samples were run in quadruplicates. Standard curves 
were produced to check the PCR efficiency using a five-fold dilution series of 
cDNA. Efficiency (E) of primer pairs was obtained from the slope of the 
calibration curve generated. The relative expression was calculated on the 
basis of ‘delta delta Ct’ (DDCt) values. Normalisation of the target gene was 
achieved by using β-actin as a reference gene. 
2.4.4 hPXR activation assay 
2.4.4.1 Background 
Regulation of CYP3A4 mRNA gene expression is mostly related to the 
binding of xenobiotics to nuclear receptors, such as the hPXR, which are DNA 
binding and ligand-regulated transcriptional factor. An interesting feature of 
hPXR is its ligand-binding domain (LBD) (Xie, 2009). hPXR LBD is hydrophobic 
and it is able to change its shape in order to better accommodate numerous 
xenobiotics, such as antibiotics, calcium channel blockers, dietary 
supplements, environmental pollutants and herbal medicines (Chang, 2009, 
Shukla et al., 2011). 
In the case that no ligand binds to hPXR, CYP3A4 transcription is 
inhibited by orphan nuclear receptors, such as the small heterodimer partner 
(SHP) and the silencing mediator of retinoid and thyroid hormone receptors 
(SMRT). These receptors are transcribed by coactivators, such as steroid 
receptor coactivator-1 (SRC-1), hepatocyte nuclear factor a (HNFa), and 
peroxisome proliferator-activated receptor g coactivator-1-a (PGC-1a) (Figure 
2-6A). 
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Upon xenobiotic binding, hPXR translocates into the nucleus and blocks 
the transcription of SHP/SMRT. The ligand-PXR then forms a heterodimer 
complex with the retinoid X receptora (RXRa), which will then bind to the 
xenobiotic responsive enhancer molecule/PXRE (XREM/PXRE) region of the 
CYP3A4 promoter to initiate the expression of the enzyme (Figure 2-6B) (Xie, 
2009). 
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Figure 2- 6 Graphical representation of the activation of PXR nuclear receptor by a xenobiotic (drug), resulting in 
the expression of CYP in presence of coactivators. A, in absence of a ligand, the orphan nuclear receptors small 
heterodimer partner (SHP) and silencing mediator of retinoid and thyroid hormone receptor (SMRT) are transcribed 
in presence of the coactivators steroid receptor coactivator-1 (SRC-1), hepatocyte nuclear factor a (HNF4a)  and 
peroxisome proliferator –activated receptor g coactivator-1a (PGC-1a). As a result, no CYP transcription will occur. 
B, in presence of a ligand (drug), the PXR receptor translocates to the nucleus of the cell and the ligand-PXR 
complex will form a heterodimer with RXR. CYP transcription will initiate upon the binding of the complex coactivators 
(SRC-1, HNF4a and PGC-1a)-ligand-PXR-RXR complex will bind to the xenobiotic responsive enhancer molecule 
(XREM)/PXRE region.   
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2.4.4.2 Experiment protocol 
Four RENISUS plant extracts (Erythrina mulungu Benth., Cordia 
verbenaceae A. DC., Solanum paniculatum L. and Lippia sidoides Cham.) were 
subject to hPXR activation assays. The experiment protocol for hPXR activation 
assay required first the adding of a luciferase reporter gene, which is a 
downstream of the PXRE. Once the ligand binds to the PXRE, the amount of 
luciferase enzyme is quantified by the addition of luciferin substrate and 
detection after cell lysis.  
After 24 hours seeding, HeLa cells (4 × 104 cells/well) were transiently 
co-transfected with 60ng of pM-Gal4-PXR-LBD and 240ng of Gal4 luciferase 
reporter using lipofectamine 2000 reagent according to the manufacturer’s 
protocol. Transfected cells were treated with increasing concentrations of plant 
extract and/or rifampicin 1µM (EC50). Luciferase activity was measured after 24 
hours, according to the manufacturer’s protocol in a 20/20n Glomax 
luminometer and reported as a response (%) compared to cells treated only 
with RIF.  
2.4.5 Intracellular GSH assay 
2.4.5.1 Background 
GSH is a ubiquitous and unusual tripeptide thiol (L-γ-glutamyl-L-
cysteinylglycine) or α-amino acid found in the cortex, medulla, cytosol, 
mitochondria, molecules, blood and most frequently in the liver of various 
mammalian cells in millimolar range (0.5-10mM). It is known to function either 
directly or indirectly in many important biological phenomena, including the 
synthesis of proteins and DNA, transport, enzyme activity, metabolism and 
protection of cells (Meister and Anderson, 1983). Out of all the functions of 
GSH, two are relevant in the process of cell detoxification. They are: (1) its role 
as an antioxidant by removing potentially toxic electrophilic compounds such 
as free radicals, peroxides, and alkylating agent (Ionescu and Caira, 2005, 
Allen et al., 2000) and (2) its role in phase II metabolism of xenobiotics. In 
general, both roles relate to the general function of GSH to protect cells against 
oxygen toxicity (Fahey and Sundquist, 2006).  
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Figure 2- 7 Chemical structures of the reduced GSH (A) and oxidized GSH (GSSG) (B). The tripeptide is 
formed by the amino acids glutamate, L-cysteine, and glycine.  
 
GSH exists in two different forms within cells: the reduced sulfhydryl form 
(GSH) and the glutathione disulphide form (GSSG) (Figure 2-7). In healthy 
cells, GSSG is less than 0.2% of the total GSH concentration. Oxidative stress 
has a profound effect on the cellular thiol balance and can lead to a decreased 
GSH/GSSG ratio in many body organs. Reactive oxygen species (O2-, OH-, 
H2O2 and R-OOH) as well as xenobiotics are neutralised by GSH through a 
cascade of detoxification mechanisms involving the enzymes glutathione 
peroxidases (GPx), GST and GR (Rahman et al., 2007). 
GSH synthesis occurs in the cytosol through a two-step ATP-requiring 
enzymatic process.  First, g-glutamylcysteine is formed by the conjugation of L-
cysteine and glutamate. This step is catalysed by the g-glutamylcysteine 
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synthase (Figure 2-8A). The second step is catalysed by the enzyme GSH 
synthase. The previous formed compound g-glutamylcysteine conjugates with 
the amino acid glycine to generate g-glutamylcysteinylglycine, or GSH (Figure 
2-8B) (Lu, 2013) . 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2- 8 The two-step intracellular GSH synthesis. A, g-glutamylcysteine is formed by the conjugation 
of L-cysteine and glutamate, catalised by g-glutamylcysteine synthase. B, g-glutamylcysteine conjugates 
with glycine to generate g-glutamylcysteinilglycine (GSH). This step is catalised by GSH synthase. 
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Conjugation with GSH avoids the reaction of electrophilic compounds to 
nucleophilic ones in macromolecules such as proteins and nucleic acids. When 
the conjugate is formed, it has to undergo further metabolic reactions in order 
to form mercapturic acid, which has a transport, binding and scavenger function 
whereby transferases is alkylated by the action of reactive intermediates 
(protective and detoxification role). The final product is then eliminated from the 
organism (Sies and Ketterer, 1988).  
The thioether (GSH conjugate) undergoes enzymatic reactions and 
these mechanisms are catalysed by the enzyme GGT which hydrolyses the 
glutathione-S-conjugate at the g-glutamyl bond. GGT enzyme (transpeptidase) 
removes glutamate from the conjugate yielding a dipeptide, which is 
subsequently attacked by the second GGT enzyme (peptidase) to remove the 
amino acid glycine. The cysteine conjugate formed then undergoes then N-
acetylation reaction by N-acetyltransferase (NAT) yielding N-acetylcysteine 
conjugate. Acetylation is a mechanism in which an acetyl group (CH3-COO-) is 
transferred to a molecule (in this case, an acetylation of amine group) by N-
acetylase. This is a “ping-pong” mechanism made in two steps where the N-
acetylase catalyses the transfer of the acetyl group from acetyl-CoA to the GSH 
conjugate and forms an acetyl-enzyme that will then undergo the acetylation of 
the arylamine with regeneration of the enzyme (Figure 2-10) (Ionescu and 
Caira, 2005). This detoxification pathway can also be detected in vitro by using 
HepG2 cells as model system (Rebbeor et al., 1998). 
 
 	 105	
R S Cys
Gly
Glu
Glu
R S Cys
Gly
NH2
Gly
R-S-Cys-NH2
R-S-Cys-NH-CO-CH3
transpeptidase
peptidase
Mercapturic AcidN-acetylase
N-acetylcystein
mercapturic acid conjugate
R-S-Cys-NH2 R-S-Cys-NH-CO-CH3
Acetyl-CoA
CoA-SH
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
	
Figure 2- 10 N-acetylation of mercapturic acid. 
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Figure 2- 9 Formation of mercapturic acid conjugate from a GSH conjugate. After the conjugation of 
GSH with the metabolite, the complex is released from the cell where is firstly borken down by a 
transpeptidase (g-glutamyl transferase) followed by the release of the amino acid glutamate. The 
remaining part of the complex is broken down once again by a dipeptidase, which will dissociate the 
amino acid glycine from the rest of the molecule to form the mercapturic acid. In order to improve the 
polarity of the mercapturic acid, an acetyl group is added to the molecule to form the N-acetylcystein 
mercapturic acid conjugate, which will be further excreted in the urine. 
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 Disease conditions or xenobiotics that induce oxidative stress, in turn 
affect intracellular GSH concentrations. By measuring the intracellular GSH 
levels in the presence of the plant extracts, we can determine if the extracts will 
enhance or diminish the detoxification effects of GSH. Several protocols for 
measurement of intracellular GSH levels have been published using chemical, 
enzymatic, high-pressure chromatographic, and flow cytometric methods. 
However, issues including low throughput caused by a complicated and time-
consuming sample preparation and the use of large amounts of samples made 
it necessary the develop a microassay, which uses a 96-well microtiter plate to 
measure GSH levels in HepG2 cells (Allen et al., 2000). The method used in 
the intracellular determination of GSH levels was adapted from that described 
by Allen and coworkers (2000) and Rahman and coworkers (2007) with slight 
modifications (Allen et al., 2000, Rahman et al., 2007).  
The assay was based on the reaction of GSH with DTNB (5, 5’-dithio-
bis (2-nitrobenzoic acid), also known as Ellman’s reagent to produce TNB (5-
thio-2-nitrobenzoic acid), a yellow coloured chromophore which can be 
measured spectrophotometrically at 405nm, and an oxidized GSH-TNB adduct 
(GS-TNB). The GS-TNB adduct was reduced by GR in the presence of NADPH 
to form GSH and TNB, with the former being recycled back into the system to 
produce more TNB (Figure 2-11)  (Rahman et al., 2007).  
The kinetic reaction is similar to an SN2 mechanism. The nucleophile 
(GSH anion - GS-) attacks the disulphide bridge of DTNB (5,5’dithiobis-2-
nitrobenzoic acid) in order to form the monothiol anion TNB that is highly 
coloured, which has a maximal absorbance at 412nm. The absorbance of TNB 
formed corresponds to the amount of intracellular GSH in the sample. The 
enzyme GR in presence of NADPH will reduce the disulphide product (GS-
TNB), therefore recycling therefore GSH back into the reaction (Szajewski and 
Whitesides, 1980, Allen et al., 2000, Rahman et al., 2007). 
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Figure 2- 11 Enzymatic recycling of GSH from glutathione disulphide (GSSG) by glutathione reductase 
(GR) in the presence of NADPH. GSH reacts with DTNB to GS-TNB and TNB, with subsequent reduction 
of the former to GSH. TNB can be measured at 405 nm. (Adapted from Rahman et al., 2007). 
 
The GSSG present in the sample is also reduced by GR to form two 
molecules of GSH. Thus, the amount of GSH measured represented the sum 
of reduced and oxidised GSH in the sample. The rate of change in absorbance 
of TNB at 405nm is linearly proportional to the total concentration of GSH in the 
sample. The concentration of an unknown sample can therefore be determined 
by calculating from the linear equation or the regression curve generated from 
several standard concentrations of GSH. 
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2.4.5.2 Experiment protocol 
            HepG2 cells (4 x 104 cells per well) were seeded out in sterile, flat 
bottom 96-well plates and incubated overnight to allow for cell attachment. The 
next day, the cells were treated with the plant extracts (100µg/mL) to be tested 
in triplicates. Three wells were not treated with any drug and served as the 
media control, while three other wells were treated with buthionine 
sulphoximine (BSO) (10µM) as the positive control. All drug/extract incubations 
were done for 24 hours. 
          Prior to commencing the GSH assay, the following solutions were 
prepared: phosphate buffer solution containing 168mL of a 286mM solution of 
sodium phosphate dibasic in distilled water, 32mL of a 286mM solution of 
sodium phosphate monobasic and 6.3mM EDTA; 5% SSA in double distilled 
water; 0.1% Triton X-100; 1mM stock solution of reduced glutathione in 5% 
SSA solution; and 10mM DTNB in phosphate buffer solution. Apart from the 
DTNB, all the other solutions were able to be stored in the fridge at 2 - 4 °C for 
up to a week. 2.39mM or 2mg/mL β-NADPH in phosphate buffer solution was 
freshly prepared on the day of the assay. 
          24 hours after incubation of the extract/drug, the cells were washed with 
PBS (200µL per well) and the PBS was aspirated off. 0.1% Triton X-100 (60µL) 
was added to each well of the plate containing cells and then shaken on a 
microplate shaker for 2 minutes to lyse the cells. The UV light of the laminar 
flow hood was turned off for the rest of the assay to minimise GSH oxidation.  
         Subsequently, 5% SSA solution (25µL) was added and the plate shaken 
for another 2 minutes. After shaking, the lysed cell solution (25µL) was 
transferred to the wells of the next three inner columns of the plate. 5% SSA 
solution (25µL) was added to each well of the first column of the plate as a 
blank. A double dilution of a standard solution of reduced glutathione in 5% 
SSA (25µL), starting from 100µM GSH as the highest concentration was then 
prepared.  
           The GSH reaction buffer needed for the assay was prepared by adding 
the freshly prepared β-NADPH (1mL) and GR (3µL) (equivalent to 2 units of 
GR) to the phosphate buffer solution (7.5mL) for each 96-well plate. This was 
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vortexed for 5 seconds and then the DTNB solution (1mL) was immediately 
thawed and added to the reaction buffer and then vortexed for another 5 
minutes. All solutions to be used were kept on ice until needed. The reaction 
buffer (125µL) was added to each well of the 96-well plate containing either the 
blank SSA solution (25µL), the GSH standards (25µL) or the cell lysate solution 
(25µL). The microplate was immediately covered and then wrapped in foil paper 
and then shaken in the microplate for 15 seconds. Immediately after, the 
absorbance of the wells of the microplate was read in a kinetic cycle in the 
TECAN plate reader every 30 seconds for 5 minutes at 405nm (11 readings).           
The slope of the curve obtained from the 11 readings of each of the GSH 
standard concentrations (otherwise known as the I-slope), which represents the 
rate of change of GSH levels at that concentration plotted against the GSH 
concentration to give a regression curve (otherwise known as the F-slope 
curve). The concentration of GSH in the samples from the cell lysate solutions 
was then estimated by substituting the average I-slope values for each of the 
extract/drug into the equation of the F-slope curve (Ezuruike, 2015). 
           
2.4.6 GGT activity assay 
2.4.6.1 Background 
GGT is a membrane-localised enzyme that plays a key role in the 
maintenance of GSH at normal levels in the body. The enzyme provides the 
aminoacid cysteine, which is the precursor for GSH synthesis. As GSH cannot 
be hydrolysed by general peptidases due to its unusual peptide bond linking 
glutamate and cysteine through the g-carboxyl group of glutamate instead of 
the conventional a-carboxyl group, GGT has the crucial function of breaking 
down that bond. The enzyme catalyses the cleavage of the g-glutamyl bond of 
GSH and the transfer of the g-glutamyl group to water, amino acids or peptides.  
The amino acid cysteine is fundamental for GSH synthesis in the cell. In 
this cycle, GSH is transported out of the cell and it is first broken-down by GGT, 
form g-glutamyl aminoacid and cysteinylglycine. g-glutamyl aminoacid is 
transported back into the cell and metabolised to release the amino acid and 5-
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oxoproline, which will then be further converted to glutamate and 
reincorporated to GSH. Cysteinylglycine is cleaved by dipeptidases to produce 
glycine and cysteine, which is transported back into the cell. The majority of 
cysteine uptake by the cell is to synthesise GSH and the remaining part is used 
for the synthesis of proteins and/or broken down into sulphate and taurine 
(Figure 2-12). When GGT activity is deficient, GSH molecule is not cleaved and, 
as a consequence, the cells are unable to re-uptake the cysteine for the 
tripeptide synthesis.  
 In order to conduct our GGT activity enzymatic assay we used HepG2 
cells, which displays a relatively high activity of the enzyme. Also, GGT activity 
in HepG2 cells are comparable to that seen in human liver and higher than the 
activity found in rat liver (Rebbeor et al., 1998). The GGT enzyme activity assay 
was performed using GpNA as it consists of the release of p-nitroaniline, which 
was monitored by spectrophotometer at 405nm. The GGT catalyses the 
transfers of the g-glutamyl group from the substrate GpNA (colourless) to the 
acceptor glycylglycine (gly-gly), liberating the chromogen p-nitroaniline, which 
is proportional to the GGT present.  
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Figure 2- 12 The g-glutamyl cycle. When GSH is transported out of the cell, the enzyme gamma-glutamyl 
transferase (GGT) will break down the tripeptide and transfer the g-glutamyl moiety to an amino acid, 
forming g-glutamyl amino acid and cysteinylglycine. The g-glutamyl amino acid is transported back to the 
cell where it will be metabolized to release the amino acid and 5-oxoproline, which will be converted to 
glutamate and reincorporated into GSH. Dipeptidase will break down cysteinylglycine into glycine and 
cysteine. The latter will be transported back to the cell to be reincorporated into GSH. The amount of 
cysteine which is not used for GSH synthesis will be incorporated into newly synthesized proteins and/or 
broken down into sulphate and taurine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.6.2 Experiment protocol 
GGT activity assay was conducted according Rebbeor and coworkers 
(1998) with slight modifications. Briefly, after 24 hours of incubation of HepG2 
cells (1 × 106 cells/well) with the GGT inhibitor acivicin (5µM) or plant extracts 
(100µg/mL), media was aspirated and cells were washed with PBS. 4mL of pre-
warmed Gly-Gly buffer (115mM Tris, 138mM Gly-Gly) and 400µL of the 
substrate GpNA (29.6mg/mL of HCl 0.5mmol/L) were added to the wells and 
plates were incubated for 10 minutes. Subsequently, 500µL of the content of 
each well were transferred to 24-well plates and absorbance was measured in 
the plate reader (405nm). The absorbances were converted into absolute 
amounts by means of a calibration line using p-nitroaniline (Rebbeor et al., 
1998). 
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2.4.7 Modulation of P-glycoprotein dependant Rh-123 efflux in Caco-2 
cells 
2.4.7.1 Background 
Rh-123 is a cationic hydrophilic fluorescent P-gp substrate, which has 
been used as a probe to assess the functional activity of P-gp in a variety of 
cell lines and assays (Lee et al., 1994). In the intestine, the absorptive transport 
of Rh-123 occurs primarily by a passive diffusion process via the paracellular 
pathway. However after absorption, Rh-123 is secreted back into the lumen, 
first of all via a transcellular uptake process through the basolateral membrane 
followed by P-gp mediated efflux through the apical membrane (Troutman and 
Thakker, 2003).  
Caco-2 VCR cells were used for this drug accumulation/efflux assay 
where the amount of the Rh-123 retained by the cells after an incubation period 
(in the presence or absence of inhibitors) was measured spectrofluorometrically 
(Chieli and Romiti, 2008). Compounds that interact with the P-gp transporter 
either as substrates or inhibitors as depicted in figure 2-13 modulate the P-gp 
mediated efflux of Rh-123 and could therefore be identified.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2- 13 Schematic representation of the inhibition of Rh-123 efflux by modulators of the P-
glycoprotein transporter. Rh-123 is a fluorescent dye and a P-gp substrate. Upon cell uptake, Rh-123 will 
be effluxed out by P-gp in an ATP-requiring process. In presence of a p-glycoprotein inhibitor, the efflux 
in reduced allowing the accumulation of Rh-123 in the cell, which is detected and quantified by a 
spectrofluorometer. 
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2.4.7.2 Experiment protocol 
The protocol used for this assay is as described in Chieli and coworkers 
(2009), with slight modifications (Chieli et al., 2009). Caco-2 VCR cells to be 
used were routinely grown in the appropriate complete growth media in 75cm2 
tissue culture flasks as described in section 2.4.1.3. The culture media of the 
cells were usually changed a day before plating out to ensure that the cells 
were in their exponential stage of growth. The media of Caco-2 VCR cells was 
replaced with complete media without vincristine at this point.  
80 to 90% confluent culture flask of cells were trypsinised and then 
plated out in the inner wells of a sterile 96-well plate at a density of 1.5 x 104 
cells/well in full culture media (without vincristine). The cells were then placed 
in the incubator overnight to allow for attachment. The next day, the growth 
media of the cells was changed to serum free media (without 10% FBS). This 
was to ensure a more uniform condition for the majority of the cell population 
and to prevent adsorption of drugs to the serum proteins. The microplates were 
then replaced back in the incubator for 24 hours.  
On the day of the assay, Rh-123 (5µg/mL) solution in serum free media 
sufficient for the assay was prepared from a stock solution in DMSO (5mg/mL) 
(solution A). All the extracts to be tested were then prepared (100µg/mL) in 
solution A (solution B), while 20µM verapamil (Securon® I.V. 2.5mg/mL, Abbot 
Laboratories Limited) was also prepared in solution A as positive control 
(solution C). The media in each of the wells of the microplate was then aspirated 
off and then replaced with either solution A, B or C in replicates. The 
microplates were placed back in the incubator for 2 hours to allow for 
intracellular Rh-123 accumulation within the cells. During this time, 20µM 
verapamil in PBS (solution D) was also prepared and stored in the fridge at 4°C. 
After the two hours of incubation, the media in the wells were all 
aspirated off and each well was washed three times, gently but quickly with the 
ice cold solution D (200µL) to stop the P-gp efflux activity. 0.1% Triton X-100 in 
PBS (100µL) was then added to each well and then placed in the incubator for 
15 minutes to lyse the cells and completely solubilise the intracellular Rh-123. 
Cell lysates (80µL) were transferred to a 96-well black plate and the 
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fluorescence intensity of each well was measured in a Tecan® plate reader 
(Exc-485nm, Em-525nm). The cellular accumulation of Rh-123 for each of the 
extracts was expressed as the percentage of the accumulation measured for 
Rh-123 only (solution A), that is under control conditions. 
2.4.8 Statistical Analysis  
Collected data were analysed as means ± SD of at least three independent 
experiments. Statistical significance was measured by student t-test and one-
way ANOVA followed by Bonferroni correction using GraphPad InStat 
(GraphPad Software Inc., La Jolla, CA, USA). Results with a value of p < 0.05 
were considered significant.  
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3 RESULTS  
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3.1 AUTHORISATION FOR ACCESSING THE BRAZILIAN GENETIC 
HERITAGE COMPONENT FROM CGEN AND YIELD OF PLANT 
EXTRACTS 
The authorisation from CGEN for the initiation of our research with the 
Brazilian plant extracts was issued in May 2014 (Appendix 7.4). A total number 
of twenty-four plant samples comprising twenty-three species from nineteen 
families were collected from either the “Farmácias vivas” or bought from the 
herbal suppliers in Brazil in 2014.  
All samples were extracted by infusing with hot water. The yields of the 
different plant samples varied from as low as 5.03% w/w (Artemisia absinthium) 
to as high as over 14.95% w/w (Cordia verbenaceae) (Table 3-1). 
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Table 3- 1Tabular summary of plant samples - Collection & Extraction 
Plant name Family Local name Plant Part Sample 
ID 
Place of 
collection/purchase 
Extraction 
method 
Yield 
(%w/w) 
Apuleia ferrea (Mart.) Baill.  Leguminosae Pau-ferro Stem-bark AF1 Florien Infusion 14.18 
Artemisia absinthium L. Compositae Losna Herb AA1 Florien Infusion 5.03 
Bidens pilosa L.  Compositae Picão Leaves BP1 Florien Infusion 6.44 
Casearia sylvestris Sw. Salicaceae Guaçatonga Aerial parts CAS Florien Infusion 7.52 
Cordia verbenaceae A. DC.  Boraginaceae Erva-baleeira Leaves CV1 Farmácia Viva Infusion 14.95 
Costus spicatus (Jacq.) Sw. Costaceae Cana-de-macaco Leaves CS1 Florien Infusion 9.58 
Equisetum arvense L. Equisetaceae Cavalinha Herb EA1 Florien Infusion 8.93 
Erythrina mulungu Benth.  Leguminosae Mulungu Stem-bark  EM1 Santos Flora Infusion 5.77 
Lamium album L.  Lamiaceae Urtiga-branca Herb LA1 Florien Infusion 7.65 
Lippia sidoides Cham.  Verbenaceae Alecrim-pimenta Leaves LS1 Farmácia Viva Infusion 13.33 
Malva sylvestris L.  Malvaceae Malva Flower 
Leaves 
MSF 
MSH 
Florien 
Florien 
Infusion 
Infusion 
6.16 
11.87 
Maytenus ilicifolia Mart. ex 
Reissek 
Celastraceae Espinheira-santa Leaves MI1 Florien Infusion 8.49 
Morus nigra L.  Moraceae Amoreira-preta Leaves MN1 Florien Infusion 10.68 
Passiflora incarnata L.  Passifloraceae Maracujá Leaves PI1 Florien Infusion 9.13 
Persea americana Mill.  Lauraceae Abacateiro Leaves PA1 Florien Infusion 7.19 
Rhamnus purshiana DC.  Rhamnaceae Cáscara-sagrada Stem-bark RP1 Santos Flora Infusion 12.33 
Salix alba L.  Salicaceae Salgueiro-branco Leaves SA1 Florien Infusion 12.51 
Schinus terebinthifolia Raddi Anacardiaceae Aroeira Stem-bark ST1 Florien Infusion 11.49 
Solanum paniculatum L.  Solanaceae Jurubeba Aerial parts SP1 Santos Flora Infusion 9.27 
Solidago microglossa DC.  Compositae Arnica brasileira Aerial parts SM1 Santos Flora Infusion 13.43 
Syzygium jambolanum (Lam.) 
DC.  
Myrtaceae Jambolão Leaves  SJ1 Santos Flora Infusion 10.05 
Tabebuia avellanedae Lorentz 
ex Griseb.  
Bignoniaceae Ipê Stem-bark TA1 Santos Flora Infusion 13.10 
Vernonia polyanthes Less.  Compositae Assa-peixe Aerial parts VP1 Florien Infusion 14.72 
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3.2 PHYTOCHEMICAL ANALYSIS 
HPTLC analysis in the four RENISUS Brazilian native plants showed 
that Cordia verbenaceae A. DC. contains caffeic acid at Rf = 0.87 and 
chlorogenic acid at Rf = 0.38. Solanum paniculatum L. contains gallic acid at 
Rf = 0.81, rutin at Rf = 0.20 and chlorogenic acid at Rf = 0.38. Lippia sidoides 
Cham. contains luteolin at Rf = 0.86 and minor amounts of quercetin at Rf = 
0.90. Erythrina mulungu Benth. did not contain any of these metabolites in 
significant amounts (Figures 3-1, 3-2 and 3-3 and table 3-2).  
HPLC fingerprinting analysis targeting phenolic compounds showed the 
presence of tannins, chlorogenic acid, caffeic acid, rutin, phenolic acids and 
glycosylated flavonoids in most of the samples (Table 3-2 and Appendix 7.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3- 1 365nm after derivatization. 
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Figure 3- 3 365nm before derivatization. 
 
Figure 3- 2 235nm after derivatization. 
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 Table 3- 2 Tabular summary of phenolic compounds present in plant samples detected by HPTLC and HPLC-DAD. 
Plant name Phenolic standards detected in sample based on HPTLC* and HPLC-DAD* analysis 
Apuleia ferrea (Mart.) Baill. Tannins* 
Artemisia absinthium L. Chlorogenic acid* 
Bidens pilosa L. Chlorigenic acid*, Caffeic acid* and flavonoids* 
Casearia silvestris Sw. Chlorogenic acid* and phenolic acids* 
Cordia verbenaceae A. DC. Caffeic acid*, chlorogenic acid*, phenolic acids* 
Costus spicatus (Jacq.) Sw. Glycosylated flavonoids* and quercetin* 
Equisetum arvense L. Caffeic acid acid*, phenolic acids* and glycosylated flavonoids* 
Erythrina mulungu Benth. None*, tannins*, phenolic acids*, glycosylated flavonoids* 
Lamium album L. Tannins*, chlorogenic acid*, glycosylated flavonoids*, phenolic acids* 
Lippia sidoides Cham. Luteolin*, quercetin*, flavonoids* 
Malva sylvestris L. (MSH and MSF) Phenolic acids* and flavonoids*  
Maytenus ilicifolia Mart. ex Reissek Glycosylated flavonoids* 
Morus nigra L. Chlorogenic acid* 
Passiflora incarnata L. Glycosylated flavonoids* 
Persea americana Mill. Chlorogenic acid* and Glycosylated flavonoids* 
Rhamnus purshiana DC. Chlorogenic acid* and Glycosylated flavonoids* 
Salix alba L. None* 
Schinus terebinthifolia Raddi Phenolic acids* 
Solanum paniculatum L. Gallic acid*, rutin*, chlorogenic acid** and Glycosylated flavonoids* 
Solidago microglossa DC. Chlorogenic acid* and Glycosylated flavonoids* 
Syzygium jambolanum (Lam.) DC. Glycosylated flavonoids* 
Tabebuia avellanedae Lorentz ex Griseb. Tannins*, phenolic acids* 
Vernonia polyanthes Less. Glycosylated flavonoids* 
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3.3 SRB, NEUTRAL RED AND MTT ASSAYS FOR DETERMINATION OF 
CELL VIABILITY/CYTOTOXICITY 
The three selected cell viability assays were conducted after 24 hours 
incubation with either the plant extracts or drugs. Viability of HepG2, Caco-2 
VCR and HeLa was assessed prior to evaluation of the extracts using ethanol 
and hydrogen peroxide (H2O2) as positive references (Figure 3-4). As all the 
extracts were completely dissolved in water, no DMSO was used in the 
samples. 
The maximum non-toxic concentration (MNTC) values were determined 
for all the extracts using HepG2 and Caco-2 VCR cell lines. The MNTC of 
Erythrina mulungu Benth, Cordia verbenaceae A. DC, Solanum paniculatum L. 
and Lippia sidoides Cham. were also assessed in HeLa cells. Initially, the 
experiment was conducted using concentrations of extracts ranging from 100 
to 1000µg/mL. However, no toxicity was found in concentrations above 
100µg/mL (viability ³ 80%) (Table 3-3). Therefore, our preclinical study was 
conducted using 100µg/mL of each extract, which is considered a higher limit 
than necessary to get physiological relevant results.  
 
 
 B 
C 
Figure 3- 4 Viability of (a) HepG2, (b) Caco-2 VCR and (c) HeLa cells in presence of different concentrations 
of ethanol and H2O2 (Results show mean ± SEM, N³3). 
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Plant name Sample ID % Viability HepG2 (100µg/mL) % Viability Caco-2 VCR (100µg/mL) % Viability HeLa 
(100µg/mL) 
Apuleia ferrea (Mart.) Baill.  AF1 87.59 ± 0.213 80.96 ± 0.033 - 
Artemisia absinthium L. AA1 81.06 ± 0.099 93.01 ± 0.188 - 
Bidens pilosa L.  BP1 92.38 ± 0.021 92.15 ± 0.056 - 
Casearia silvestris Sw. CAS 99.82 ± 0.012 90.36 ± 0.134 - 
Cordia verbenaceae A. DC.  CV1 98.16 ± 0.131 99.96 ± 0.091 97.44 ± 0.118 
Costus spicatus (Jacq.) Sw. CS1 99.07 ± 0.010 95.98 ± 0.064 - 
Equisetum arvense L. EA1 87.04 ± 0.055 92.08 ± 0.138 - 
Erythrina mulungu Benth.  EM1 95.57 ± 0.101 97.61 ± 0.172 98.13 ± 0.196 
Lamium album L.  LA1 96.80 ± 0.053 92.18 ± 0.156 - 
Lippia sidoides Cham.  LS1 96.79 ± 0.014 96.85 ± 0.051 95.66 ± 0.235 
Malva sylvestris L.  MSF 88.07 ± 0.084 98.93 ± 0.203 - 
MSH 92.88 ± 0.070 94.79 ± 0.202 - 
Maytenus ilicifolia Mart. ex Reissek MI1 97.16 ± 0.108 97.17 ± 0.230 - 
Morus nigra L.  MN1 99.81 ± 0.012 97.23 ± 0.129 - 
Passiflora incarnata L.  PI1 99.97 ± 0.072 94.69 ± 0.175 - 
Persea americana Mill.  PA1 97.12 ± 0.013 99.13 ± 0.113 - 
Rhamnus purshiana DC.  RP1 98.34 ± 0.012 89.97 ± 0.320 - 
Salix alba L.  SA1 81.68 ± 0.014 83.72 ± 0.074 - 
Schinus terebinthifolia Raddi ST1 84.58 ± 0,045 84.83 ± 0.109 - 
Solanum paniculatum L.  SP1 92.47 ± 0.121 98.78 ± 0.080 96.12 ± 0.109 
Solidago microglossa DC.  SM1 97.52 ± 0.192 93.49 ± 0.215 - 
Syzygium jambolanum (Lam.) DC.  SJ1 93.75 ± 0.048 82.82 ± 0.140 - 
Tabebuia avellanedae Lorentz ex Griseb.  TA1 99.74 ± 0.014 82.72 ± 0.111 - 
Vernonia polyanthes Less.  VP1 93.04 ± 0.021 95.95 ± 0.079 - 
Table 3- 3 Tabular summary of cytotoxicity of plant extracts in HepG2, Caco-2 VCR and HeLa cells.	
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Table 3- 4 Tabular summary of the purity and quality of RNA using NanoDrop. The ratio of absorbance 
260nm and 280nm is used to assess the purity of RNA. The ratio ±2.0 is generally accepted as “pure” for 
RNA. The ration 260/230 is used as a secondary mesure of nucleic acid purity and the ratio should also be 
±2.0. 
 
3.4 CYP3A4 MRNA GENE EXPRESSION 
3.4.1 Integrity and NanoDrop reading-assessment of the purity and 
quality of RNA 
The two rRNAs 28s and 18s were visible in all RNA samples, which 
attest its full integrity. Purity and quality of RNA were assessed by differential 
UV readings as described in section 2.4.3.2.3. The materials were of 
acceptable quality (ratio ± 2.0) to undergo mRNA amplification as seen in table 
3-4. 
 
Samples Sample 
ID 
RNA 
concentration 
(ng/uL) 
A260 A280 A260/A280 A260/A230 
Control (DMSO 0.2%) CTR 639.00 18.475 9.237 2.00 2.21 
RIF 50µM RIF 657.4 16.434 8.122 2.02 2.07 
DMSO 1% DMS 544.0 13.600 6.754 2.01 2.19 
Apuleia ferrea (Mart.) 
Baill.  
AF1 269.5 6.738 3.547 1.90 2.31 
Artemisia absinthium 
L. 
AA1 645.9 16.147 8.745 1.85 2.31 
Bidens pilosa L.  BP1 771.4 19.285 9.628 2.00 2.21 
Casearia silvestris Sw. CAS 570.9 14.272 7.458 1.91 1.87 
Cordia verbenaceae A. 
DC.  
CV1 688.4 17.211 8.752 1.97 2.40 
Costus spicatus 
(Jacq.) Sw. 
CS1 694.6 17.364 9.028 1.92 2.23 
Equisetum arvense L. EA1 628.2 15.705 8.090 1.94 2.30 
Erythrina mulungu 
Benth.  
EM1 573.5 14.337 7.382 1.94 2.43 
Lamium album L.  LA1 588.9 14.722 7.382 1.99 2.28 
Lippia sidoides Cham.  LS1 691.4 17.284 8.792 1.97 2.19 
Malva sylvestris L.  MSF 567.4 14.184 7.210 1.97 2.30 
MSH 628.8 15.721 8.200 1.92 2.29 
Maytenus ilicifolia 
Mart. ex Reissek 
MI1 597.1 14.926 7.861 1.90 2.28 
Morus nigra L.  MN1 452.8 11.321 5.913 1.91 2.19 
Passiflora incarnata L.  PI1 747.9 18.696 10.089 1.86 2.30 
Persea americana Mill.  PA1 568.7 14.217 7.206 1.97 2.38 
Rhamnus purshiana 
DC.  
RP1 638.3 15.957 8.066 1.98 2.05 
Salix alba L.  SA1 461.5 11.537 5.908 1.95 2.08 
Schinus terebinthifolia 
Raddi 
ST1 425.8 10.645 5.577 1.91 1.85 
Solanum paniculatum 
L.  
SP1 690.3 17.257 8.928 1.93 2.33 
Solidago microglossa 
DC.  
SM1 599.1 14.978 7.974 1.88 2.23 
Syzygium jambolanum 
(Lam.) DC.  
SJ1 368.1 9.203 4.709 1.95 1.91 
Tabebuia avellanedae 
Lorentz ex Griseb.  
TA1 774.6 19.364 9.730 1.99 2.31 
Vernonia polyanthes 
Less.  
VP1 654.5 16.363 8.418 1.94 2.40 
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3.4.2 Real-time qPCR efficiency 
Both CYP3A4 and β-actin primers sequences revealed the specificity of 
the target amplification. The baseline and threshold were properly set. Standard 
curve demonstrated good regression coefficient and efficiency. Melting curve 
analysis revealed a single peak for each pair of primers (Figures 3-5, 3-6, 3-7, 
and 3-8). These results allowed us to select β-actin as potential normaliser 
gene.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3- 5 CYP3A4 primer calibration curve. 
Figure 3- 6 CYP3A4 primer melting curve. 
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Figure 3- 8 b-actin primer calibration curve. 
Figure 3- 7 b-actin primer melting curve. 
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3.4.3 Polymerase chain reaction (PCR) 
RIF (50µM), a known CYP3A4 inducer, was able to significantly increase 
CYP3A4 expression in HepG2 cells (4.95-fold; p<0.001). DMSO 1% inhibited 
CYP3A4 expression in 2.7-fold (p<0.01). Therefore, we used these two drugs 
as inducer/positive and negative reference drug, respectively, in our studies.  
Apuleia ferrea (Mart.) Baill., Casearia silvestris Sw., Equisetum arvense 
L., Maytenus ilicifolia Mart. ex Reissek, Passiflora incarnata L., Persea 
americana Mill., Rhamnus purshiana DC., Salix alba L., Schinus terebinthifolia 
Raddi, Syzygium jambolanum (Lam.) DC.  and Vernonia polyanthes Less. were 
able to induce CYP3A4 mRNA expression at significant levels ranging from 
1.53 fold (Rhamnus purshiana DC.) to 4.88-fold (Schinus terebinthifolia Raddi).  
Lamium album L. and Solanum paniculatum L., on the other hand, 
inhibited CYP3A4 mRNA gene expression in 1.96 and 2.40-fold respectively, 
showing a similar effect to DMSO 1% (p<0.01). 
Artemisia absinthium L., Bidens pilosa L., Cordia verbenaceae A. DC., 
Costus spicatus (Jacq.) Sw., Erythrina mulungu Benth., Lippia sidoides Cham., 
Malva sylvestris L. (flower and herb), Morus nigra L., Solidago microglossa DC. 
and Tabebuia avellanedae Lorentz ex Griseb. were not able to modulate 
CYP3A4 expression in a significant manner compared to non-treated cells 
(Figure 3-9 and Appendix 7.6). 
By mimicking the traditional use of the selected herbs, we surprisingly 
observed that about 54% of the extracts were able to interfere with CYP3A4 
mRNA gene expression at the tested concentration of 100µg/mL. Out of the 
extracts that were able to modulate CYP3A4 expression, two are native to 
Brazil: Vernonia polyanthes Less. (induces CYP3A4 expression) and Solanum 
paniculatum L. (inhibits CYP3A4 expression). 
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Figure 3- 9 Effect of 24-hour incubation of extracts  (100µg/mL) or the positive control rifampicin (50µM) and the negative control DMSO 1% in CYP3A4 mRNA gene 
expression in HepG2 cells. Thirteen extracts – CAS, EA1, RP1 (p<0.05), MI1, PI1, PA1 (p<0.01), AF1, SA1, ST1, SJ1 and VP1 (p<0.001) produced statistically significant 
increase in CYP3A4 mRNA gene expression in HepG2 cells based on one-way ANOVA test followed by Bonferroni correction. LA1 (p<0.05) and SP1 (0.01), on the other 
hand, were able to decrease CYP3A4 expression. 
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3.4.4 hPXR antagonistic effect of Solanum paniculatum L. 
To further investigate whether the diminished expression of CYP3A4 
mRNA gene by Solanum paniculatum L. treatment was mediated by an 
antagonist effect upon hPXR, we performed a reporter gene assay. As we can 
observe, co-transfected HeLa cells treated with RIF (1µM) and serial dilutions 
of Solanum paniculatum L. extract show a dose-response inhibition upon hPXR 
transcription activity. The maximal inhibition was close to 60% with an IC50 of 
0.38mg/mL (Figure 3-10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3- 10 Antagonistic effect of Solanum paniculatum L. extract on RIF-induced hPXR activation. HeLa 
cells were co-transfected with expression vector pM-Gal4-PXR-LBD and Gal4 luciferase reporter and 
treated with increasing concentrations of Solanum paniculatum L. in the presence of RIF 1μM (EC50). 
Luciferase activity was measured after 24h and normalized as a percentage of RIF treated cells. 
 
Inhibition of hPXR reporter gene assay was not due to interference of 
the extract with the luciferase activity since it did not show any effect on 
luciferase activity in HeLa cells transfected with CMV-luciferase expression 
vector. Additionally, this extract showed an agonist effect in HeLa cells co-
transfected with thyroid hormone receptor beta 1 ligand binding domain and 
Gal4 luciferase reporter treated with triiodothyronine (T3). We did not use 
Renilla luciferase assay as an internal control since several authors have 
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described the limitations of Renilla luciferase as an internal control of 
transcription efficiency (Figures 3-11, 3-12, and 3-13) (Shifera and Hardin, 
2010, Ho and Strauss, 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3- 11 Agonistic effect. HeLa cells were co-transfected with expression vector pM-Gal4-PXR-LBD 
and Gal4 luciferase reporter and treated with vehicle, rifampicin (RIF) or increasing concentrations of 
Solanum paniculatum L. Luciferase activity was measured after 24 hours and reported as fold induction 
compared to vehicle. Results represent data from three independent experiments performed in triplicate. 
*** p ≤ 0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3- 12 HeLa cells were co-transfected with expression vector pM-Gal4-dTRb1-LBD and Gal4 
luciferase reporter and treated with vehicle, T3 or increasing concentrations of Solanum paniculatum L. 
Luciferase activity was measured after 24 hours and reported as fold induction compared to vehicle. 
**p≤0.01; ***p≤0.001. 
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Figure 3- 13 HeLa cells were transfected with expression vector CMV luciferase reporter and treated with 
vehicle, 1.6 or 2.0 mg/ mL of Solanum paniculatum L. Luciferase activity was measured after 24 hours 
and reported as fold induction compared to vehicle.  
 
We also evaluated the effect of the other three native extracts (Erythrina 
mulungu, Lippia sidoides, and Cordia verbenaceae) on hPXR transcription 
activity. We observed that Erythrina mulungu Benth. is an hPXR partial agonist 
since it increased hPXR reporter gene transcription activation in a dose-
dependent manner, but not as strong as RIF. Lippia sidoides Cham. did not 
show any effect on hPXR. Cordia verbenaceae A. DC. failed to increase hPXR 
transcription activity. When we treated the cells with Cordia verbenaceae A. 
DC. extract the transcription activity of RIF was impaired by 50% suggesting an 
antagonist effect. However, this is due to unspecific effects, since inhibition was 
also observed with a high affinity thyroid hormone receptor (Figures 3-14 to 3-
20). 
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Figure S 10 HeLa cells were transfected with expression vector CMV luciferase reporter and treated 
with S. paniculatum. Lucifearase activity was measured after 24 hours and reporter as fold induction 
compared to vehicle.  
 
 
4.2 Erythrina	mulungu	displays	a	partial	agonist	effect	on	hPXR	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S 11 Agonism effect assay. HeLa cells were co-transfected with expression vector pM-Gal4-
PXR-LBD and Gal4 luciferase reporter and treated with vehicle, Rifampicin or increasing 
concentrations of E. mulungu. Lucifearase activity was measured after 24 hours and reporter as fold 
indu tion compared to vehicle. **p ≤ 0.01; ***p ≤ 0.001. 
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3.4.6 Erythrina mulungu Benth. displays a partial agonistic effect on 
hPXR luciferase reporter gene assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3- 14 Agonistic effect. HeLa cells were co-transfected with expression vector pM-Gal4-PXR-LBD 
and Gal4 luciferase reporter and treated with vehicle, RIF or increasing concentrations of Erythrina 
mulungu Benth. Luciferase activity was measured after 24 hours and reported as fold induction compared 
to vehicle. *p ≤0.05; **p ≤ 0.01; ***p ≤ 0.001. 
 
3.4.7 Lippia sidoides Cham. does not display any effect on hPXR 
luciferase reporter gene assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3- 15 Agonistic effect. HeLa cells were co-transfected with expression vector pM-Gal4-PXR-LBD 
and Gal4 luciferase reporter and treated with vehicle, RIF or increasing concentrations of Lippia sidoides 
Cham. Luciferase activity was measured after 24 hours and reported as fold induction compared to 
vehicle. ***p ≤ 0.001. 
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Figure 3- 16 Antagonistic effect. HeLa cells were co-transfected with expression vector pM-Gal4-PXR-
LBD and Gal4 luciferase reporter and treated with vehicle, RIF without and with increasing concentrations 
of Lippia sidoides Cham. Luciferase activity was measured after 24 hours and reported as fold induction 
compared to vehicle. **p ≤ 0.01. ***p ≤ 0.001. 
 
3.4.8 Cordia verbenaceae A. DC. displays an antagonistic effect on both 
hPXR and TRb1 but not CMV luciferase reporter gene assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3- 17 Agonistic effect. HeLa cells were co-transfected with expression vector pM-Gal4-PXR-LBD 
and Gal4 luciferase reporter and treated with vehicle, RIF or increasing concentrations of Cordia 
verbenaceae A. DC. Luciferase activity was measured after 24 hours and reported as fold induction 
compared to vehicle. ***p ≤ 0.001. 
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Figure 3- 18 Antagonistic effect. HeLa cells were co-transfected with expression vector pM-Gal4-PXR-
LBD and Gal4 luciferase reporter and treated with vehicle, RIF without or with increasing concentrations 
of C. verbenaceae. Luciferase activity was measured after 24 hours and reported as fold induction 
compared to vehicle. ***p ≤ 0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3- 19 Antagonistic effect on TRb1. HeLa cells were co-transfected with expression vector pM-
Gal4-dTRb1-LBD and Gal4 luciferase reporter and treated with vehicle, T3 without and with increasing 
concentrations of Cordia verbenaceae A. DC. Luciferase activity was measured after 24 hours and 
reported as fold induction compared to vehicle. *p≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. 
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Figure 3- 20 HeLa cells were co-transfected with expression vector CMV luciferase reporter and treated 
with vehicle or with increasing concentrations of Cordia verbenaceae A. DC. Luciferase activity was 
measured after 24 hours and reported as fold induction compared to vehicle. 
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3.5 ESTIMATION OF INTRACELLULAR GSH LEVELS IN HEPG2 CELLS 
The rate of change in the kinetic absorbance of TNB for the different 
GSH standard concentrations is linearly proportional to the amount of GSH in 
each sample. Thus, a graph plot of the slopes of each GSH standard 
concentration against the GSH concentration, otherwise known as the F-slope 
curve can be used to estimate the amount of GSH in the treated wells given 
their individual slopes (Figures 3-21 and 3-22).  
The GSH concentration obtained for the control cells was 29.91 ± 
0.36µM. Twenty extracts- Apuleia ferrea (Mart.) Baill., Bidens pilosa L., 
Casearia silvestris Sw., Cordia verbenaceae A. DC., Costus spicatus (Jacq.) 
Sw., Equisetum arvense L., Lamium album L., Lippia sidoides Cham., Malva 
sylvestris L. (flower and herb), Maytenus ilicifolia Mart. Ex Reissek, Passiflora 
incarnata L., Persea americana Mill., Rhamnus purshiana DC., Salix alba L., 
Schinus terebinthifolia Raddi, Solanum paniculatum L., Solidago microglossa 
DC., Tabebuia avellanedae Lorentz ex Griseb. and Vernonia polyanthes Less. 
- decreased the intracellular GSH concentration beyond levels seen in the 
control cells. This decrease was found to be statistically significant (P£0.05, 
0.01 and 0.001). The majority of the extracts decreased GSH levels at a 
comparable level to that produced by the positive control BSO, which 
decreased intracellular GSH levels to 17.78 ± 1.70µM (P£0.001). Only one 
extract - Erythrina mulungu Benth. - was able to increase GSH levels at a 
significant level 47.05 ± 2.0 (Figure 3-23 and Appendix 7.7).  
Similar to what has been observed on CYP3A4 mRNA gene expression, 
native Brazilian extracts were also able to cause changes in GSH levels. Cordia 
verbenaceae A. DC., Lippia sidoides Cham., and Solanum paniculatum L. 
depleted GSH levels whereas Erythrina mulungu Benth. displayed the opposite 
effect.  
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Figure 3- 22 The F-slope is created according the values of each standard concentration obtained in figure 3-
21, which is used to estimate the amount of GSH in each sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3- 21 Graph plot of the rate of change in TNB absorbance at the different GSH standard 
concentrations. 
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Figure 3- 23 Effect of 24-hour incubation of extracts  (100µg/mL) on the intracellular GSH levels in HepG2 cells. Twenty extracts (AF1, BP1, CAS, CV1, CS1, EA1, LA1, LS1, 
MSF, MSH, MI1, MN1, PI1, PA1, RP1, SA1, ST1, SP1, SM1, SJ1, TA1 and VP1 produced statistically significant (p£0.05, 0.01 and 0.001) decrease in GSH concentrations 
based on one-way ANOVA test followed by Bonferroni correction. Only one extract EM1 Was able to increase intracellular GSH levels. 
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3.6  GGT ACTIVITY 
The GGT activity in HepG2 cells was measured according to the amount 
of p-nitroaniline liberated in the cell surface transferase reaction and calculated 
using a calibration curve.  
The GGT inhibitor acvicin (5µM) was able to significantly decrease GGT 
activity by almost 70% (p<0.001) compared to non-treated cells. Cordia 
verbenacea A. DC., Persea americana Mill., Salix alba L. and Syzygium 
jambolanum (Lam.) DC. lowered GGT activity by 48%, 31%, 36% and 35% 
respectively (p<0.01). Costus spicatus (Jacq.) Sw. and Schinus terebinthifolia 
Raddi were also able to inhibit GGT activity by 33% and 32% respectively 
(p<0.05). Decreased GGT activity by these extracts except for Syzygium 
jambolanum (Lam.) DC. indicates a possible correlation with this effect and the 
observed depletion of GSH levels. 
On the other hand, Apuleia ferrea (Mart.) Baill., Passiflora incarnata L. 
and Rhamnus purshiana DC. significantly increased GGT activity in 63% 
(p<0.001), 33% (p<0.05) and 60% (p<0.001) respectively (Figure 3-24 and 
Appendix 7.8). Although the GGT activity in the cells treated with these plant 
extracts was increased, GSH levels were also lowered by the same samples. 
Therefore, this depletion may be correlated to another mechanism. 
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Figure 3- 24 Effect of 24-hour incubation of extracts  (100µg/mL) on the GGT activity in HepG2 cells. Six extracts – CS1, ST1 (p<0.05), CV1, PA1, SA1, SJ1 (p<0.001) produced 
statistically significant decrease in GGT activity based on one-way ANOVA test followed by Bonferroni correction. PI1 (p<0.05), AF1 and RP1 (p<0.001), on the other hand, were 
able to increase GGT activity. 
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3.7 MODULATION OF P-GLYCOPROTEIN DEPENDENT RH-123 EFFLUX 
IN CACO-2 VCR CELLS 
The intracellular Rh-123 fluorescence in the cells incubated with Apuleia 
ferrea (Mart.) Baill., Salix alba L., Schinus terebinthifolia Raddi and Syzygium 
jambolanum (Lam.) DC. was significantly higher than cells treated only with Rh-
123. This indicates increased efflux inhibition by these extracts.  
The effect of Salix alba L. (192.5%) and Syzygium jambolanum (Lam.) DC. 
(182.39%) in the efflux activity was relatively similar to the one found in the 
positive control verapamil (181.78%). The Rh-123 fluorescence in Caco-2 VCR 
cells was higher in Apuleia ferrea (Mart.) Baill. (412.72%) and Schinus 
terebinthifolia Raddi (442.61%), indicating strong efflux inhibition caused by 
these extracts (Figure 3-25 and Appendix 7.9).  
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Figure 3- 25 Increased intracellular Rh-123 concnetration in Caco-2 VCR cells in the presence of either extracts or verapamil (20µM). Four extracts – AF1, SA1, ST1 
and SJ1 – were able to significantly increase Rh-123 concentration in the cells (p<0.001). One-way ANOVA folowed by Bonferroni’s post test was carried out to 
determine the significance of extracts. 
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3.8 SUMMARY OF THE EFFECTS OF SELECTED RENISUS MEDICINAL 
PLANTS IN CYP3A4, HPXR, GSH, GGT AND P-GP 
The effects of the twenty-four plant extracts assessed in our study in the 
selected targets have been displayed in this section.  In order to provide a clear 
overview of our work, we summarise our results in table 3-5: it outlines the 
effects (many multiple, some absent) of the researched extracts on the 
researched targets.  
 
Table 3- 5 Effects of RENISUS plant species in the in vitro studied targets. 
RENISUS plant species Sample ID Type(s) of interaction(s) 
Apuleia ferrea (Mart.) Baill.  AF1 ­CYP3A4, ¯GSH, ­GGT,  
¯P-gp efflux 
Artemisia absinthium L. AA1 No effects on the researched 
targets 
Bidens pilosa L.  BP1 ¯GSH 
Casearia silvestris Sw. CAS ­CYP3A4, ¯GSH 
Cordia verbenaceae A. DC.  CV1 ¯GSH, ¯GGT, * 
Costus spicatus (Jacq.) Sw. CS1 ¯GSH, ¯GGT 
Equisetum arvense L. EA1 ­CYP3A4, ¯GSH 
Erythrina mulungu Benth.  EM1 ­GSH. * 
Lamium album L.  LA1 ¯CYP3A4, ¯GSH 
Lippia sidoides Cham.  LS1 ¯GSH, * 
Malva sylvestris L.  MSF ¯GSH 
MSH ¯GSH 
Maytenus ilicifolia Mart. ex Reissek MI1 ­CYP3A4, ¯GSH 
Morus nigra L.  MN1 No effects on the researched 
targets 
Passiflora incarnata L.  PI1 ­CYP3A4, ¯GSH, ­GGT 
Persea americana Mill.  PA1 ­CYP3A4, ¯GSH, ¯GGT 
Rhamnus purshiana DC.  RP1 ­CYP3A4, ¯GSH, ­GGT, ¯P-
gp efflux 
Salix alba L.  SA1 ­CYP3A4, ¯GSH, ¯GGT 
Schinus terebinthifolia Raddi ST1 ­CYP3A4, ¯GSH, ¯GGT, ¯P-
gp efflux 
Solanum paniculatum L.  SP1 ¯CYP3A4*, ¯GSH 
Solidago microglossa DC.  SM1 ¯GSH 
Syzygium jambolanum (Lam.) DC.  SJ1 ­CYP3A4, ¯GGT, ¯P-gp efflux 
Tabebuia avellanedae Lorentz ex 
Griseb.  
TA1 ¯GSH 
Vernonia polyanthes Less.  VP1 ­CYP3A4, ¯GSH 
* antagonistic effect on hPXR 
* partial agonistic effect on hPXR 
* no effect on hPXR 
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4 GENERAL DISCUSSION 
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4.1 IN VITRO STUDIES OF RENISUS MEDICINAL PLANTS IN THE 
SELECTED TARGETS  
We present for the first time in vitro preclinical data for a selection of 
RENISUS medicinal plants. These plants were assessed for their effects on 
selected metabolic and transporter targets as a step towards producing their 
potential HDI profile. While some of these plants are native to Brazil, the 
majority are consumed all around the world by many people on a daily basis; 
these results, therefore, not only may help Brazil to better integrate the use of 
these plants into clinical practice, but will also certainly prompt further research 
in Europe, North America and worldwide.   
It was necessary to balance a number of factors in the experimental 
design. These factors included the nature of the samples (herbal extracts), their 
number, as well as a lack of consensus between the academy, regulatory 
bodies, and industry.  
Our results show that 22 out of the 24 plant extracts screened have a 
significant effect with at least one of the selected targets and therefore have the 
potential to interact with essential drugs prescribed in Brazil. These metabolic 
HDI may also be complicated by intrinsic factors such as genetic 
polymorphisms, disease, age, and sex.  
Taking into account all these aspects, we will discuss in the following 
pages the rationale behind our experimental approach, the interpretation of our 
results within the context of HDI, and their potential clinical impact in the case 
of Brazil.  
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4.1.1 Experimental approaches to the in vitro metabolism and transport 
studies 
Drug metabolism studies are an essential step in the preclinical 
development of medicines. To this end, in vitro models must provide vital 
information on the effects of the lead drug candidate (LDC) upon drug 
metabolising enzymes, such as the CYP, as a step towards predicting potential 
DDI. Many in vitro experimental models of drug metabolism and disposition 
make use of cells; HH or their microsomes (HLM), for example, are considered 
the best models for enzyme inhibition, whereas HLM is the preferred test 
system for enzyme induction. Caco-2 cells are a common choice for transporter 
studies (Zhang et al., 2012a). Several other models have been successfully 
developed to replace the use of cells, and have been validated for predicting 
the effects of single drug entities in the metabolism with similar correlation to 
HLM. Such is the case of characterised metabolic recombinant enzymes 
(CYP1A2, 2C9, 2C19, 2D6, and 3A4) expressed in Escherichia coli, which has 
been developed by the pharmaceutical company AstraZeneca (McGinnity and 
Riley, 2001). The use of in silico models has become more common in the 
pharmaceutical industry in recent years to speed up the selection of the best 
lead candidates at this stage of drug development (Steinmetz and Spack, 
2009). 
In order to be accepted by regulatory bodies, drug metabolism models 
must be robust, validated and reproducible. However, unlike the requirements 
for synthetic drug studies, there is no regulatory requirement for preclinical 
metabolism studies of traditional herbal medicines and no substantial industrial 
activity exists on this side. Metabolism studies on traditional herbal medicines 
are normally only initiated upon the receipt of case reports documenting a 
supposed interaction, which trigger warnings from the regulators. Otherwise, 
such studies originate from purely academic-driven programmes focused on 
demonstrating the potential effects of traditional herbal medicines on metabolic 
and transporter targets (Brantley et al., 2014); these studies are generally 
carried out by adapting protocols to their own needs, thus leading to an array 
of different experimental approaches.  
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The established principles and models used for metabolism studies in 
synthetic drugs are directly applicable to herbal medicines (He et al., 2010). 
However, they would require significantly high budgets and infrastructure. Due 
to the particular scope of the academic activities, a case can thus be made 
regarding the choice of cell lines. HH are generally replaced by other cell 
models like HepG2 and HepaRG cells for determination of metabolic activities. 
The hepatoma cell line HepG2 is one of the most popular models for 
pharmacological and toxicological in vitro studies in academia despite having 
lost some liver functions, and its supply is readily available from any public cell 
bank (Guo et al., 2011). The HepaRG cell line is derived from another 
hepatocellular carcinoma cell and was selected for our project because it 
maintains important metabolic activities lost in HepG2 cells. But it is significantly 
more expensive and only available through a private company and still has lost 
many functions when compared to HH (Szabo et al., 2013).   
The high costs of HepaRG and HH cells forces many researchers to use 
the cheaper HepG2 cell line. A vial containing 2-3 x 106 HepG2 cells costs 
around 330 GBP and stocks can be made for further use whenever they are 
needed. On the other hand, a vial containing 10 million HepaRG cells would 
cost nearly double at about 600 GBP, and cells would have to be plated out in 
24-well plates for immediate use. Furthermore, HepG2 is an immortal cell line 
and therefore it is suitable for long-term maintenance. It generally reaches 70 
– 80% confluence within 48 hours, which allows the conduction of medium and 
high throughput screenings. Long-term maintenance of HepaRG and HH with 
high availability, on the other hand, could be very challenging in traditional two-
dimensional monolayer cultivation systems (Klein et al., 2014).  
Caco-2 cells are one of the most used in vitro models for the assessment 
of P-gp transporter activity within most pharmaceutical industries (Eneroth et 
al., 2001) and reports of use of Caco-2 for transporter studies in herbal 
medicines have been also well documented (Li et al., 2014, Wu et al., 2016, 
Yoshida et al., 2006). The reasons for choosing this cell model for efflux studies 
are similar to those that were applied to HepG2: the reduced costs and rapid 
availability for immediate use.  
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The budget available for preclinical studies and the number of samples 
to be analysed, therefore, limit the approaches that researchers may select in 
terms of cell models and methodologies applied to them. In our case, the annual 
budget of 5,000 GBP per year (3 years) restricted us to the screening of a 
maximum of twenty-four plant extracts in six different cell-based assays using 
both HepG2 and Caco-2 cells. Samples in triplicates and quadruplicates had to 
be run at least three times to optimise experiments. With the exception of real-
time polymerase chain reaction (RT-PCR), our experiments were carried out 
using more affordable colorimetric and fluorimetric assays in 96-well plates in 
order to maximise the number of samples analysed per time.  
GSH is unique among the phase II conjugation mechanisms due to its 
role in the conjugation of phase I metabolites and in the protection of the body 
against several diseases. This was determinant for the selection of this target 
in our studies. P-gp was chosen due to its well-known efflux activity that can 
affect the absorption of many drugs; indeed, this is an important studied target 
in the industry during drug discovering stage.  
Conduction of CYP3A4 gene expression was made using RT-PCR, 
which is the most used technique for such a study. Due to the costs of RT-PCR 
reagents, it was necessary to focus our phase I metabolism study on the 
expression of CYP3A4 despite other CYPs because it is responsible for 
metabolising more than 50% of the currently marketed drugs. The 
fundamentals of RT-PCR have been previously covered in section 2.4.3. 
Despite the availability of several protocols for HH, the numerous steps and 
reagents used to produce the cDNA and to amplify the CYP3A4 gene had to 
be all optimised as this technique is highly dependent on the instrumentation 
and the cell line.  
The studies found in the literature made use of different concentrations 
of the gene inducer, total RNA and time of the treatment to achieve significant 
levels of CYP3A4 expression with different cell lines. For instance, Li and 
coworkers (2013) used RT-PCR for determination of the CYP expression in 
HepG2 cells by using 1µg of total RNA. The amount of RIF used to achieve 2.5 
fold induction was 10µM for 48 hours treatment (Li et al., 2013). Modarai and 
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coworkers (2011), on the other hand, needed to use 2.5µg of total RNA and 
RIF 50µM treatment over a period of 96 hours of exposition to achieve 3.83-
fold induction also in HepG2 cells (Modarai et al., 2011a). Lau and coworkers 
(2013) conducted a research on the effects of ethanol extracts of the Chinese 
herbs Oldenlandia diffusa (Willd.) Roxb. (Rubiaceae), Codonopsis tangshen 
Oliv. (Campanulaceae), Rehmannia glutinosa (Gaertn.) DC. (Plantaginaceae) 
and Astragalus propinquus Schischkin (Leguminosae) on CYP3A4 expression 
using human colon adenocarcinoma-derived LS180 cells. In that experiment, 
the amount of RNA used for cDNA synthesis was not disclosed but a 24 hours 
treatment with RIF 10µM was reportedly enough to achieve 8-fold induction 
(Lau et al., 2013). Likewise, Liu and coworkers (2012) did not indicate the 
amount of total RNA used but their treatment of the colon adenocarcinoma 
LS174T cells with RIF 20µM for 24 hours resulted in 3-fold induction (Liu et al., 
2012).  
Contrary to the study conducted by Li and coworkers (2013), the 
treatment of our HepG2 cells using RIF 10µM for 48 hours did not significantly 
change the CYP3A4 expression using 1µg of total RNA. In order to increase 
CYP3A4 expression using this inducer, some researchers may decide to 
increase the amount of total RNA amplified, as was the case in Modarai and 
coworkers (2011). However, we managed to achieve almost 5-fold induction by 
treating our HepG2 cells using the same RIF concentration for the same time 
treatment as Modarai and coworkers (2011) and the same total RNA 
concentration used by Li and coworkers (2013).  
The achievement of the optimum protocol for CYP3A4 expression using 
HepG2 allowed the assessment of the twenty-four plant extracts. Solanum 
paniculatum L. and Lamium album L. were the only herbal extracts that 
decreased CYP3A4 gene expression. In section 3.4.4 we demonstrated that 
this down-regulation in Solanum paniculatum L. is due - at least in part - to an 
antagonistic effect of the plant extract on hPXR (Mazzari et al., 2016).  
Although the method proved to be robust and reproducible, our final 
results must be put into the context of the limitations of HepG2 as a model for 
induction studies (Gerets et al., 2012): the poor response to induction was 
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overcome by the sensitivity of RT-PCR and to the adjustment of the 
concentration of the controls (Mazzari et al., 2016). 
Herbal medicines, like any other xenobiotic, are also able to act as 
agonists or antagonists of hPXR and consequently modulate the expression of 
drug metabolising enzymes and transporters. A study published by Awortwe 
and coworkers (2015) demonstrated that the crude extract and fractions of 
Echinacea purpurea (L.) Moench (Compositae) up-regulated CYP1A2, 
CYP3A4 and MDR1 gene expression by activation of hPXR in HepG2 cells 
(Awortwe et al., 2015). Yeung and coworkers (2008) also demonstrated that 
Ginkgo biloba extract was able to induce CYP3A4, CYP3A5 and ABCB1 gene 
expression by activating the hPXR in LS180 cells (Yeung et al., 2008).   
As previously mentioned in sections 1.4.1 and 2.4.4.1, the nuclear 
receptor hPXR is responsible for the transcription of numerous metabolising 
enzymes. However, in some cases, the transcription of enzymes may be 
initiated via the activation of another receptor. For example, a study conducted 
by Westerink and Schoonen (2007) found that the level of expression of 
CYP3A4 increased after the treatment of HH and HepG2 cells with hPXR 
activators but this was not observed for CYP2C8. Using hPXR agonists such 
as RIF, the expression of CYP3A4 was increased in both HH and HepG2. On 
the other hand, overexpression of CYP2C8 after hPXR agonist treatment was 
detectable in HH but not in HepG2 cells (Westerink and Schoonen, 2007). 
Therefore, expression of CYP2C8 in HepG2 cells might happen via activation 
of a different receptor, such as CAR.     
Several techniques such as flow cytometry and colorimetric assays have 
been used and published by academic researchers for the measurement of 
intracellular GSH levels. For example, Staal and coworkers (1992) 
demonstrated that it is possible to measure the amount of intracellular GSH in 
T cells in HIV-infected individuals using a flow cytometry protocol (Staal et al., 
1992). GSH levels have been also assessed using flow cytometry in cell lines 
like human acute lymphoblastoid leukaemia cells (Morales et al., 2005), MCF-
7 (mammary carcinoma), HCT-8 (colon carcinoma) and MGH-U1 (bladder 
carcinoma) (Hedley and Chow, 1994). The sensitivity of the technique is the 
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biggest advantage of flow cytometry. However, the operational costs and the 
expenses involving the purchasing of materials are the biggest drawbacks.   
For the analysis of the effects of twenty-four plant extracts on 
intracellular GSH levels, it was necessary to find protocols that would allow the 
assessment of multiple samples at the same time and at a low cost. Among the 
protocols for determination of intracellular GSH levels using colorimetric 
assays, we found a suitable kinetic assay published by Allen and coworkers 
(2000) wherein intracellular GSH levels were analysed in 96-well microtiter 
plates. This protocol allowed us to work with six different samples at the same 
time in triplicates. Another similar protocol published by Rahman and coworkers 
(2007) was used to compare the results found with the Allen and coworkers 
(2000) protocol. Both procedures were merged into a single method, which was 
used by our group.  
Recycling methods have been previously used by academic researchers 
to evaluate the effects of herbal medicines on GSH levels. Guan and coworkers 
(2012) for instance used the recycling assay to assess the effects of liquirtin 
apioside (LA), the main flavonoid component from Glycyrrhiza uralensis Fisch. 
(Leguminosae) on adenocarcinomic human alveolar epithelial cells (Guan et 
al., 2012). Yoon and coworkers (2012) conducted a study in rat liver 
homogenates previously treated with the water extract of Agrimonia eupatoria 
L. (Rosaceae) by using the recycling method (Yoon et al., 2012). The HepG2 
cell line has also been used by Kang and coworkers (2011), who performed the 
recycling kinetic assay to quantify the amount of GSH in HepG2 cells treated 
with the wild vegetable Youngia denticula Kitam (Kang et al., 2011). 
The implementation of the GSH recycling method in our study showed 
that, with the exception of Apuleia ferrea (Mart.) Baill., Erythrina mulungu 
Benth., Morus nigra L. and Syzygium jambolanum (Lam.) DC., all the remaining 
tested extracts were able to lower intracellular GSH levels, an important 
metabolite involved in the clearance of xenobiotics and the detoxification of 
reactive species (Xie, 2009). The variations of intracellular GSH may be related 
to different effects:  
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(a) the inhibition/induction of enzymes involved in its biosynthesis, such 
as glutamate-cysteine ligase (GCL) and glutathione synthase (Lu, 2013);  
(b) the increase (or the inhibition) of GSH efflux from cells (Aw et al., 
1986, Lu et al., 1990, Fernandez-Checa et al., 1988) which may also be 
associated with cell death (De Nicola and Ghibelli, 2014);  
(c) the formation (and the possible release) of GSH-adducts which could 
also cause a reduction of the detectable intracellular GSH (if it is not 
compensated by a new GSH synthesis) (Blair, 2010);  
(d) a modulation of GST activity which could also explain changes in 
both intra- and extracellular GSH levels (Tolson and Wang, 2010).  
Regarding the first possibility (a), the presence of active compounds in 
the extracts could be depleting GSH in a similar manner BSO does, that is, by 
inhibiting the GCL enzyme (Marengo et al., 2008). In order to identify these 
active compounds, a bioguided isolation strategy would be needed. Literature 
data reports that polyphenols such as gallic acid and derivatives, flavonoids 
such as luteolin, chrysin, and apigenin, among others, induce GCL expression 
rather than inhibiting its activity (Panich et al., 2012, Huang et al., 2013). The 
second possibility (b) is less likely to happen due to cell death, as we were 
working with concentrations of plant extracts more than ten times lower than 
their maximum non-toxic concentration (>1000µg/mL). More refined 
experiments would be needed to attest the formation of GSH-adducts, as stated 
in the third possibility (c). As for the fourth and final possibility, (d) is another 
target that should be studied if the mechanism of GSH depletion needs to be 
unveiled. 
Erythrina mulungu Benth. was the only extract found to increase GSH 
levels. Although this effect is not harmful in itself, the plant’s ability to cause 
HDI cannot be ruled out. Safety warnings are still necessary regarding these 
other types of interactions that may be important in this case.  
Changes in the intracellular GSH levels could also be linked to a non-
functional γ-glutamyl cycle. This cycle serves as a continuous source of 
cysteine, which plays a key role in GSH synthesis (section 2.4.5.1). Deficiency 
of GGT activity could potentially lower GSH levels due to loss of cysteine (as 
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glutathione) in the urine. Therefore, it is possible that GSH synthesis could be 
impaired due to the absence of this amino acid (Lu, 2013, Chevez-Barrios et 
al., 2000).  
In the present study, we hypothesised that reduction of GSH levels in 
HepG2 cells caused by the herbal extracts could be correlated with an inhibition 
of GGT activity. This hypothesis was also the subject of an investigation made 
by Jean and coworkers (2002). In their experiment, deficiency in GGT activity 
detected in the lung of mice resulted in lower GSH levels and, consequently, 
increased oxidative stress to the organ (Jean et al., 2002). On the other hand, 
another study suggests that depletion of GSH levels would cause an increased 
GGT activity as an adaptive response in order to provide more cysteine for GSH 
synthesis (Chinta et al., 2006).  
The evaluation of GGT activity may mechanistically clarify the variation 
of intracellular GSH levels in HepG2 cells. The standard enzymatic assay for 
determination of the GGT activity is carried out by quantifying the amount of p-
nitroaniline produced by the breakdown of GpNA in the sample. However, 
another enzymatic method published by Wickham and coworkers (2011) has 
been proposed. This new method assesses the hydrolytic activity of GGT 
measured by a coupled assay in which the glutamate released by the hydrolysis 
of the g-glutamyl bond is oxidised by glutamate dehydrogenase, reducing NAD+ 
to NADH. In presence of diaphorase, the produced NADH reduces 
iodonitrotetrazolium to INT-formazan, which is a coloured product that can be 
detected spectrophotometrically (Wickham et al., 2011). The standard method 
was chosen for our in vitro GGT activity analysis because it is the most 
commonly assay used among researchers and it is not a coupled experiment 
like the one reported by Wickham and coworkers (2011), which is more time- 
and reagent-consuming. 
Indeed, the reduction of GSH levels found in HepG2 cells treated with 
Cordia verbenacea A. DC., Costus spicatus (Jacq.) Sw., Persea americana 
Mill., Salix alba L., Schinus terebinthifolia Raddi and Syzygium jambolanum 
(Lam.) DC. turned out to be due - at least in part- by its ability to lower GGT 
activity. However, Bidens pilosa L., Casearia silvestris Sw., Equisetum arvense 
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L., Lamium album L., Lippia sidoides Cham., Malva sylvestris L., Maytenus 
ilicifolia Mart. Ex Reissek, Solanum paniculatum L., Solidago microglossa DC., 
Tabebuia avellanedae Lorentz ex Griseb., and Vernonia polyanthes Less, did 
not affect GGT activity in a significant way, so GSH levels in those cases may 
have been affected via other mechanisms.  
We attempted the dereplication of potential GGT inhibitors in several 
Brazilian native species using HPTLC analysis. The flavonoid luteolin was 
found in Lippia sidoides Cham. and gallic acid was found in Solanum 
paniculatum L. Those compounds have been reported to deplete intracellular 
GSH levels. A study published by Balyan and coworkers (2015) demonstrated 
that intracellular GSH levels were significantly depleted by luteolin in the human 
melanoma SK-MEL-28 cell line. This was explained by an inhibition of GST 
activity via competitive reversible and irreversible mixed mechanisms (Balyan 
et al., 2015). Another study published by Locatelli and coworkers (2009) 
showed that gallic acid was able to deplete intracellular GSH levels in 
melanoma cells through inhibition of the activity of γ-Glutamyl-cysteine 
synthetase (Locatelli et al., 2009). Gallic acid has been also proven to inhibit 
GGT activity in mice (Mahajan and Mahmood, 2009). 
Some herbal medicines that have been reported to affect both phase I 
and phase II metabolisms are also known to influence the bioavailability of 
drugs by modulating other targets such as P-gp. For example, the efflux of 
xenobiotics mediated by P-gp in intestinal cells has been reported to be affected 
by herbal drugs like SJW. This is due to a substrate overlap at receptor sites of 
P-gp caused by the consumption of herbal medicines and synthetic drugs with 
similar functional groups (Awortwe et al., 2014).   
Several in vitro preclinical studies are available in the existing literature 
to determine if a xenobiotic is a P-gp substrate or inhibitor. Among them, the 
bidirectional transport assay, ATPase activity assay, and uptake/efflux assay 
are the most commonly used, and for such studies, Caco-2 cells have been 
extensively used in both the industry and in academia. Several advantages can 
bolster the use of this cell line for efflux studies. First, Caco-2 resembles the 
human intestinal barrier in morphology and polarity. It expresses numerous 
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proteins, including P-gp, and it is one of the most employed models in 
preclinical investigation to predict the gastrointestinal permeability. Second, 
Caco-2 is recommended by the US FDA (Food and Drug Administration) as an 
integral component of the Biopharmaceutics Classification System (BCS). 
Third, it is the most commonly used cell model in the industry to screen new 
chemical entities and for the prediction of DDI and HDI (Awortwe et al., 2014).  
 The screening of in vitro P-gp activity with Caco-2 cells is not devoid of 
drawbacks. One is the reported downregulation of the P-gp expression during 
cell culturing process. In addition, the P-gp expression is quite variable in this 
cell line which seems to be correlated with its origin and passage number 
(Shirasaka et al., 2008). In order to overcome these issues, several authors 
have proposed new ways to induce P-gp expression in Caco-2 cells.  
For instance, Eneroth and coworkers (2001) overexpressed P-gp in 
Caco-2 cells prior to applying their use in a calcein AM extrusion screening 
assay. To do so, they cultured normal Caco-2 cells in media containing several 
concentrations of vincristine. The group concluded that an optimal level of P-
gp was achieved using vincristine 25nM and that it would be suitable for their 
calcein AM extrusion method (Eneroth et al., 2001).  
Shirasaka and coworkers (2006, 2008) managed to increase the 
expression of P-gp by culturing Caco-2 cells in media containing vinblastine 
50nM. The mRNA concentration of P-gp increased in more than 4-fold 
compared to normal Caco-2 cells. This group proposed some possible reasons 
for the overexpression of P-gp in Caco-2 cells treated with vinca alkaloids. One 
possibility was that the overexpression of P-gp was mediated by the activation 
of hPXR. Another proposed explanation was that P-gp expression in Caco-2 is 
not uniform and that the vinca alkaloids treatment would have probably killed 
the cells with low P-gp expression, therefore acting as a selection process 
instead of induction. No conclusion has been reached about the correct P-gp 
overexpression mechanism yet (Shirasaka et al., 2006, Shirasaka et al., 2008). 
To complicate matters further, studies on P-gp efflux inhibition may use 
different substrates. A commonly used substrate probe is digoxin, however 
concerns have been raised about the use of this drug due to the high variability 
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in the results. Jouan and coworkers (2016) carried out an in vitro evaluation of 
P-gp efflux inhibition comparing Rh-123 vs. digoxin transport. The authors 
concluded that Rh-123 is the most convenient substrate for characterising the 
effects of several P-gp inhibitors, including verapamil. Importantly, the inter-
laboratory reproducibility of digoxin transport experiments was lower when 
compared to the results found using Rh-123. Therefore, the predictability of 
drug interactions could be questioned using this substrate (Jouan et al., 2016).   
Thus, in our study we followed the protocol involving the overexpression 
of P-gp as reported by Eneroth and coworkers (2001). This resulted in an 
increased P-gp activity of Caco-2 cells cultured with vincristine compared to 
normal Caco-2, which made the conduction of our preclinical study possible. 
Despite this, the IC50 of verapamil – a reference for P-gp inhibition – in normal 
Caco-2 cells is not significantly different than in overexpressing Caco-2 cells 
after vincristine treatment (Mazzari et al., 2016). 
These considerations involving cell models, suitable techniques and 
methodologies were crucial for the execution of the present study. As academic 
researchers continue to improve these aspects in order to provide better 
techniques for more reliable results, prediction of HDI made in early 
development stages will become more reliable and feasible for both industry 
and academia. Although most models and techniques used in the private sector 
are still out of reach of the average academic group, researchers in academia 
have been applying cutting-edge techniques to overcome the limitations of less 
sensitive models, thus making such studies accessible to all levels of research 
investment. 
This is probably one of the reasons why research on HDI has 
considerably improved over the years (Figure 1-1), even as funding is 
becoming very limited in many countries. The in vitro assessment of the effects 
of herbal medicines in metabolic and transporter targets is an important step 
for prediction of HDI. Some examples involving our findings and the influence 
of intrinsic factors in the metabolism will be further discussed.  
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4.2 IMPLICATIONS OF HERBAL MEDICINES AND INTRINSIC FACTORS 
ON THE METABOLISM AND EFFLUX 
In chapter 1, we showed that metabolism studies involving herbal 
medicines have been widely reported, especially since 1999. Since then, a 
plethora of herbal medicines has been the subject of studies for several targets, 
mainly CYP and P-gp. We also mentioned in section 1.4 that drug metabolising 
enzymes can be induced and/or inhibited by xenobiotics, which also 
encompasses herbal medicines. Some examples of documented HDI were 
provided in section 1.6 and, in order to map the potential HDI of the medicinal 
plants from RENISUS, we conducted a literature review of their effects on main 
metabolic and transporter targets (Table 1-2).  
Besides xenobiotics, some intrinsic factors such as genetic 
polymorphism, disease, age, and sex could cause alterations in the expression 
and activity of those targets. We will integrate here these factors together with 
the findings of our literature review and the results of our preclinical study. We 
will also take into account the mix of races in Brazil which contribute to a variety 
of genetic polymorphisms in the country, and have been partially revealed by 
REFARGEN. We sought in this way to theoretically predict HDI between 
RENISUS medicinal plants and RENAME essential medicines. Hence, 
consumption of those herbal medicines could be carefully evaluated by the 
Brazilian physicians in the light of these considerations and the treatment that 
the patient is being submitted to.   
4.2.1 RENISUS herbal medicines as modulators of metabolism and efflux 
and potential HDI with RENAME essential medicines 
At this stage of our work, we can affirm that various herbal medicines 
have been found to affect both the metabolism and the efflux in vitro and in vivo 
in certain cases. Our literature review disclosed the effects of various medicinal 
plants that comprise RENISUS in the selected research targets. We previously 
mentioned in section 1.8 that in 1975 Brazil adopted a list of essential medicines 
named RENAME and that physicians in SUS should only prescribe medications 
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present in that list to the patients. Nevertheless, due to the future inclusion of 
more herbal medicines (apart from the 12 that are already in RENAME), the 
likelihood of HDI has increased.    
As a step towards the implementation of herbal medicines in SUS and 
their safe consumption with synthetic drugs, we have thus provided some 
potential HDI based both on the literature review and original laboratory 
research findings.  
4.2.1.1 Potential HDI between RENISUS herbal medicines and RENAME drugs 
As previously mentioned, the expression of the main CYP isoforms 
found in the liver (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and 
CYP3A4/5/7) can be induced and/or inhibited by xenobiotics. Indeed, various 
RENISUS and RENAME drugs have been identified as inhibitors and/or 
inducers of those CYP isoforms. Therefore, it is possible that HDI could occur 
with the concomitant use of those drugs. We highlight here that our in vitro 
evaluation must now be clinically assessed in order to infer whether the 
following suggested interactions are likely to happen or not.   
Beginning with CYP1A2, our literature review revealed that nine 
RENISUS medicinal plants were found to interfere with the activity of CYP1A2. 
The beta-blocker propranolol and the tricyclic antidepressant clomipramine are 
essential drugs extensively prescribed in Brazil. The biotransformation of 
propranolol and clomipramine starts with the N-dealkylation, governed by S-
mephenytoin (CYP1A2) for the former and the N-demethylation of the side 
chain of the molecule of the latter to form the active metabolite 
desmethylclomipramine (DCIP) (Nielsen et al., 1996). Therefore, plant species 
that inhibit CYP1A2 such as Eucalyptus globulus, Glycine max, 
Harpagophytum procumbens, Mentha piperita, Phyllanthus amarus, and 
Punica granatum must be avoided during the treatment period with these drugs. 
This is, however, theoretical and in this case no reports have thus far been 
found in the literature. 
The anticoagulant warfarin is prescribed for the treatment of venous 
thrombosis and pulmonary embolism. The metabolism of this drug can easily 
be altered by CYP1A2 inhibitors. A rare case of interaction of warfarin with 
 	 158	
garlic (Allium sativum) supplements has been reported, leading to excessive 
bleeding (Baxter and Stockley, 2008). Other cases of HDI were detected after 
coadministration of Curcuma longa, Glycine max, Harpagophytum 
procumbens, Punica granatum and Trifolium pratense with Warfarin, resulting 
in metabolic alterations (Liu et al., 2013, Cambria-Kiely, 2002, Ramsay et al., 
2005, Komperda, 2009, Heck et al., 2000).  
Regarding the enzyme CYP2C9, HDI involving RENISUS and RENAME 
could also happen. The active metabolites E-3174, norfluoxetine, 4’-HPPH and 
6-hydroxy fluvastatin, are formed through the action of CYP2C9 on the 
essential drugs losartan, fluoxetine, phenytoin, and fluvastatin, respectively 
(von Moltke et al., 1997, Scripture and Pieper, 2001, Joy et al., 2009). 
Concomitant consumption of those drugs along with the RENISUS medicinal 
plants Allium sativum, Eucalyptus globulus, Harpagophytum procumbens, 
Mentha piperita, Punica granatum, Trifolium pratense and Zingiber officinale 
could affect the formation of these substances because of their inhibitory effects 
on the enzyme. 
Ibuprofen is a common medication prescribed by SUS to combat pain 
and inflammation. The drug is also included in the WHO Model List of Essential 
Medicines as a drug for pain and palliative care and as an antimigraine 
medicine (WHO, 2012, WHO, 2013). Ibuprofen is mostly metabolised by 
CYP2C9 leading to the formation of the active metabolite (S)-ibuprofen. Herbal 
species that are substrates for CYP2C9 may inhibit the formation of (S)-
ibuprofen, potentially leading to therapeutic failure (Mo et al., 2009).  
Metabolism studies with the plant species Allium sativum, Eucalyptus 
globulus, Mentha piperita and Trifolium pratense revealed that they are able to 
inhibit CYP2C19 (Foster et al., 2001, Unger and Frank, 2004). Due to the 
extensive use of these herbal medicines that are metabolised by CYP2C19, 
HDI at this level could be very frequent but so far no clinical report has been 
found.  
Regarding CYP2D6, the popular medicinal plants  Eucalyptus globulus, 
Harpagophytum procumbens, Mentha piperita, Phylanthus amarus, Punica 
granatum and Trifolium pratense are shown to inhibit the activity of the enzyme 
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in liver cells (Mazzari and Prieto, 2014a). The intake of these herbal drugs may 
increase chances of ADRs, although no reports on HDI involving those 
medicinal plants and essential drugs were found in the literature.  
As well as CYP2D6, our study showed that several plants like Allium 
sativum, Momordica charantia, Phyllanthus amarus, Phyllanthus urinaria and 
Punica granatum were able to decrease the levels and the activity of CYP2E1 
in the liver (Taubert et al., 2006, Le Bon et al., 2003, Raza et al., 1996, Hari 
Kumar and Kuttan, 2006, Shen et al., 2008, Faria et al., 2007b, Faria et al., 
2007a). As acetaminophen is also metabolised by CYP2E1, NAPQI can be also 
formed at this metabolic route. Therefore, consumption of these medicinal 
plants could reduce the formation of the toxic metabolite. For example, species 
of the Phyllanthus genus are traditionally used for conditions such as jaundice, 
gonorrhea, frequent menstruation, diabetes and as a pain killer (Naaz et al., 
2007, Patel et al., 2011). A study revealed that Phyllanthus urinaria inhibits 
CYP2E1 activity in hepatocytes and it also attenuates acetaminophen-induced 
hepatotoxicity in mice. The experiment was conducted by treating a total of 37 
mice with acetaminophen at a dose of 550mg/kg of body weight on day one in 
order to induce liver injury. The mice were then divided into two groups: the first 
group was treated with Phyllanthus urinaria extract from day two to four 
whereas the second group just received water. The final results indicated that 
the herbal drug was able to inhibit the formation of NAPQI and, consequently, 
prevent liver failure (Hau et al., 2009).  
Among the studied CYPs, CYP3A is the most relevant family of phase I 
metabolism (Wienkers and Heath, 2005). Some HDI cases involving CYP3A 
and RENISUS medicinal plants have been described in the literature. For 
example, HIV-positive patients are commonly treated with the essential drug 
saquinavir. At the same time, dietary supplements such as garlic and/or 
immune system boosters such as cat’s claw (Uncaria tomentosa) can be used 
to help prevent, combat and improve health. In 1998, a case report was 
published demonstrating that saquinavir is a substrate of CYP3A4 and that 
garlic (an inhibitor of CYP3A) was able to interfere with the metabolism of the 
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drug, leading to failures in therapy and possible drug resistance (Chen et al., 
2011).  
Another example of a CYP3A substrate is the HMG-CoA reductase 
inhibitor atorvastatin. This essential medicine is prescribed to patients with 
dyslipidemia to reduce levels of total cholesterol, low-density lipoprotein 
cholesterol (LDL), triglycerides, and very low-density lipoprotein cholesterol 
(VLDL) and to increase high-density lipoprotein cholesterol (HDL) levels. A 
study conducted in 2012 showed that the half-life of the drug was increased in 
rats treated with Allium sativum L. due to inhibition of CYP3A4 by the herbal 
medicine (Reddy et al., 2012).  
We report for the first time the following herbal drugs to cause changes 
in CYP3A4 gene expression in vitro: Apuleia ferrea (Mart.) Baill., Casearia 
silvestris Sw., Equisetum arvense L., Lamium album L., Maytenus ilicifolia Mart. 
Ex Reissek, Passiflora incarnata L., Persea americana Mill, Rhamnus 
purshiana DC., Salix alba L., Schinus terebinthifolia Raddi, Solanum 
paniculatum L., Syzygium jambolanum (Lam.) DC. and Vernonia polyanthes 
Less. These will need to be clinically investigated to prevent such negative 
interactions in patients as those discussed above.    
Those cases of potential HDI involving CYPs can also be explored in 
phase II conjugation mechanisms. According to our literature review, twenty-
three RENISUS plant species were found to affect the intracellular GSH levels. 
Our preclinical study showed that twenty-one other plant extracts are able to 
significantly modulate the intracellular GSH levels in HepG2 cells. 
The metabolite NAPQI, generated by the metabolism of acetaminophen, 
undergoes  GSH conjugation which is then metabolised and eliminated from 
the body (Baxter and Stockley, 2008). When production of NAPQI exceeds liver 
stores of GSH, however, the organ is damaged due to the attachment of NAPQI 
to liver proteins (Alipour et al., 2013). Thus, a combined therapy of 
acetaminophen and herbal species that deplete GSH levels should be 
monitored for these herbs. 
A study demonstrated that consumption of garlic extract protects 
hepatocytes against acetaminophen-induced GSH depletion. In order to 
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measure GSH levels, hepatocytes were isolated from male Sprague-Dawley 
rats and incubated with different concentrations of garlic extract at three 
different times: before, at the same time and 30 minutes after addition of 
acetaminophen. The results were collected at different time points (from 0 to 
150 minutes) and it was observed that the intake of garlic extract is able to 
protect hepatocytes against acetaminophen-induced toxicity by increasing 
intracellular GSH levels (Anoush et al., 2009).  
Consumption of garlic also seems to decrease CYP3A4 activity, thereby 
increasing the half-life of drugs like acetaminophen. However, GSH synthesis 
is stimulated by this herbal medicine (Mazzari and Prieto, 2014a). 
Consequently, the generated NAPQI would be promptly neutralised by GSH 
and its toxic effects may be unlikely to happen.   
In our study, the P-gp efflux activity was also modulated by certain herbal 
medicines. Achillea millefolium was shown to inhibit P-gp whereas Allium 
sativum was shown to activate the transporter (Mazzari and Prieto, 2014a). Our 
preclinical study revealed that P-gp activity was affected by only four extracts, 
Apuleia ferrea (Mart.) Baill., Rhamnus purshiana DC., Schinus terebinthifolia 
Raddi, and Syzygium jambolanum (Lam.) DC.. The clinical implications 
associated with these findings would theoretically affect the bioavailability of 
drugs coadministered with those P-gp substrates, but it would need to be 
confirmed through future clinical studies. 
HDI cases have already been reported on the P-gp level. For example, 
the HIV-protease inhibitor saquinavir (substrate of CYP3A4) is absorbed in the 
intestine via P-gp. As garlic extracts may induce P-gp efflux activity, the 
outcome of concomitant consumption of the herbal medicine with the drug 
could potentially reduce the bioavailability of the latter (Williamson et al., 2009). 
On the other hand, we found that Apuleia ferrea (Mart.) Baill., Rhamnus 
purshiana DC., Schinus terebinthifolia Raddi and Syzygium jambolanum (Lam.) 
DC. could successfully increase the Rh-123 concentration in Caco-2 VCR cells, 
an effect directly correlated to an inhibition of the P-gp efflux activity. Thus, it 
may be possible to increase the bioavailability of saquinavir if the drug is 
coadministered with these herbal extracts.  
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While our overview of HDI focuses on the potential harm and health risks 
to patients who use these herbal drugs, other studies have attempted to provide 
evidence of the potential benefits of HDI. For the most part, such beneficial 
cases are related to the effects of plant extracts on P-gp efflux activity, which 
could result in increased bioavailability of prescription drugs with poor oral 
bioavailability.  
Zhang and coworkers (2007), for example, showed that curcumin from 
turmeric (Curcuma longa L.) is capable of down-regulating intestinal P-gp 
expression, which could then increase the bioavailability of the beta blocker 
celiprolol (Zhang et al., 2007). Bansal and coworkers (2008) also found that the 
flavonoid quercetin could increase the Cmax of the anticancer drug irinotecan, 
which could in turn benefit the patients being treated (Bansal et al., 2008).  
While such findings seem to be very promising examples for improved 
therapy using herbal medicines, each HDI requires careful consideration and a 
thorough review. Data collected from our literature review, for example, 
suggests that consumption of Curcuma longa L. could also decrease the 
expression of CYP1A2. According to Pavithra and coworkers (2009), when 
taken alone the drug norfloxacin has limited absorption in the gastrointestinal 
tract, whereas after intake of curcumin the plasma concentration of norfloxacin 
increases (Pavithra et al., 2009). However, norfloxacin is a well-known CYP1A2 
inhibitor (Kobayashi et al., 2011). While the absorption of norfloxacin could be 
improved by coadministration of curcumin, therefore, their concomitant use 
could drastically reduce the CYP1A2 expression and compromise the 
metabolism of some other CYP1A2 substrates that may also have been 
prescribed to the patient, such as acetaminophen or propranolol. Considering 
these factors, it remains unclear whether such an HDI would actually benefit a 
patient. 
The beneficial effect of the flavonoid quercetin on irinotecan can be also 
questioned. Although irinotecan is also metabolised by CYP3A4 (Santos et al., 
2000), Choi and coworkers (2011) showed that quercetin is able to inhibit 
CYP3A4 activity in a concentration-dependant manner (Choi et al., 2011). As a 
consequence, although the plasma concentration of irinotecan is increased by 
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the HDI with P-gp, the effects of the drug could be exacerbated by decreased 
CYP3A4 activity caused by quercetin.  
The suggested benefits of HDI should thus be carefully assessed. As 
herbal extracts contain numerous pharmacological active substances, they 
could affect multiple metabolic and transporter targets at the same time. Hence, 
one beneficial effect could be masking an undesirable one that imposes risk to 
the patient. Indeed, our preclinical study showed that most of the herbal 
medicines were able to affect more than one target. Apuleia ferrea (Mart.) Baill., 
Rhamnus purshiana DC., Schinus terebinthifolia Raddi and Syzygium 
jambolanum (Lam.) DC., for example, were able to inhibit the P-gp activity in 
Caco-2 VCR cells. But they were also able to modulate the CYP3A4 expression 
and GSH levels. Thus, it is not clear whether the use of these drugs would 
ultimately prove an advantage with regards to enhancing drug bioavailability, 
as this benefit could be compromised by the effect of herbal medicines on 
metabolic enzymes and other detoxification mechanisms. Nevertheless, as 
research produces greater knowledge of the herbal medicines’ metabolic 
profiles, combination therapies to improve their therapeutic outcomes will be 
possible in the foreseeable future.  
4.2.2 Intrinsic factors that impact in the regulation of metabolism and 
efflux 
In the risk-benefit analysis of HDI, other key factors must also be taken 
in consideration. This includes, of course, the intrinsic factors that each patient 
will present. All the efforts made by using herbal medicines to improve the 
absorption of drugs with poor oral bioavailability could be jeopardised due to 
the presence of genetic polymorphisms and other factors such as disease, age, 
and sex of the patient. We will cover those cases and their impact on the 
metabolism in the following sections below. 
4.2.2.1 Genetic polymorphism 
Metabolism of drugs is not only affected by the coadministration of 
herbal medicines or other drugs. In many cases, the effects of a drug vary 
among subjects and these variations may not be directly correlated to the 
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patient’s treatment. It has been found that people from different races around 
the globe may have a variant allele of a single gene that is responsible for 
producing a metabolising enzyme. This allele will codify the expression of 
variants of the drug metabolising enzyme, resulting in differences in the enzyme 
expression. For example, Caucasian and Negro populations have a 
proportional expression of fast and slow acetylators, whereas Asian groups 
have 90% fast acetylators (Shenfield, 2004).  
Cases of genetic polymorphism involving metabolising enzymes and 
proteins have been reported. For instance, Wei-lin and coworkers (2006) 
reported a case of dose adjustment of the immunosuppressive drug tacrolimus 
because of genetic polymorphism. Tacrolimus dose regulation was required in 
Chinese liver transplant patients due to the presence of polymorphisms in 
CYP3A5, which was found to decrease the bioavailability of the drug (Wei-lin 
et al., 2006).  
ADRs caused by genetic polymorphism involving the expression of P-gp 
have been also reported in the literature. Charles and coworkers (2012) 
reported that a patient who was receiving amlodipine for controlling a 
cardiovascular disorder developed a gingival hyperplasia as a result of 
inflammation and fibrosis, which could be correlated with the use of 
anticonvulsants, antihypertensive calcium antagonists, and the 
immunosuppressant cyclosporine. DNA analysis from a blood sample revealed 
that the patient presented an MDR1 3435C/T gene polymorphism, which may 
have modified the P-gp expression in the endothelial layers of blood vessels in 
the gingiva. As a consequence, this genetic polymorphism could have 
worsened the inflammatory response to the drug and may thus be the reason 
of this side effect (Charles et al., 2012).  
Cases of genetic polymorphism were found among the Brazilian 
population, which is comprised of a plethora of ethnic groups. As stated in 
section 1.5.1, the assessment made by REFARGEN in the Brazilian population 
demonstrated that genetic polymorphism could cause some ethnic subgroups 
to present ADRs, leading to increased or decreased levels of drug metabolising 
enzymes such as CYPs and transporters.  
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CYP1A2, for instance, is considered to be highly inducible and 
polymorphic. Two polymorphisms have been found to be common among 
South Brazilians: the CYP1A2*1F and *1K alleles, which cause higher and 
decreased enzyme expression, respectively (Kohlrausch et al., 2014). Their 
high frequency of both alleles in Southern Brazilians, therefore, suggests that 
this ethnic subgroup possesses a higher risk of ADRs. 
The CYP2C9*2 and *11 alleles are found in higher frequency in white 
Brazilians, whereas CYP2C9*3 is mostly found in browns and CYP2C9*5 in the 
black Brazilian population. These polymorphisms decrease the enzyme activity 
in vitro (Zhou et al., 2009), and for that reason consumption of medicinal plants 
such as garlic, eucalyptus, devil’s claw, mentha, pomegranate, red clover, and 
ginger may further inhibit their function or expression, potentially causing HDI 
within these ethnic groups.  
Approximately twenty-four variants of CYP2C19 are known. Three of 
them have been found by REFARGEN to exist in the Brazilian population: 
CYP2C19*2, CYP2C19*3, and CYP2C19*17. The alleles *2 and *3 appear not 
to affect the enzyme activity, whereas CYP2C19*17, which is the most 
prevalent, increases in vitro activity thereby potentially decreasing the 
pharmacological effects of CYP2C19 drug substrates, such as diazepam and 
phenobarbital (Mazzari and Prieto, 2014a).  
Among the CYPs studied by REFARGEN, polymorphisms on CYP2D6 
are the most present in the Brazilian population. To date, seventy-two variants 
of this isoform have been found in humans and, according to REFARGEN 
sixteen were detected in Brazilians from all researched ethnics groups: 
CYP2D6*1, *2, *3, *4, *5, *9, *10, *17, *29, *34, *35, *39, *41, *1XN, *2XN, and 
*4XN. An increase in enzyme activity was found on the alleles *1XN and *2XN, 
whereas a decrease of activity was found on *9, *10, *17, *29, and *41 (Cai et 
al., 2006). The chances of undesirable effects caused by disturbances in the 
bioavaioability of CYP2D6 drug substrates, such as the essential medicines 
atenolol and propranolol for example, are therefore elevated in these groups. 
Polymorphisms on CYP2E1 in the Brazilian population have not yet 
been mapped by REFARGEN. CYP3A5 polymorphisms among Brazilians have 
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been reported with the most frequent alleles being CYP3A5*1, *3, *6 and *7. 
The alleles *3 and *6 decrease enzyme activity in vitro, whereas *1 and *7 
showed no effects (Zhou et al., 2009). Interestingly, the allele *3 is the most 
common variation of this isoform in all groups in Brazil (Refargen, 2014). Since 
it reduces the enzyme activity, intake of herbal medicines that exert the same 
effect should be strongly avoided in order to prevent HDI. 
Similar studies on polymorphisms in the Brazilian population of enzymes 
involving GSH conjugation, such as GST, have not been carried out by 
REFARGEN. Some reports, however, point out its existence and frequencies 
among this population. Rossini and coworkers (2002), for instance, reported 
the existence of GST polymorphisms in a group of 519 Brazilians from Rio de 
Janeiro. GSTM1 is involved in the detoxification of polycyclic aromatic 
hydrocarbons and some mutagens, whereas GSTT1 catalyses the metabolism 
of halomethanes by human erythrocytes. Rossini and coworkers (2002) found 
that the null allele, that is, no expression of the enzyme, was detected in 
approximately 10% of the studied population (Rossini et al., 2002). Null 
individuals are generally more susceptible to DNA damage by the action of GST 
polymorphisms like GSTM1 and GSTT1. The existence of these 
polymorphisms is thought to be common among multi-ethnic populations such 
as in Brazil. Therefore, the extensive list of plant species found to affect the 
GSH conjugation mechanism plus the presence of such polymorphisms could 
potentially increase chances of HDI among Brazilians. 
REFARGEN has not yet published data about polymorphisms on UDP- 
glucuronosyltransferase enzymes. However, information about polymorphic 
UGTs and their impact on adverse drug reactions and cancer susceptibility has 
been reported (Guillemette, 2003). Also, no data was found about genetic 
polymorphisms in the Brazilian population on enzymes responsible for 
sulphation, methylation and acetylation conjugation mechanisms to date. 
Studies have shown that the gene ABCB1, which encodes P-gp, is very 
polymorphic and that the pharmacokinetics of several P-gp substrates could be 
significantly altered (Scheiner et al., 2010). REFARGEN has identified three 
ABCB1 polymorphisms in the Brazilian population: 1236T (rs1128503), 
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2677nonG (rs2032582) and 3435T (rs1045642). Further studies on drugs that 
affect the regulation of ABCB1 are needed to prevent a HDI on that level in the 
future.  
4.2.2.2 Disease 
In section 1.5.2, we briefly showed that malaria-infected people could 
present decreased hepatic CYP activity compared to healthy subjects. Indeed, 
diseases can have a direct effect on both expression and activity of metabolic 
enzymes and transporters. For instance, a report published by Morgan (2009) 
showed that inflammation associated with chronic diseases can lead to the 
down-regulation of CYP3A4. Also, patients with secondary hepatic cancer 
showed lower levels of CYP1A2, CYP2C and CYP2E1 compared to the control 
group (Morgan, 2009).  
A case report published by Lopez Galera and coworkers (2008) showed 
that a 45-year-old, HIV-positive woman with cirrhosis caused by a hepatitis C 
infection was not responding satisfactorily to the treatment of the anti-HIV 
drugs. The patient had no good adherence to the HIV treatment, so she was 
then asked whether she was making use of any other medicines, including 
herbal medicines. Surprisingly, the patient had been taking Uncaria tomentosa 
preparation for 2 months, probably to enhance her immune system. She was 
asked to cease taking the herbal medicine, and after 15 days the Cmin values 
of the anti-HIV drugs were normalised. Uncaria tomentosa has a high inhibitory 
capability to CYP3A4, which causes an increase in the Cmin values for 
antiretroviral agents leading to an increased risk of toxicity. The combined 
therapy with these two agents has been shown to be a potential risk for HIV 
patients (Lopez Galera et al., 2008).  
Uncaria tomentosa is one of the RENISUS herbal medicines and the 
case report by Lopez Galera and coworkers (2008) correlates to the in vitro 
inhibitory effect in CYP3A4 reported by Budzinski and coworkers (2000). 
Furthermore, two herbal medicines from our preclinical study, Lamium album 
L. and Solanum paniculatum L., were also able to decrease CYP3A4 
expression. Consumption of these herbal medicines by HIV-positive patients 
should, therefore, be avoided until clinical evidence proves its safety. 
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Besides phase I, phase II mechanisms like GSH conjugation could be 
impaired due to lower levels of GSH found in people with certain health 
conditions. A study conducted by Droge and Breitkreutz (2000) showed that the 
immune system works best when the GSH levels of lymphoid cells are kept 
within optimal levels. The study showed that some HIV-infected patients lose 
the GSH precursor cysteine at more levels than a non-infected person. GSH 
deficiency was thus observed to result in low protection of the cells against 
ROS, but the GSH levels in the lymphoid cells were restored with the 
administration of NAC (Droge and Breitkreutz, 2000). Low intracellular GSH 
levels have been correlated to a wide array of health conditions including 
neurodegenerative diseases such as Parkinson’s and Alzheimer, eye diseases 
such as cataracts, glaucoma and macular degeneration, osteoporosis, cancer 
cardiovascular diseases, pulmonary diseases, cystic fibrosis and inflammatory 
diseases (Lomaestro and Malone, 1995, Ballatori et al., 2009).  
In another relevant case report published by Senadhi and coworkers 
(2012), a 26-year-old man recently diagnosed with HIV was admitted to hospital 
presenting some symptoms that included yellow eye discoloration, dark 
coloured urine, and nausea. A liver function exam revealed elevated levels of 
the liver enzymes aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), alkaline phosphatase (ALP) and serum bilirubin. Mild hepatomegaly was 
also detected by an abdominal computed tomography, and no signs of acute 
hepatitis (A, B, and C) were detected. Serum acetaminophen levels were also 
unremarkable. After a few appointments, the patient disclosed he was making 
use of the herbal medicines fucoisan, maya nut, and finger millet, which are 
traditionally used in some parts of Africa for HIV treatment. He was asked to 
discontinue the herbal HIV medications, and after 2 weeks his liver function 
went back to normal, and his symptoms also disappeared. The authors 
suggested that the GSH levels of the patient were already lowered due to the 
HIV infection and that the herbal medicines may have lowered those levels 
even further, and the self-administered herbal medicines were thus the likely 
cause of the patient’s increased susceptibility to drug-induced hepatitis 
(Senadhi et al., 2012).  
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Such case reports raise concerns about the intake of most of the herbal 
medicines of our preclinical study. Herbal medicines like Passiflora incarnata L. 
or Salix alba L., for example, are commonly used by the Brazilian population 
for controlling anxiety and as anti-inflammatory respectively. Consumption of 
the herbal medicines that were found to deplete GSH levels in our study could, 
therefore, cause the same effects as those of the African ones used by the 
patient in Senadhi and coworkers (2012).    
GSH deficiency has been associated with defects of some enzymes that 
take part of GSH synthesis, such as g-glutamylcysteine ligase, glutathione 
synthase, GGT, dipeptidase, and 5-oxoprolinase. GGT disorders, for example, 
can cause central nervous system abnormalities, and cases of GGT deficiency 
are commonly present in cases of increased GSH concentration in the urine 
(glutathionuria) and in the blood plasma will be found. Glutathionuria is caused 
by the inability of GGT to break down GSH that is filtered and secreted in the 
renal tubular fluid. A study conducted with mice revealed that problems 
associated with GGT deficiency may cause not only glutathionuria, but also 
glutathionemia, growth failure, cataracts, lethargy, shortened life span and 
infertility (Ballatori et al., 2009).  
The importance of GSH in the maintenance of the optimum state of the 
cells and its pivotal role in xenobiotic detoxification makes it the most important 
phase II conjugation mechanism. It is essential, therefore, that prescription of 
herbal medicines be made carefully by the physician in order to avoid more 
complications with the patient’s health. 
HDI may increase health risks among patients with preexisting diseases, 
such as those which may affect the P-gp expression in organs and tissues. For 
example, Jeynes and Provias (2013) showed that brain samples from patients 
with Alzheimer’s disease present significant differences in P-gp expression in 
both the hippocampal and superior temporal parts of the brain, as compared to 
a normal brain (Jeynes and Provias, 2013). Jeynes and Provias (2013) also 
found decreased P-gp expression in the patient’s inflamed intestinal epithelium, 
which has been previously reported to aggravate Alzheimer’s disease (Blokzijl 
et al., 2007). 
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Di Rosa and Di Rosa (2014) published a case report suggesting that low 
P-gp levels in the BBB could be correlated to catatonia, which is a subtype of 
schizophrenia. Their report showed that a 20-year-old man experienced many 
symptoms of catatonia, such as immobility, negativism, and sweating after an 
overdose of loperamide. Loperamide is a P-gp substrate and has an agonistic 
effect on the opioid receptors. In clinical doses, loperamide is safe and P-gp 
prevents the drug from crossing the BBB (Di Rosa and Di Rosa, 2014).  
In these cases we have described, it is possible that inhibition of the P-
gp efflux activity could have also been caused by consumption of herbal 
medicines. In section 1.9, we showed that Achillea milefolium L. and Curcuma 
longa L. have been reported to inhibit the P-gp activity, and in our preclinical 
study, Apuleia ferrea (Mart.) Bail., Rhamnus purshiana DC., Schinus 
terebinthifolia Raddi, and Syzygium jambolanum (Lam.) DC. presented the 
same inhibitory effect. Although no clinical evidence of P-gp inhibition caused 
by these four has been reported yet, based on the current evidence we report 
here, prescription of these herbal medicines should be avoided to patients with 
the above conditions. 
4.2.2.3 Age 
Age-related changes in some metabolic enzymes and transporters have 
also been identified by researchers, which would contribute to possible HDI in 
patients with certain conditions. Ku and coworkers (2010) reported that the 
levels of CYPs varied in male rats aged 3, 12, 26 and 104 weeks. CYP1A1 was 
only detected in 3-week-old-rats, whereas CYP1A2, CYP2B1, and CYP2E1 
had their maximum expression in same-age rats, although the levels 
significantly decreased at 12 and 26 weeks. Other CYPs like CYP2C11 and 
CYP3A4 have been found at low levels in aged rats (Yun et al., 2010). 
Aging can also affect GSH levels. Neurodegenerative diseases like 
Parkinson’s and Alzheimer’s disease have been associated with the generation 
of ROS and low levels of GSH in the brain. This was demonstrated by a case 
study (Zhu et al., 2006) of two groups of rat subjects, one of whom was young 
and the other aged. The results showed that GSH was significantly reduced in 
the aged rat group due to the diminished activity of g-glutamylcysteine 
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synthase, which is one of the enzymes responsible for GSH synthesis. From 
the evidence, the study concluded that the aged animals could therefore be 
more vulnerable to oxidative stress and, consequently, to age-related 
neurodegeneration diseases (Zhu et al., 2006).  
Erden-Inal and coworkers (2002) also showed a correlation between 
aging and GSH depletion. They investigated the GSH levels in plasma collected 
from 176 healthy individuals, which were split into five groups according to their 
age: G1 (0.2 -1 years old), G2 (2-11 years old), G3 (12-24 years old), G4 (25-
40 years old) and G5 (41-69 years old). The GSH levels in G1 and G5 were 
considerably lower than in the remaining groups (Erden-Inal et al., 2002). In the 
case of newborns, vulnerability to pathologies such as distress syndrome, 
bronchopulmonary dysplasia and periventricular leukomalacia may be a 
potential consequence of free radical-induced damage caused by oxidative 
stress (Ozsurekci and Aykac, 2016). Older people, on the other hand, could be 
more susceptible to previously mentioned conditions like Parkinson and 
Alzheimer’s disease, liver disease, cancer and diabetes (Pandey and Rizvi, 
2010).  
An example of drug toxicity due to low GSH levels in children has been 
published by Sia and Chan (2006). The case report shows a situation where a 
2-year-old child suffered acute liver failure due to paracetamol poisoning. The 
girl was admitted to hospital, presenting a high body temperature, decreased 
consciousness and a high heartrate. Liver function exam found the AST, ALT 
and ALP levels to be abnormally high, and viral studies excluded the presence 
of hepatitis B, C, and HIV. However, the toxicology test revealed high 
concentrations of paracetamol in her blood circulation. After the administration 
of NAC, the paracetamol level and liver enzymes began to decrease, and after 
10 days of treatment, she was discharged from the hospital (Sia and Chan, 
2006).  
The diagnostic in Sia and Chan (2006)’s report revealed that the girl was 
suffering from paracetamol overdose. In section 4.2.1.1 we showed that 
paracetamol (acetaminophen) is first metabolised by CYPs in the liver, resulting 
in the formation of the toxic metabolite NAPQI, which is neutralised by GSH. 
 	 172	
We also mentioned that some RENISUS herbal medicines may decrease both 
GSH levels and CYP expression, such as Lamium album L. and Solanum 
paniculatum L. (Table 3-5). According to Suzuki and coworkers (2010), one of 
the CYPs that metabolise paracetamol (CYP1A2) only reaches 80% of its 
normal activity in 3-year-old children or more (Suzuki et al., 2010). Therefore, 
use of herbal medicines in children up to 3 years old should be carefully 
assessed, especially since their levels of metabolising enzymes are distinct 
from adults, and misapplication could lead to serious health consequences. 
Use of herbal medicines among children is becoming more frequent in 
some countries. In Germany, for example, a study published by Du and 
coworkers (2014) detected the use of herbal medicines among 17,450 German 
subjects. Approximately 5.8% were children who were using at least one herbal 
medicinal product, and that the highest consumption was made by children 
younger than 6 years old (Du et al., 2014). 
Conversely, de Souza Silva and coworkers (2014) reviewed the use of 
herbal medicines by elderly people in North America, Europe, and Asia. The 
study showed that the elderly population of those areas are active costumers 
of herbal medicines with the most popular being chamomile, garlic, and ginger 
(de Souza Silva et al., 2014). Our literature review confirms that some species 
of chamomile, garlic, and ginger are CYP3A4 inhibitors (Mazzari and Prieto, 
2014a).   
Although it is not known whether herbal medicines may have a higher 
impact on the expression and activity of drug-metabolising enzymes and 
transporters among children and the elderly, consumption should be 
accompanied by the advice and recommendation of a health professional. More 
active pharmacovigilance is strongly advised for these groups. 
A study on aging-related P-gp expression was conducted by Wu and 
coworkers (2009). They demonstrated that older mice presented increased P-
gp expression; this could be a response of their organism to prevent the 
accumulation of toxic substances in the body (Wu et al., 2009).  
Another study conducted by Warrington and coworkers (2004) 
suggested that age-related change in the P-gp expression is tissue-specific. In 
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this rat study, hepatic P-gp expression increased with age whereas renal P-gp 
levels were lowered in the old kidneys (Warrington et al., 2004). 
Unfortunately, case reports demonstrating problems with drug therapies 
due to aging-related P-gp expression remain scarce and more research is 
needed. Although our preclinical study found that only four herbs were able to 
inhibit the efflux activity, their consumption by both children and elderly people 
should be carefully monitored. 
4.2.2.4  Sex  
Another aspect that must be considered in drug metabolism is the 
gender-related differences in the expression of CYPs, GSH, and P-gp. Sex-
related changes in CYP1A2 activity in the Chinese population was investigated 
by Ou-Yang and coworkers (2000). Their study had 229 healthy subjects (120 
men and 109 women), and the results showed that CYP1A2 activity is 
significantly higher in Chinese men than in women (Ou-Yang et al., 2000). As 
a consequence, a higher dose of the CYP1A2 drug substrate acetaminophen, 
for example, would be required in Chinese women in order to obtain a 
pharmacological effect.  
Variation in GSH levels in males and females was the subject of a study 
published by van Lieshout and Peters (1998). Their research was conducted 
by collecting blood samples from 124 healthy subjects (61 females and 63 
males) from different age groups. When stratified according to age group, their 
results did not show differences between the GSH levels between males and 
females (van Lieshout and Peters, 1998).    
We previously mentioned in section 1.5.4 that hormones could be the 
reason for different levels of metabolic enzymes between men and women. 
Suzuki and coworkers (2006) showed that sex hormones may also be the 
reason for the gender-related difference in P-gp expression that was observed 
in rats (Suzuki et al., 2006). Also, it has been shown that female steroid 
hormones like oestrogens and progesterone are able to modulate the 
expression levels of CYP2E1 in female mouse liver, affecting the metabolism 
of numerous drugs (Konstandi et al., 2013).  
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The aforementioned study conducted by Du and coworkers (2014) also 
showed that consumption of herbal medicines is higher among boys aged 0 – 
2 years. Those figures change in children between the ages 3 – 17, where girls 
are shown to use more herbal medicines than boys (Du et al., 2014).  
Another study published by Stjernberg and coworkers (2006) showed 
the profile of herbal medicines users in the Swedish municipality of Karlskrona. 
In total, 1380 people were surveyed (576 males and 804 females). 
Approximately 20.7% of the female group admitted to using herbal medicinal 
products while this figure was only 16.8% among the male group (Stjernberg et 
al., 2006).  
The lack of published studies regarding the impact of gender differences 
on HDI limits our discussion on this matter, but there is evidence that it is 
possible. Future research should be encouraged to further investigate the 
potential associations between HDI, patient health outcomes, and the intrinsic 
factors discussed (genetic polymorphism, disease, age and sex) (Sultan et al., 
2015). Due to the scarcity of existing published data, the pharmacovigilance 
system plays an important role in collecting and providing information of 
patients presenting ADRs due to HDI to regulatory agencies to better identify 
whether any of those intrinsic factors could be contributing to the side effects.  
4.2.3 Active pharmacovigilance is needed for detection of HDI 
All the factors discussed here represent obstacles for an optimum drug 
therapy, one that is effective and with no undesirable side effects. Despite all 
the intrinsic factors a patient will present, the risks of intoxication or therapy 
failure caused by consumption of a herbal medicine could be considerably 
avoided if its effects on the metabolism and efflux activity were anticipated. 
Notwithstanding, due to the lack of regulation in this matter, HDI is mostly found 
at market stages and the pharmacovigilance systems are thus more likely to 
detect and report those cases.  
Pharmacovigilance systems of many countries have been reporting 
cases of HDI to the WHO monitoring centre over the years. Countries like the 
United States, Germany, Australia, Canada, Switzerland and the United 
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Kingdom, for instance, were responsible for the highest number of HDI reports 
until 2012. In total, 27 countries reported cases of HDI to the WHO. However, 
there have been no cases of HDI reported from the Brazilian pharmacovigilance 
to the WHO to date (Mazzari and Prieto, 2014b).  
Brazil implemented its pharmacovigilance system in 1999, immediately 
after the creation of ANVISA. Currently, the Centro Nacional de Monitorização 
de Medicamentos (National Centre for Drug Monitoring), or CNMM, uses the 
electronic platform Sistema de Notificações em Vigilância Sanitária (National 
Notification System for Adverse Events and Technical Complaints), or 
NOTIVISA, for the collection of ADRs in the country. Created in 2009, the 
NOTIVISA aims to receive notifications of adverse events (AE) and technical 
complaints cases (TC) of various products approved by ANVISA, including 
herbal medicines. By means of this system, this information is received by 
health professionals in hospitals, clinics, and laboratories, by ANVISA and other 
local health surveillance units, and also by professionals working in drug stores 
and local pharmacies. The NOTIVISA system also allows Brazilian citizens to 
notify any case of AE and TC, enabling a higher provision of information related 
to the safety of the drug (Mazzari and Prieto, 2014a). 
A study published in 2010 showed that 165 AE herbal medicines were 
received by the pharmacovigilance centre between 1999 and 2009. Among 
them, only two might have occurred as a result of HDI: Atropa belladonna L. 
(Solonaceae), which was administered with acriflavine, methenamine and 
methylthioninium causing hepatitis in the patient, and Pygeum africanum 
Hook.f. (Rosaceae), which caused a headache due to its use in conjunction 
with rupatadine fumarate (Balbino and Dias, 2010). Neither Atropa belladonna 
nor Pygeum africanum are RENISUS species, and those HDI cases involving 
the plants were not reported to the WHO.  
The scarcity of HDI reports in the country may be related to factors such 
as the lack of promotion of rational use of medicinal plants and herbal 
medicines as well as insufficient training of health professionals who are in the 
best position to detect these cases. Currently, there is a high number of 
professionals who can legally prescribe medicinal plants and herbal medicines 
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to the Brazilian population. In addition to doctors, dentists, and nurses, 
pharmacists, and nutritionists have the authorisation of their respective Federal 
Councils to prescribe these products (Camargo and Barros de Leça Pereira, 
2013). However, because many of these professionals are not properly trained 
to safely indicate a combined herbal-synthetic drug therapy, detection of HDI 
by these health professionals becomes more challenging (Rates, 2001). 
Detection of HDI by pharmacovigilance systems remains difficult, and in 
the case of the Brazilian system the few cases recorded in the country have not 
been properly reported to the WHO. The line between what should and should 
not be reported to the WHO is not well defined. For example, the Atropa 
belladonna case which resulted in hepatitis (Balbino and Dias, 2010) could be 
considered a case of high HDI risk when compared to the observed interaction 
of rupatadine fumarate with Pygeum africanum, which resulted in a headache. 
Although hepatitis is far more severe ADR than a headache, both cases should 
have been transmitted to the WHO. Both cases were published by Balbino and 
Dias (2010), but according to the report published by Skalli and Bencheikh 
(2012), no HDI report from Brazil was received until then (Skalli and Soulaymani 
Bencheikh, 2012). 
 It is not clear what HDI risk level the Brazilian pharmacovigilance 
currently deems severe enough to a formalise into a report to the WHO. Thus, 
more attention should be given to that aspect in order to improve HDI 
information in the country. 
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5 CONCLUSIONS 
In 2008, Brazil became a model country for the field of traditional 
medicines by defining a list of beneficial herbal medicines considered 
‘essential’, and implementing an agenda to make the complete implementation 
of herbal medicines at a clinical level possible in the foreseeable future. This 
action taken by Brazil is a leading example of the current global trend towards 
the integration of herbal medicines into the healthcare system. 
Our literature review has highlighted that little is yet known about native 
Brazilian plants. Most of the data relates to herbal medicines used worldwide, 
such as garlic, mint and devil’s claw. We have interpreted this data within the 
context of the unique range of intrinsic factors including the genetic make-up of 
the Brazilian population and how this may cause interactions with essential 
drugs prescribed within the Brazilian healthcare system. It is evident that an 
enormous task must be undertaken to understand the effects of most local plant 
species in both metabolic and transporter mechanisms. 
The present preclinical study provides evidence that the administration 
of some of RENISUS herbal medicines may possibly cause in vitro 
disturbances to metabolic mechanisms. More refined studies would be 
necessary to ascertain the in vivo and/or clinical significance of such 
interactions. At this point, we can suggest that active pharmacovigilance is 
recommended especially for the plants that affected multiple targets, such as 
Apuleia ferrea (Mart.) Baill., Rhamnus purshiana DC. and Schinus 
terebinthifolia Raddi, which were able to modulate all targets in our preclinical 
study.  
Finally, it is our opinion that the Brazilian pharmacovigilance system may 
be underreporting HDI, and that there is a need to review the threshold of HDI 
risk level for reports being passed onto the WHO. Another important factor for 
the prevention or reduction of HDI cases is the awareness of not only health 
professionals, but also the regulatory authorities and consumers themselves. 
All these groups must realise the issues that medicinal plants and herbal 
medicines can cause when coadministered with synthetic drugs. The 
increasing cases of self-medication with medicinal plants and herbal medicines 
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endanger the patient's health, especially when there is no medical monitoring. 
Therefore, healthcare professionals including doctors, pharmacists, and nurses 
should encourage their patients to disclose the use of either medicinal plants 
or herbal medicines to prevent cases of HDI. In case of a suspected HDI, health 
professionals must not hesitate to report it immediately to the 
pharmacovigilance system. This will enable ANVISA to post a warning about 
risks of interactions between these drugs, which must be sent to the WHO in a 
more consistent manner (Skalli and Soulaymani Bencheikh, 2012).  
5.1 THE WAY FORWARD 
Our research group conducted for the first time some in vitro preclinical 
research using the twenty-four plant extracts from RENISUS medicinal plants 
to evaluate their effects in CYP3A4 mRNA gene expression, GSH levels, and 
P-glycoprotein activity. However, clinical studies must be carried out in order to 
confirm the potential HDI of RENISUS medicinal plants. According to PNPIC, 
Oswaldo Cruz Foundation (Fiocruz) is the Brazilian institution responsible for 
the creation of toxicology research centres that could be used for conducting 
the clinical trials with those plants. 
Besides Fiocruz, numerous institutions in Brazil are involved in the 
implementation of herbal medicines in the SUS. A better integration of those 
organisations would promote a better and safer usage of herbal medicines in 
the country. For instance, ANVISA could develop a regulation policy to improve 
research on the safety of traditional herbal medicines, which could be achieved 
with the participation of academia in the experimental process.  
REFARGEN has been doing remarkable work by mapping the genetic 
polymorphisms in the Brazilian population. This study should be now expanded 
to other groups of Brazilian living in different parts of the country in order to 
have a better understanding of the impact of the genetic polymorphism among 
the entire population. 
Continued education of health professionals about the prescription of 
herbal medicines is strongly needed to keep the professional updated, and this 
could be achieved by local campaigns made by the SUS. Better awareness of 
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HDI could certainly help those professionals in the moment of prescription and 
in the identification of a potential interaction in the presence of undesirable 
ADRs during the patient treatment.   
With these changes, it is expected that herbal medicines will be used in 
a more effective and rational manner, avoiding incorrect coadministration with 
synthetic drugs and thus helping to prevent possible cases of HDI, both in Brazil 
and among populations around the world. 
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7.4 AUTHORISATION TO ACCESS THE BRAZILIAN GENETIC 
HERITAGE GIVEN BY CGEN/CNPQ 
 
 
6223768071168241
AUTORIZAÇÃO DE ACESSO E DE REMESSA DE AMOSTRA DE COMPONENTE DO
PATRIMÔNIO GENÉTICO nº 010295/2014-3
O CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPq, credenciado pelo
Conselho de Gestão do Patrimônio Genético (CGEN/MMA), por meio da Deliberação CGEN n° 246, de 27 de agosto de
2009, para autorizar instituições nacionais, públicas ou privadas, que exerçam atividades de pesquisa e desenvolvimento
nas áreas biológicas e afins, a acessar e remeter amostras de componente do patrimônio genético para fins de pesquisa
científica sem potencial de uso econômico, neste ato representado pelo seu Diretor de Ciências Agrárias, Biológicas e da
Saúde, nos termos da Portaria CNPq nº 104/2011, autoriza a instituição abaixo qualificada a acessar e remeter amostras
de componentes do patrimônio genético.
Instituição: UNIVERSIDADE DE BRASILIA - UNB
CNPJ: 000.381.740/0001-43
Representante Legal: JAIME MARTINS DE SANTANA
Cargo/Função: Decano (Pró-Reitor) de Pesquisa e Pós-Graduação
CPF: 308.595.651-49 RG: 358372
Projeto: ESTUDO DE INTERAÇÕES MEDICAMENTOSAS ENTRE AS ESPÉCIES VEGETAIS CONSTANTES NA
RELAÇÃO NACIONAL DE PLANTAS MEDICINAIS DE INTERESSE DO SUS (RENISUS) E MEDICAMENTOS
CONVENCIONAIS
Coordenador do Projeto: Damaris Silveira
CPF: 464.405.696-00 RG: 2430447 - SSP / DF
Finalidade do projeto: A RENISUS (Relação Nacional de Plantas de Interesse para o SUS) foi lançada em 2008 pelo
Ministério da Saúde com o objetivo de selecionar espécies vegetais com atividades medicinais que possam ser integradas
à Relação Nacional de Plantas Medicinais (RENAFITO), sendo disponibilizada à população pelo Sistema Único de Saúde
(SUS). Para que esta meta seja alcançada, estudos farmacológicos e toxicológicos devem ser realizados para que plantas
medicinais e fitoterápicos possam ser prescritos aos pacientes de forma segura. Este projeto tem, como principal objetivo,
fazer uma avaliação in vitro das 71 espécies vegetais presentes na RENISUS em células hepáticas e avaliar sua
segurança quando a planta medicinal ou o fitoterápico for administrado com algum medicamento sintético. Estudos desta
natureza são muito relevantes, uma vez que o uso de produtos naturais vem crescendo muito nos últimos anos no Brasil e
no mundo. Os conceitos errôneos de que a administração de plantas medicinais é segura e isenta de efeitos colaterais
podem trazer sérias consequências para a saúde pública. Um xenobiótico de qualquer natureza (como uma planta
medicinal ou fitoterápico, por exemplo), uma vez administrado, será metabolizado pelas enzimas do fígado. A(s)
substância(s) química(s) presente(s) naquele composto podem agir aumentando ou diminuindo a atividade ou a
expressão das enzimas presentes no metabolismo de fase I (citocromo P-450) e fase II (glutationa S-transferases,
UDP-glucuroniltransferases, Sulfotransferases, etc.) que podem também impactar a metabolização de medicamentos
sintéticos quando estes foram concomitantemente administrados. O resultado desta interação se dá por alterações no
processo farmacocinético do medicamento sintético, podendo afetar qualquer etapa do ADME (absorção, distribuição,
metabolização e excreção), aumentando a toxicidade ou diminuindo e eficácia do medicamento dependendo da ação do
produto natural. Portanto, devido à necessidade de se conhecer mais profundamente a ação das espécies vegetais da
RENISUS no mecanismo metabólico e identificar possíveis interações medicamentosas entre plantas medicinais e
medicamentos sintéticos, este estudo toxicológico previamente aprovado e financiado pelo CNPq se faz de grande
impacto para o Ministério da Saúde no processo de implementação da RENISUS e para futuros projetos envolvendo
plantas medicinais e fitoterápicos no SUS.
Amostras a serem acessadas:
Grupos Taxonômicos: Todos as espécies contidas na Relação Nacional de Plantas de Interesse ao SUS (RENISUS):
Achillea millefolium, Allium sativum, Aloe spp (Aloe vera ou Aloe barbadensis), Alpinia (Alpinia zerumbet ou Alpinia
speciosa), Anacardium occidentale, Ananas comosus, Apuleia ferrea = Caesalpinia ferrea, Arrabidaea chica, Artemisia
absinthium, Baccharis trimera, Bauhinia spp (Bauhinia affinis, Bauhinia forficata ou Bauhinia variegata), Bidens pilosa,
Calendula officinalis, Carapa guianensis, Casearia sylvestris, Chamomilla recutita = Matricaria chamomilla, Chenopodium
ambrosioides, Copaifera spp, Cordia spp (Cordia curassavica ou Cordia verbenacea), Costus spp (Costus scaber ou
Costus spicatus), Croton spp (Croton cajucara ou Croton zehntneri), Curcuma longa, Cynara scolymus, Dalbergia
subcymosa, Eleutherine plicata, Equisetum arvense, Erythrina mulungu, Eucalyptus globulus, Eugenia uniflora ou Myrtus
brasiliana Foeniculum vulgare, Glycine max, Harpagophytum procumbens, Jatropha gossypiifolia, Justicia pectoralis,
Kalanchoe pinnata = Bryophyllum calycinum, Lamium album, Lippia sidoides, Malva sylvestris, Maytenus spp (Maytenus
aquifolium ou Maytenus ilicifolia),Mentha pulegium, Mentha spp (M. crispa, M. piperita ou M. villosa), Mikania spp (Mikania
glomerata ou Mikania laevigata), Momordica charantia, Morus spp., Ocimum gratissimum, Orbignya speciosa, Passiflora
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spp (Passiflora alata, Passiflora edulis ou Passiflora incarnata), Persea spp (P. gratissima ou P. americana), Petroselinum
sativum, Phyllanthus spp (P. amarus, P.niruri, P. tenellus e P. urinaria), Plantago major, Plectranthus barbatus = Coleus
barbatus, Polygonum spp (Polygonum acre ou Polygonum hydropiperoides), Portulaca pilosa, Psidium guajava, Punica
granatum, Rhamnus purshiana, Ruta graveolens, Salix alba, Schinus terebinthifolius = Schinus aroeira, Solanum
paniculatum, Solidago microglossa, Stryphnodendron adstringens = Stryphnodendron barbatimam, Syzygium spp (S.
jambolanum ou S. cumini), Tabebuia avellanedae, Tagetes minuta, Trifolium pratense, Uncaria tomentosa, Vernonia
condensata, Vernonia spp (Vernonia ruficoma ou Vernonia polyanthes), Zingiber officinale
Tipo de material/quantidade de amostras: O tipo de amostra dependerá da espécie. A quantidade aproximada será:
folhas,sumidades floridas ou partes aéreas: 500 g; caule, raiz ou bulbos: 800 g; frutos ou sementes: 600 g
Local de depósito de subamostra: UNIVERSIDADE DE BRASILIA
Equipe do projeto: DAMARIS SILVEIRA / CPF 464.405.696-00
ANDRE LUIS DIAS ARAUJO MAZZARI / CPF 090.900.047-69
YANNA KARLA DE MEDEIROS NOBREGA / CPF 020.423.464-62
YRIS MARIA FONSECA / CPF 045.789.276-52
PEROLA DE OLIVEIRA MAGALHAES / CPF 248.940.408-32
LUIZ ALBERTO SIMEONI / CPF 043.388.018-08
FRANCISCO DE ASSIS ROCHA NEVES / CPF 186.580.591-20
RICCARDO PRATESI / CPF 000.079.941-68
CHRISTOPHER WILLIAM FAGG / CPF 694.231.131-68
JOSE M PRIETO / CPF ..-
Validade da Autorização: 15/05/2014 a 01/05/2018
A instituição acima qualificada deverá enviar ao CNPq, por meio do Coordenador do Projeto, relatório anual sobre o
andamento do projeto de pesquisa, nos termos do Decreto nº. 4.946/2003. O roteiro para confecção do relatório está
disponível em http://www.cnpq.br/web/guest/relatorio-de-atividades. Os relatórios devem ser enviados ao CNPq em meio
eletrônico, para o endereço apg@cnpq.br e, preferencialmente, em formato .pdf.
Esta autorização está vinculada às informações, declarações e termos de compromisso firmados pelo coordenador do
projeto e pelo representante legal, constantes do Processo n° 010295/2014-3. Atividades de acesso aos conhecimentos
tradicionais associados, de acesso e de remessa de componente do patrimônio genético com finalidade comercial,
aplicação industrial, bioprospecção ou desenvolvimento tecnológico não estão autorizadas.
Caso seja identificado uso econômico de produto ou processo, passível ou não de proteção intelectual, originado das
amostras de componente do patrimônio genético acessado no âmbito desta autorização, a instituição beneficiada se
compromete a adotar as providências cabíveis, nos termos da legislação vigente, junto ao CGEN/MMA.
Se ocorrer coleta de espécie não autorizada ou não identificada, deverá ser observado o que consta no Decreto nº 6.514,
de 22/07/2008, no que refere à flora e fauna, e em particular sobre espécies ameaçadas de extinção ou de endemismo
estrito.
A remessa de amostra de componente do patrimônio genético deverá ser precedida da assinatura do Termo de
Transferência de Material (TTM) ou do Termo de Responsabilidade para Transporte de Amostra de Componente do
Patrimônio Genético (TRTM). A remessa para instituições nacionais está isenta de autorização prévia. Contudo, a
remessa para instituições sediadas no exterior depende de autorização prévia do CNPq, nos termos das resoluções do
CGEN 15/2004 e 20/2006. Os modelos dos termos, assim como as citadas resoluções, estão disponíveis em
http://www.cnpq.br/web/guest/remessa-e-transporte e devem ser enviados ao CNPq em meio eletrônico para o endereço
apg@cnpq.br, preferencialmente em formato .pdf. Ainda, para a remessa de componente do patrimônio genético para
instituição sediada no exterior, deverá ser solicitada ao Instituto Brasileiro do Meio Ambiente e dos Recursos Naturais
Renováveis - IBAMA, por meio de formulário específico e mediante a apresentação de TTM ou TRTM, licença de
exportação complementar a autorização de remessa, especialmente quando se tratar de remessa de espécies constantes
nos Anexos da Convenção sobre o Comércio Internacional das Espécies da Flora e Fauna Selvagens em Perigo de
Extinção (Cites).
Brasília, 15 de Maio de 2014
Marcelo Marcos Morales
Diretor de Ciências Agrárias, Biológicas e da Saúde
Para visualizar a versão digital da Autorização de Acesso e de Remessa de Amostra de Componente do Patrimônio
Genético, V.Sa. poderá utilizar a ferramenta disponibilizada pelo CNPq para esse fim na página
http://servicosweb.cnpq.br/visualizador/</a> e informar o número do protocolo 6223768071168241 para recuperá-la do
banco de dados do CNPq, ou poderá selecionar o arquivo salvo em seu computador (em formato PKCS7). V.Sa. pode
também usar outro aplicativo disponível no mercado capaz de reconhecer arquivos no padrão PKCS7 para fazer a
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Catechin
7.5 HPLC ANALYSIS  
 	 236	
Chlorogenic acid
 
  
 	 237	
Caffeic acid
  
 
 	 238	
Quercetin
  
 	 239	
Rutin
 	 240	
 
Artemisia absinthium 254nm
 	 241	
Artemisia absinthium 280nm
1,3,4 Simple phenolic acids
2 Chlorogenic acid
1
1,2,3,4
2 3
4
 	 242	
Artemisia absinthium 360nm
5 6
5,6
5,6	flavonoids
 	 243	
Apuleia ferrea 254nm
1
2
3
4
5
6,7,8,9
1
2
3
4
5
6
7
8
9
10
10
1 – 10 Not identified 
 	 244	
Apuleia ferrea 280nm
 	 245	
   
Apuleia ferrea 360nm
 	 246	
Bidens pilosa 254nm
 	 247	
Bidens pilosa 280nm
 	 248	
Bidens pilosa 360nm
3,4 flvonoids
1 Chlorogenic acid
2 Caffeic acid
1 
3
4
2 
1,2 3,4
 	 249	
Casearia sylvestris 254nm
1 Phenolic acid
2 Chlorogenic acid
1
2
1,2
 	 250	
Casearia sylvestris 280nm
3
4
3,4
3, 4 Not identified 
 	 251	
Casearia sylvestris 360nm
 	 252	
Cordia verbenaceae 254nm
 	 253	
Cordia verbenaceae 280nm
 	 254	
Cordia verbenaceae 360nm
4,5 1 Chlorogenic acid
2 Caffeic acid
3 Phenolic acid
4
3
5
1,2
1,2,3
4, 5 Not identified 
 	 255	
Costus spicatus 254nm
 	 256	
Costus spicatus 280nm
1
1 1 Not identified 
 	 257	
Costus spicatus 360nm
2
3
5
4
6
2-5 Glycosilated flavonoids
6 Quercetin
2,5 6
 	 258	
Equisetum arvense 254nm
 	 259	
Equisetum arvense 280nm
 	 260	
Equisetum arvense 360nm
1,3,6 Phenolic acid
2 Caffeic acid
4,5 Glycosilated
flavonoids
1 2
3
4
5
6
1,2,3,6 4,5
 	 261	
Erythrina mulungu 254nm
123
1 2 3 1,2,3
Tannins
 	 262	
Erythrina mulungu 280nm
4
4 Tannins4
 	 263	
Erythrina mulungu 360nm
5 Phenolic acid 6,7 Glycosilated flavonoids 8 Glycosilated
flavonoids
9,10,11 Phenolic acids
5
6 7 8
9 10
11
5 6,7 8 9,10,11
 	 264	
Lamium album 254nm
1 Tannin 2 Chlorogenic acid
1
2 3
3 Glycosilated flavonoid
1 2 3
 	 265	
Lamium album 280nm
 	 266	
Lamium album 360nm
4-7 Phenolic acids
4
5 67
4,5,6,7
 	 267	
Lippia sidoides 254nm
3,4 Flavonoids1,2
3
4
1
2
3,4
1,2 Not identified 
 	 268	
Lippia sidoides 280nm
 	 269	
Lippia sidoides 360nm
 	 270	
Malva sylvestris (flower) 254nm
3 Phenolic acid 4,5 Flavonoids
1,2 6,7,8
3
4 5
1
2
6
7
8
3 4,5
1,2 Not identified 6,7,8 Not identified 
 	 271	
Malva sylvestris (flower) 280nm
9
9 9 Not identified 
 	 272	
Malva sylvestris (flower) 360nm
 	 273	
Malva sylvestris (herb) 254nm
1,3
1
2
3
4
2,4 Flavonoids1,3 Phenolic acids
2,4
 	 274	
Malva sylvestris (herb) 280nm
 	 275	
Malva sylvestris (herb) 360nm
 	 276	
Maytenus ilicifolia 254nm
1
2
1,2 3,4
1
3
4
1-4 Glycosilated flavonoids
 	 277	
Maytenus ilicifolia 280nm
 	 278	
Maytenus ilicifolia 360nm
 	 279	
Morus nigra 254nm
1
1 Chlorogenic acid
1
 	 280	
Morus nigra 280nm
 	 281	
Morus nigra 360nm
2
3
4
2,3 4
2 - 4 Not identified 
 	 282	
Passiflora incarnata 254nm
1,2,3,4,5,6
1
2
3
4
5
6
1-6 Glycosilated flavonoids
 	 283	
Passiflora incarnata 280nm
7
7 7 Not identified 
 	 284	
Passiflora incarnata 360nm
 	 285	
Persea americana 254nm
1 Chlorogenic acid
2,3,4,5 
1
2
3 4
5
2,3,4,5 Glycosilated flavonoids
1
 	 286	
Persea americana 280nm
 	 287	
Persea americana 360nm
 	 288	
Rhamnus purshiana 254nm
1 Chlorogenic acid
2
3
4
1
2
3
4 5
6
5
6
3 Glycosilated flavonoid
1
2,4,5,6 Not identified 
 	 289	
Rhamnus purshiana 280nm
 	 290	
Rhamnus purshiana 360nm
 	 291	
Salix alba 254nm
1,2
1 2
3
3 1-3 Not identified 
 	 292	
Salix alba 280nm
4
4
4 Not identified 
 	 293	
Salix alba 360nm
 	 294	
Schinus terebinthifolia 254nm
 	 295	
Schinus terebinthifolia 280nm
1
2
1,2 1,2 Not identified 
 	 296	
Schinus terebinthifolia 360nm
3 4
4 Phenolic acid
3 4 3 Not identified 
 	 297	
Solanum paniculatum 254nm
2
1
3
1 2 3
2 Chlorogenic acid1 Not identified 3 Not identified 
 	 298	
Solanum paniculatum 280nm
 	 299	
Solanum paniculatum 360nm
4 5,6
4 5 6
5,6 Glycosilated flavonoids
4 Not identified 
 	 300	
Solidago microglossa 254nm
1
2
2 1 Chlorogenic acid
2 Glycosilated
flavonoids
1
 	 301	
Solidago microglossa 280nm
 	 302	
Solidago microglossa 360nm
 	 303	
Syzygium jambolanum 254nm
1
1
1 Not identified 
 	 304	
Syzygium jambolanum 280nm
 	 305	
Syzygium jambolanum 360nm
2 3, 5
3,5 Glycosilated
flavonoids
2
3 4 5
4
2 Not identified 4 Not identified 
 	 306	
Tabebuia avellanedae 254nm
1,2,4,5,7 3,6
1
2
3
4
5
6
7
1-7 Not identified 
 	 307	
Tabebuia avellanedae 280nm
8
8 Tannin
8
 	 308	
Tabebuia avellanedae 360nm
9
10,11,13 Phenolic acids
12
9
10
11
12
13
10,11,13
9 Not identified 
12 Not identified 
 	 309	
Vernonia polyanthes 254nm
1
2
3
4
5 6
1 2 3 4,5 6
4,5,6 Glycosilated flavonoids1-3 Not identified 
 	 310	
Vernonia polyanthes 280nm
 	 311	
Vernonia polyanthes 360nm
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7.6 TABULAR SUMMARY OF CYP3A4 MRNA GENE EXPRESSION IN 
HEPG2 CELLS (RESULTS SHOW MEAN ± SEM, N ≥ 3) 
 
 
Samples 
 
Sample ID 
Fold 
induction/inhibition 
normalised with  
b-actin 
Control (DMSO 0.2%) CTR 1 
RIF 50µM RIF 4.95 ± 0.26 
DMSO 1% DMS 0.37 ± 0.05 
Apuleia ferrea (Mart.) Baill.  AF1 4.24 ± 0.30 
Artemisia absinthium L. AA1 1.41 ± 0.24 
Bidens pilosa L.  BP1 0.84 ± 0.18 
Casearia silvestris Sw. CAS 1.57 ± 0.16 
Cordia verbenaceae A. DC.  CV1 1.45 ± 0.17 
Costus spicatus (Jacq.) Sw. CS1 1.09 ± 0.21 
Equisetum arvense L. EA1 1.62 ± 0.27 
Erythrina mulungu Benth.  EM1 0.87 ± 0.10 
Lamium album L.  LA1 0.51 ± 0.15 
Lippia sidoides Cham.  LS1 1.44 ± 0.16 
Malva sylvestris L.  MSF 0.75 ± 0.10 
MSH 0.76 ± .011 
Maytenus ilicifolia Mart. ex Reissek MI1 1.84 ± 0.24 
Morus nigra L.  MN1 1.39 ± 0.23 
Passiflora incarnata L.  PI1 1.82 ± 0.21 
Persea americana Mill.  PA1 2.02 ± 0.57 
Rhamnus purshiana DC.  RP1 1.53 ± 0.23 
Salix alba L.  SA1 3.25 ± 0.29 
Schinus terebinthifolia Raddi ST1 4.88 ± 0.19 
Solanum paniculatum L.  SP1 0.41 ± 0.15 
Solidago microglossa DC.  SM1 1.05 ± 0.06 
Syzygium jambolanum (Lam.) DC.  SJ1 4.22 ± 0.10 
Tabebuia avellanedae Lorentz ex Griseb.  TA1 1.32 ± 0.25 
Vernonia polyanthes Less.  VP1 4.22 ± 0.24 
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7.7 TABULAR SUMMARY OF INTRACELLULAR GSH 
CONCENTRATIONS IN HEPG2 CELLS (RESULTS SHOW MEAN ± 
SEM, N ≥ 3) 
 
Samples 
 
 
 
Sample ID GSH (µM /105 cells) 
Control (water) CTR 29.91 ± 0.36 
Buthionine sulfoximine (BSO) 10µM BSO 17.78 ± 1.70 
Apuleia ferrea (Mart.) Baill. AF1 16.32 ± 1.52 
Artemisia absinthium L. AA1 27.93 ± 1.72 
Bidens pilosa L. BP1 17.61 ± 1.79 
Casearia silvestris Sw. CAS 18.77± 1.83 
Cordia verbenaceae A. DC. CV1 15.98 ± 1.80 
Costus spicatus (Jacq.) Sw. CS1 22.23 ± 0.76 
Equisetum arvense L. EA1 21.76 ± 2.01 
Erythrina mulungu Benth. EM1 47.05 ± 2.0 
Lamium album L. LA1 15.98 ± 1.28 
Lippia sidoides Cham. LS1 26.34 ± 1.20 
Malva sylvestris L. 
MSF 25.94 ± 1.28 
MSH 17.96 ± 1.72 
Maytenus ilicifolia Mart. ex Reissek MI1 8.55 ± 1.32 
Morus nigra L. MN1 31.54 ± 1.50 
Passiflora incarnata L. PI1 16.82 ± 0.70 
Persea americana Mill. PA1 9.33 ± 0.57 
Rhamnus purshiana DC. RP1 11.54 ± 0.50 
Salix alba L. SA1 22.37 ± 2.51 
Schinus terebinthifolia Raddi ST1 15.70 ± 1.52 
Solanum paniculatum L. SP1 16.83 ± 1.95 
Solidago microglossa DC. SM1 21.87 ± 2.25 
Syzygium jambolanum (Lam.) DC. SJ1 27.35 ± 1.52 
Tabebuia avellanedae Lorentz ex Griseb. TA1 11.23 ± 1.60 
Vernonia polyanthes Less. VP1 19.96 ± 1.81 
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7.8 TABULAR SUMMARY OF GGT ACTIVITY IN TERMS OF µM P-
NITROANILINE CONCENTRATION IN HEPG2 CELLS (RESULTS 
SHOW MEAN ± SEM, N ≥ 3) 
Samples Sample ID µM p-nitroaniline 
per 106 cells 
 
Control (water) CTR 82.30 ± 7.48 
Acivicin 5µM ACV 25.45 ± 7.18 
Artemisia absinthium L. AA1 94.05 ± 10.95 
Apuleia ferrea (Mart.) Baill.  AF1 134.65 ± 6.26 
Bidens pilosa L.  BP1 76.93 ± 3.33 
Casearia sylvestris Sw. CAS 75.99 ± 6.79 
Cordia verbenaceae A. DC.  CV1 43.56 ± 7.26 
Costus spicatus (Jacq.) Sw. CS1 52.50 ± 12.05 
Equisetum arvense L. EA1 79.34 ± 8.72 
Erythrina mulungu Benth.  EM1 76.47 ± 7.10 
Lamium album L.  LA1 79.87 ± 5.92 
Lippia sidoides Cham.  LS1 101.46 ± 10.15 
Malva sylvestris L.  MSF 89.01 ± 9.89 
MSH 84.45 ± 9.48 
Maytenus ilicifolia Mart. ex Reissek MI1 66.61 ± 7.19 
Morus nigra L.  MN1 84.43 ± 2.41 
Passiflora incarnata L.  PI1 109.82 ± 9.22 
Persea americana Mill.  PA1 56.64 ± 4.26 
Rhamnus purshiana DC.  RP1 131.80 ± 5.64 
Salix alba L.  SA1 52.93 ± 4.12 
Schinus terebinthifolia Raddi ST1 54.70 ± 7.58 
Solanum paniculatum L.  SP1 83.87 ± 8.24 
Solidago microglossa DC.  SM1 86.01 ± 6.29 
Syzygium jambolanum (Lam.) DC.  SJ1 53.19 ± 5.10 
Tabebuia avellanedae Lorentz ex Griseb.  TA1 73.50 ± 13.01 
Vernonia polyanthes Less.  VP1 78.89 ± 1.81 
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7.9 EFFECT OF PLANT EXTRACTS ON INTRACELLULAR RH-123 
ACCUMULATION IN CACO-2 VCR CELLS (RESULTS SHOW MEAN 
± SEM, N ≥ 3) 
Samples Sample ID Intracellular Rh-
123 Fluorescence  
( % of control) 
Control (Rh-123) CTR 100 ± 1.50 
Verapamil 20µM VPM 181.78 ± 12.97 
Apuleia ferrea (Mart.) Baill. AF1 412.72 ± 63.72 
Artemisia absinthium L. AA1 113.61 ± 21.77 
Bidens pilosa L. BP1 73.59 ± 25.75 
Casearia sylvestris Sw. CAS 79.28 ± 31.73 
Cordia verbenaceae A. DC. CV1 108.45 ± 52.15 
Costus spicatus (Jacq.) Sw. CS1 81.98 ± 21.22 
Equisetum arvense L. EA1 108.36 ± 32.48 
Erythrina mulungu Benth. EM1 69.64 ± 24.72 
Lamium album L. LA1 106.18 ± 7.03 
Lippia sidoides Cham. LS1 104.63 ± 36.46 
Malva sylvestris L. MSF 100.06 ± 19.39 
MSH 97.61 ± 11.02 
Maytenus ilicifolia Mart. ex Reissek MI1 96.79 ± 17.03 
Morus nigra L. MN1 68.12 ± 23.14 
Passiflora incarnata L. PI1 108.59 ± 18.28 
Persea americana Mill. PA1 90.61 ± 25.40 
Rhamnus purshiana DC. RP1 78.50 ± 21.47 
Salix alba L. SA1 192.25 ± 16.37 
Schinus terebinthifolia Raddi ST1 442.61 ± 48.55 
Solanum paniculatum L. SP1 87.14 ± 34.63 
Solidago microglossa DC. SM1 105.70 ± 41.44 
Syzygium jambolanum (Lam.) DC. SJ1 182.39 ± 14.82 
Tabebuia avellanedae Lorentz ex Griseb. TA1 87.36 ± 7.20 
Vernonia polyanthes Less. VP1 101.61 ± 2.70 
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7.10 PUBLICATIONS 
7.10.1 Herbal medicines in Brazil: pharmacokinetic profile and potential 
herb-drug interactions 
 	 317	
 	 318	
 	 319	
 	 320	
 	 321	
 	 322	
 	 323	
 	 324	
 	 325	
 	 326	
 	 327	
 	 334	
7.10.3 In vitro effects of four native Brazilian medicinal plants in CYP3A4 
mRNA gene expression, glutathione levels, and P-glycoprotein 
activity
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